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Abstract 
This thesis focuses on applying the approach of downsizing disulfide-rich peptides for 
the development of potential drug leads, and providing insight into important 
structural features for bioactivity. Disulfide-rich peptides are widely distributed in 
nature and several hold promise for the development of novel therapeutics and diagnostic 
agents. This thesis explores the structure-function relationships of two disulfide rich 
peptides; the scorpion venom peptide chlorotoxin, and the parasitic liver fluke protein 
Ov-GRN-1. 
 
Chapter 2 focuses on chlorotoxin, a potent tumour-imaging agent that selectively 
binds to tumour cells. Interestingly, it has been shown that chlorotoxin can have 
biological effects without disulfide bonds stabilising the native fold. This finding 
suggests that smaller regions, the inter-cysteine loops, might be responsible for the 
bioactivity of chlorotoxin. To explore this hypothesis, four small fragments of 
chlorotoxin were chemically synthesised using Fmoc solid-phase peptide synthesis 
method. As expected for such small peptides, NMR analysis indicated that the 
peptides were unstructured in solution. The bioactivity of the fragments was assessed 
by cell migration and invasion assays, alongside cell surface binding and 
internalization assays. Our results indicate that a small, unstructured fragment from 
the C-terminal region plays a critical role in the bioactivity of chlorotoxin. This is an 
unusual finding as structure is often critical for bioactivity in disulfide-rich peptides. 
 
The remaining experimental chapters focus on the characterization of Ov-GRN-1, a 
protein isolated from the excretory/secretory (ES) products of the carcinogenic liver 
fluke Opisthorchis viverrini. Ov-GRN-1 belongs to the granulin family, which are 
growth factor proteins with a wide range of functions mainly involved in cell 
modulation. A recombinant version of Ov-GRN-1 causes proliferation of host 
(human) cells and can accelerate the repair of wounds in animals. However, 
recombinant expression of Ov-GRN-1 is challenging and leads to a low product yield, 
impeding its utility as a drug lead. 
 
Chapter 3 focuses on the design, structure and functional analysis of minimized 
analogues from the N-terminal region of Ov-GRN-1. A series of analogues from the N-
	 xii	
terminal region of Ov-GRN-1 were chemically synthesised by solid-phase peptide 
synthesis, oxidized by air oxidation, purified by HPLC and characterized by mass 
spectroscopy. The structure of peptides was studied by NMR spectroscopy and the 3D 
structure was calculated by CYANA and visualized by MolMol. Cell proliferation and 
wound healing activity were assessed by an in vitro xCELLigence cell proliferation assay 
and an in vivo mouse-wounding model, respectively. The structural characterization of 
the Ov-GRN-1 N-terminal truncated peptides indicated that the introduction of a non-
native disulfide bond appears to stabilize the fold and allow the peptide to form a β-
hairpin structure. This analogue, which is called Ov-GRN12-35_3s, induced cell 
proliferation and in vivo wound healing with similar potency to the full-length Ov-
GRN-1. 
 
NMR analysis of Ov-GRN12-35_3s indicated the presence of multiple conformations, 
most likely from proline cis/trans isomerisation. In Chapter 4, a series of analogues 
involving mutation of the proline residues was synthesised to investigate the role of 
proline residues in adopting the multiple confirmations by Ov-GRN12-35_3s. Utilising 
the same techniques and methods used in Chapter 3, proline residues were shown to 
have a significant influence on the structure, activity and folding of Ov-GRN12-35_3s. 
The results obtained for this chapter led to the development of a more potent analogue, 
GRNP4A, with improved folding yield.  
 
Chapter 5 further explores the structure-function relationships of granulin peptides 
through analysis of the N-terminal region of human granulin A, as well as the C-
terminal region of Ov-GRN-1. The former peptide was designed to determine if the 
non-native disulfide bond present in Ov-GRN12-35_3s could also be accomodated in a 
granulin from another species, whereas the latter represents the first truncation study 
of the C-terminal region of a granulin peptide. The same techniques and methods as 
Chapter 4 were used to synthesise and characterise the analogues. Bioactivity of 
analogues were assessed using an in vitro xCELLigence cell proliferation assay. The 
results indicated that accommodation of a non-native disuflide bond might be a 
general phenomenon in the granulin family, as the N-terminal half of the human 
granulin A protein also folds independently with three disulfide bonds, despite 
significant sequence differences to the Ov-GRN-1 peptide. We also show for the first 
time that the equivalent C-terminal half of Ov-GRN-1 does not fold into a well-
	 xiii	
defined structure, but still displays cell proliferative activity. Our results indicate that 
well-defined structures are not critical for granulin bioactivity. 
In summary, the results highlight the potential of the “downsizing” approach for 
elucidating bioactive sequences, providing insight into folding processes and the 
development of novel drug leads. One of the major findings from this thesis is the 
development of a truncated form of Ov-GRN-1 that is likely to have lower 
immunogenicity than the full-length protein because of its smaller size, is 
significantly easier to produce and more potent in a mouse wound healing assay. 
These features make it a more viable drug lead for wound healing applications, and it 
is currently being considered for commercial development. 
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1.1 Disulfide-rich peptides as therapeutics 
Interest in peptides as pharmaceuticals or biological tools has increased recently. This 
interest reflects the importance of peptides in physiological processes in living 
systems, as well as certain properties that make them excellent potential drug 
candidates such as the ability to diffuse easily through tissue unlike antibodies, low 
toxicity, and high affinity and specificity for targets (1). In addition, they can be 
synthesized chemically. The list of peptides that have been investigated for 
therapeutic potential is enormous (1, 2). Peptides and their homologues are, or have 
the potential to be, used in medicine to treat several kinds of diseases and conditions, 
including: osteoporosis, cancer, cardiovascular and cardiovascular diseases (coronary 
syndrome and angina), diabetes, allergy and asthma, analgesia, epilepsy, 
gastrointestinal, baldness, growth problems, arthritis, impotence, haemostasis 
immunity, inflammation, obesity and vaccines (1-5). 
 
Peptide-based drugs have been derived from three sources. The first group includes 
naturally occurring bioactive peptides, which are extracted from animals or plants. 
Those bioactive peptides include toxins, hormones and neurotransmitters. The second 
and third groups are non-naturally occurring peptides produced from either genetic 
libraries or chemical libraries (6, 7). Among these, the first group is the most 
preferred because naturally occurring peptides are optimized functionally against 
their ligands (6). Indeed, peptides based on naturally occurring drugs are a sensible 
option for addressing new therapeutic challenges in the coming years.  
 
Despite the potential of peptides as drug leads, they often have low stability and 
significant effort has been directed at overcoming this limitation. Both naturally 
occurring and non-native modifications can stabilize peptides. One of the most 
common naturally occurring features that can stabilize peptides is a disulfide bond. 
Recently, disulfide-rich peptides have generated considerable interest in the 
development of peptide-based therapeutics owing to their remarkable stability toward 
chemical, enzymatic, or thermal extremes brought about by their highly folded 
structures (8). Examples of disulfide rich peptides currently used in the clinic include 
ziconotide (9) and linaclotide (10) for the treatment of chronic pain and constipation, 
respectively. Numerous other peptides are being assessed as potential drug treatments 
	 3	
but also for use as imaging agents.  
 
Chlorotoxin (CTX), a disulfide-rich peptide extracted from the venom of a scorpion 
(Leiurus quinquestriatus), and granulin (Ov-GRN-1), a small disulfide-rich protein 
from the carcinogenic liver fluke Opisthorchis viverrini, have potential as diagnostic 
and/or therapeutic applications. Exploring the potential of chlorotoxin and peptides 
derived from Ov-GRN-1 is the focus of this thesis. Details regarding their biology, 
activity and structures are given in the following sections. 
1.2 Chlorotoxin: A naturally occurring peptide from scorpion venom 
Scorpions were among the first habitant arthropods of the earth (11). Their venoms 
contain a variety of compounds, with the majority being small peptides containing 
30-70 residues (12-14). There are approximately 1500 scorpion species, and despite 
the reputation for being dangerous, only 30 are considered life threatening to humans 
(15). 
 
Scorpion envenomation results in stimulation of the nervous system and the adrenal 
medulla causing a massive release of sympathetic and parasympathetic 
neurotransmitters (15-17). Recent studies have shown scorpion venom peptides can 
influence a range of proteins including platelet activating factor (PAF), complement 
system interleukins, cytokines and tumour necrosis factor (TNF) (18). Although only 
a limited number have been pharmacologically and biochemically characterized, 
there has been interest in scorpion venom peptides as potential sources for drug 
design for decades. 
 
 One of the most well-studied scorpion venom peptides is chlorotoxin, which was 
originally purified from the venom of the Israeli scorpion Leiurus quinquestriatus in 
1993 (19). Chlorotoxin is a 4 kDa neurotoxin that contains 36 amino acids and with 
four disulfide bonds at the core of its structure it is tightly folded and highly stable. 
The tertiary structure is composed of a β-hairpin and an α-helix as shown in Figure 1-
1 (19-21).  
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Figure 1-1 Schematic three-dimensional structure of chlorotoxin (PDB code 
5L1C). The chlorotoxin sequence and disulfide bond connectivity is given below the 
structure. 
 
 
1.2.1 Chlorotoxin selectively binding to tumour cells 
It was initially shown that chlorotoxin selectively binds to glioma cells but not 
normal healthy brain cells (22). Later, it has been demonstrated that it can also bind 
to other embryologically related cells and derived tumours of neuroectodermal origin 
(23). An explanation for this result is that these cells, and the tumours that originate 
from them, have a common embryologic stem, so they share genetic and antigenic 
phenotypes that appears to contribute to selective binding of chlorotoxin. In contrast 
to the high-affinity of chlorotoxin for tumour cells, more than fifteen normal human 
tissues have been shown to be negative for chlorotoxin binding. The only exception is 
human umbilical vein endothelial cells (HUVEC) (24). Chlorotoxin showed anti-
angiogenic activity on HUVEC cells in vivo and in vitro, and can also significantly 
inhibit tumour cell migration and invasion (24, 25) highlighting the potential of 
chlorotoxin in cancer treatment. 
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The selective binding of chlorotoxin to tumour cells bodes well for its application in 
cancer therapy as a tumor imaging agent (23). Tumour imaging agents have great 
potential in the treatment of cancer, particularly for brain cancer. The primary 
treatment of cancerous tissue is resection and this requires accurate imaging. Cancers 
of the brain are one of the most critical forms influenced by the success of surgical 
procedures, with more than 80% of malignant cancers recurring as a result of a 
residual tumour (26). Brain tumours are neoplasms in the pediatric and adult 
population that are often associated with considerable morbidity and mortality (27). 
Successful imaging has several benefits for both patients and surgeons: 
• Guaranteeing a long-term survival of the patient because only one remaining 
cancer cell can cause regrowth of a new tumour so by precisely defining the 
tumor boundaries tumour removal will be optimized (28, 29). 
• Maximizing radiotherapy efficiency. 
• By determining the exact size and extent of the tumour, local delivery of 
therapeutics will be enhanced. 
Whereas adequate imaging is nearly impossible due to limitations in traditional 
imaging methods such as MRI, magnetic resonance spectroscopy (MRS), and 18F-
FDG PET1 (30-34), specific binding activity of chlorotoxin to tumour cells make this 
peptide an effective optical imaging contrast agent. While most of available 
radiopharmaceuticals such as 81C6 antibodies cannot pass through the blood barrier 
brain (BBB) (33, 35, 36), it is reported that chlorotoxin and its conjugated 
biomolecules such as radiolabeled-chlorotoxin can diffuse in brain tumour cells and 
selectively bind to tumour cells, not normal cells (22, 33, 36). However, Kovar and 
colleagues used the Evan’s Blue perfusion assay to test the integrity of the BBB after 
administration of IRDye800CW chlorotoxin, and reported that the BBB was 
compromised at the site of the tumours (36), indicating this aspect of chlorotoxin 
needs more study. 
 
Several methods have been used to detect chlorotoxin binding to tumours, both in 
vitro and in vivo, including radiolabelling and fluorescent labels such as Cy5.5 (37), 
Alexa-488 (38) and IRDye800CW (36).  Initial studies used labelling of chlorotoxin 
with different I-radioisotopes in order to develop chlorotoxin as both a tumour 
																																																						1	Fluorodeoxyglucose(18	F-FDG)	Positron	Emission	Tomography(PET)	
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imaging agent and a cell proliferation controlling medicine. The tyrosine residue at 
position 29 of chlorotoxin was labelled with 131I or 125I and analyses confirmed 
chlorotoxin could selectively bind to glioma cells and serve as a glioma-specific 
marker with diagnostic and therapeutic potential (22, 33, 39). The activity of 
chlorotoxin does not change by labelling with either 131I or 125I. Further investigation 
showed γ emittance, energy level and consequently penetration properties of 131I is 
higher and deeper than other radioisotopes such as 123I and 124I (22, 33). 131I-
Chlorotoxin has been termed 131I-TM-601 and successfully passed human clinical 
trial phase I (40, 41). The results from the phase I trial were promising as 131I-
radiolabeled chlorotoxin was detectable for up to 8 days after drug injection in vivo 
(41, 42). 
 
Despite the potential of radiolabelled chlorotoxin, significant effort has been put into 
developing alternative forms of chlorotoxin for binding to tumour cells. Chlorotoxin 
conjugated to the near-infrared (NIR) fluorescent dye Cy5.5 has been termed 
“Tumour Paint”(37). Chlorotoxin-Cy5.5 effectively identifies the margin between 
tumour and normal tissue on genetically engineered or orthotopically xenografted 
mouse models of brain cancer (37). Further studies have shown that labelled 
chlorotoxin can be used to discriminate prostate cancer, intestinal cancer and sarcoma 
from normal tissue in mouse models, indicating its significant potential in the 
treatment of a range of cancers (37). There are three lysine residues at positions 15, 
23, and 27 in chlorotoxin that can react with Cy5.5. The presence of multiple lysine 
residues complicates the conjugation with Cy5.5 leading to the presence of di- and 
tri- labelled peptide (37). Although it is possible to have mixtures such as this 
approved by the US Food and Drug Administration (FDA) and similar regulatory 
agencies elsewhere, commercialisation is hindered by the fact that it is expensive and 
difficult to match the ratio of mono-, di- and tri-labelled batches in the future. Lysine 
15 and lysine 23 have been substituted with either alanine or arginine residues, which 
resulted in mono-labelled peptide that was still functional in in vivo assays (43). 
Mono-conjugated chlorotoxin is anticipated to have fewer regulatory hurdles for 
human applications than a mixture of conjugation forms, highlighting the significance 
of the results. Chlorotoxin labelled with IRDye800CW, has also successfully been 
used as a tumour-imaging agent in a spontaneous mouse model of medulloblastoma 
(36).  
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Chlorotoxin has also been used for targeting ligands in drug delivery systems (44). It 
has been shown that coating nanoparticles with Cy5.5-chlorotoxin, in order to 
visualize and image tumours, improves their uptake by tumour cells and enhances the 
effect of the loaded medicine (37, 44-53). In addition, tumors treated with chlorotoxin 
nanoparticles are detectable longer, inferring that conjugating chlorotoxin to 
nanoparticles probably changes its internalization pathway making it more resistant to 
lysosomal degradation enzymes (38).  
1.2.2 Elucidating the biological target of chlorotoxin 
Given the potential of chlorotoxin as a therapeutic it is of significant interest to 
understand how it is acting in vivo and to determine the biological target. However, 
elucidating the actual target for chlorotoxin has not been straightforward. It was 
initially thought that chloride channels were the specific receptor for chlorotoxin (54), 
but later matrix metalloproteinase-2 and annexin A2 have been proposed as other 
possible targets for chlorotoxin (39, 55). 
1.2.2.1 Chloride ion channel 
Chlorotoxin can effectively block glioma-specific chloride ion channel (ClC-3) (56, 
57). ClC-3 is one of nine subtypes of chloride ion channels (ClC) situated in various 
and widespread sub-cellular places. A few of ClCs that are plasma membrane channel 
have an essential role in ion transportation. The other CIC proteins are situated in 
the endosomal-lysosomal apparatus to either acidify or modify chloride concentration 
of the vesicles (58).  
 
The ClC-3 voltage-gated chloride channel is highly and selectively expressed in 
glioma cells (57, 59) and end-stage patient biopsies (59), consistent with it being a 
target for chlorotoxin. ClC-3 is a type of Cl-/H+ exchanger that is mainly expressed in 
the membrane of endosomal/lysosomal vesicles and synaptic vesicles (58, 59) and is 
involved in cell cytoskeleton rearrangements and consequently cell shape and 
movements during cell migration and invasion (22, 60, 61). Interestingly, it is 
reported that chlorotoxin can inhibit rat colonic enterocyte CI- channels when only 
applied to the cytoplasmic surface (62). 
	 8	
1.2.2.2 Matrix metalloproteinase-2 
MMP-2 belongs to a superfamily of zinc-dependent endopeptidases, and has been 
identified as another target for chlorotoxin (55). There are four variations of MMPs 
(MMP-1, MMP-2, MMP-3 and MMP-9), which are not normally expressed in normal 
brain cells, but they are overexpressed in tumour cells (63-65) consistent with it being 
a target for chlorotoxin. Interestingly, chlorotoxin appears to interact with MMP-2 
but not other isoforms of MMPs (55).  
 
MMP-2 is part of a lipid raft-anchored complex, which is involved in cell migration 
and invasion. The other components of this complex are membrane type-I MMP 
(MT1-MMP), a transmembrane inhibitor of metalloproteinase-2 (TIMP2), αvβ3 
integrin, and other proteins (55, 66). MT1-MMP converts MMP-2 to an active 
enzyme by proteolytic cleavage of the MMP-2 proenzyme (67-69). The MMP-2 
complex is internalized via clathrin-mediated endocytosis into cells following binding 
of chlorotoxin (38, 64). Receptor-mediated endocytosis was also observed when 
chlorotoxin was conjugated to nanoparticles (70). The interaction between 
chlorotoxin with MMP-2 decreases the surface expression of ClC-3 and potentially 
de-functionalizes ClC-3 channels (60), suggesting a pathway for how chlorotoxin can 
effectively inhibit tumour cell migration and invasion (25, 55, 61). Further 
investigation showed that after internalization of chlorotoxin, it localizes near the 
trans-Golgi in human glioma, lung carcinoma and normal vascular endothelial cells, 
while in normal human dermal fibroblast (NDHF) and astrocytes the chlorotoxin 
vesicle trafficking pattern is different and chlorotoxin is distributed throughout the 
cytoplasm (38).  
 
There is a direct relation between the high level of MMP’s expression and 
malignancy of tumours (71-73). Also, MMP-2 has a key role in migration and 
invasion of glioma cells (74). It is reported that chlorotoxin can inhibit MMP-2 via 
two main mechanisms, firstly it reduces the surface expression of active MMP-2 due 
to internalization of MMP-2 upon chlorotoxin exposure, furthermore it inhibits its 
enzymatic activity (55). Chlorotoxin can inhibit MMP-2 activation in pancreatic 
cancer cells via the same mechanism (75).  
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Although MMP-2 appears to be involved in chlorotoxin binding to tumor cells, the 
evidence on how these two molecules specifically bind is controversial (37, 55). 
Although recombinant His-CTX co-purified with MMP-2 using affinity 
chromatography (55), in another study recombinant MMP-2 did not show any 
specific binding to CTX:cy5.5 conjugates in pull down experiments (37).  
1.2.2.3 Annexin A2 
Subsequent studies have identified annexin A2 as a novel binding partner of 
chlorotoxin in multiple tumour cell lines as well as human umbilical vein endothelial 
cells (HUVEC) (39). Annexin A2 is overexpressed in several human cancers 
including high-grade glioma consistent with it being a target for chlorotoxin (39). 
Although chlorotoxin binds to HUVECs it has higher affinity for glioma cells and 
when conjugated has very high selectivity for tumour cells in in vivo assays (36, 37). 
 
Annexins are ubiquitous soluble proteins with the hallmark feature of calcium-
dependent binding to phospholipid membranes. They are important for the health of 
organisms, and the term ‘annexinopathies’ has been coined for annexin-related 
diseases (76). All known members of this protein family possess a distinctive, highly 
conserved fold (77) . This fold enables general adapter-like functions at the surface of 
phospholipid membranes (78) and confers diverse roles to these proteins including 
vesicular transport (endo- and exocytosis), and membrane attachment of the 
cytoskeleton (79). Several annexins, and in particular annexin A2, have also been 
implicated in extracellular functions (80) but always with the involvement of 
membrane surfaces. 
 
Annexin A2 is involved in a multitude of cellular signaling processes, including the 
endocytic transport and localisation of activated epidermal growth factor receptor. 
Activation of the receptor at the cell surface elicits signaling events that regulate a 
variety of cellular processes. For signal termination, the receptor needs to be 
internalized and targeted to lysosomes for degradation –a process which is regulated 
by calcium-binding proteins, including annexin A2 (79). In the context of chlorotoxin 
internalisation, the involvement of annexin A2 in early endocytosis, i.e. the formation 
and pinching off of clathrin-coated vesicles (81) is of particular interest. Structurally, 
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annexin A2 has features that are not shared by other members of this family (82). Its 
N-terminal region binds with high affinity to the small S100A10 protein (also called 
p11), a member of the S100-family of proteins (83). The annexin A2 N-terminus is 
α-helical and binds p11 only in the acetylated form. The binding of p11 modulates 
the in vitro properties of annexin A2 and probably also its in vivo function (84). 
1.2.3 Structure activity relationships of chlorotoxin  
In addition to understanding the biological target, understanding the structural 
features important for function is likely to facilitate the development of chlorotoxin as 
a therapeutic. Peptides such as chlorotoxin are well suited to structural analysis with 
NMR spectroscopy because of their small size, solubility in water and well-defined 
structures. The methods used for NMR analysis of peptides have been reviewed and 
several studies have highlighted the potential of this technique in elucidating 
structure/function relationships of peptides (85-88). 
 
There has been limited structure function studies done on chlorotoxin but there are 
related peptides that provide the opportunity to assess the natural structural and 
functional variation. Three chlorotoxin-like peptides have been reasonably well 
studied. The sequence of these peptides is compared to chlorotoxin in Table1-1. 
 
 AaCTx, a 34-residue peptide from the venom of Androctonus australis, has four 
disulfide bonds and shares 61% identity to chlorotoxin (Table 1-1). AaCTx is less 
potent at inhibiting glioma cell migration and invasion than chlorotoxin (89). BmK 
CT, a 35 amino acid peptide with four disulfide bonds and 68% amino acid identity 
to chlorotoxin was purified from the Chinese scorpion Buthus martensii Karsch 
venom. BmK CT showed similar activity to chlorotoxin regarding inhibition of 
migration and invasion of glioma cells via interaction with the MMP-2 receptor and 
blocking of ClC-3 in glioma cells (52). GaTx1 is a 34 amino acid peptide extracted 
from the venom of the scorpion Leiurus quinquestriatus hebraeus. It shares 79% 
homology sequence identity with chlorotoxin and acts on a receptor from the ATP-
binding cassette transporters (ABC) family. This receptor can act as a ClC (90).   
 
The activity of these three peptides provides insight into the structure function 
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activity particularly with AaCTx displaying lower bioactivity than chlorotoxin. 
However, further study is required to more fully understand the important structural 
features for binding to tumour cells. 
 
 
Table 1-1 The sequence alignment of chlorotoxin and selected chlorotoxin-like 
peptides. 
 
Peptide Sequence 
Chlorotoxin MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR-- 
AaCTx MCIPCFTTNPNMAAKCNACCGSRR-GSCRGPQCIC--- 
BmK CT -CGPCFTTDANMARKCRECCGGIG--KCFGPQCLCNRI 
GaTx1 -CGPCFTTDHQMEQKCAECCGGIG--KCYGPQCLCNR- 
The sequence of the chlorotoxin (19), AaCTX (89), BmK CT (52) and GaTx1 (90) 
are cited accordingly. 
 
 
A recent study has shown that the structure function relationships of chlorotoxin 
might be quite complicated. Ojeda and colleagues explored the importance of each of 
the four disulfide bonds in chlorotoxin structure and activity. Briefly, they replaced 
each cysteine pair or all of the cysteine residues with L-α-aminobutryic acid and 
found that the disulfide bonds of chlorotoxin are essential for its stability and 
structure but not for its migration inhibitory effect (24). This interesting finding 
implies that one of the individual inter-cysteine loops might play a role in the activity. 
This hypothesis will be explored in this thesis. 
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1.3 Ov-GRN-1:  A liver fluke granulin protein 
Ov-GRN-1 is a protein from the carcinogenic liver fluke Opisthorchis viverrini, 
which is one of only three known carcinogenic eukaryotic pathogens (91) and is 
classified as a group 1 carcinogen by the international agency for research on cancer 
(IARC) (92). O. viverrini transmits to humans through eating raw cyprinid fishes 
containing the metacercarial stage of O. viverrini (93) and stimulates cellular 
proliferation and tumorogenesis of cholangiocytes in bile ducts via excretory-
secretory products (ES) (91, 94, 95) that can finally lead to cholangiocarcinoma 
(CCA), bile duct cancer after 30-40 years of infection (94). CCA is invasive, highly 
metastatic with a dismal prognosis and patients die within 3-6 months of diagnosis 
(94, 96). The association between the occurrence of CCA and the presence of liver 
flukes has been known for about 50 years (97) and confirmed by WHO (98).  
 
Analysis of the ES products of O. viverrini has revealed a complex mixture of 
proteins that have been associated with cancer and cell proliferation, including 
proteases of different mechanistic classes and orthologues of mammalian growth-
factor like proteins and anti-apoptotic proteins (99, 100). Transcriptome analysis and 
the ES proteome screening have shown that a homologue of human granulin, a 
growth factor protein, exists in the ES products and it has been termed Ov-GRN-1 
(100, 101).  
 
Ov-GRN-1 plays a potential role in establishing a tumorigenic environment during 
chronic infection (99, 101) and is the first helminth-derived growth factor described 
from a pathogen to cause proliferation of mammalian cells (99, 101).  This finding 
led to the hypothesis that the natural physiological role for Ov-GRN-1 is to stimulate 
wound healing in bile duct epithelia damaged by feeding and other activities of the 
liver flukes (101, 102). Based on this hypothesis it was shown that the ES products of 
O. viverrini can accelerate the repair of wounds in cultured human cholangiocytes 
(101, 102), and wound repair is significantly diminished by silencing Ov-grn-1 gene 
expression in the fluke (101, 102). Picomolar concentrations of recombinant Ov-
GRN-1 induced angiogenesis and significantly accelerated wound repair in mice 
(101).  
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Although the exact mechanism of action of Ov-GRN-1 has not been fully determined 
several studies have provided details regarding changes in gene expression profiles. 
Investigation on Ov-GRN-1 downstream signaling pathways showed it induce gene 
expression of proteins involved in carcinogen pathway alongside with wound healing 
pathways (102). Three pathways appear to be involved. Firstly, Ov-GRN-1 
principally over expresses proteins involved in spliceosomes, endoplasmic reticulum 
(ER) protein processing and metabolic pathways (102). The main role of the 
spliceosome is splicing pre-RNA to mRNA (103). As RNA splicing has the main role 
in the epithelial-mesenchymal transition (EMT) process, Ov-GRN-1 can indirectly 
regulate EMT (102). EMT is a biological process including multiple biochemical 
changes in epithelial cells that finally lead to acquiring mesenchymal cell phenotype 
including migration and invasion capacity and resistance to apoptosis (104). 
Mesenchymal cells are involved in both wound repair and tumor metastasis but the 
mechanism is still unclear (104). Therefore, by overexpressing spliceosome proteins, 
Ov-GRN-1 can indirectly contribute to both wound healing and tumorigenesis. 
 
 Secondly, Ov-GRN-1 up regulates genes encoding proteins from the CXCL family 
of cytokines (CXCL1, 2, 5 and 8). The CXCL chemokine family has an important 
role in wound healing and angiogenesis (105, 106) and the receptor (CXCR2) for this 
family shares downstream signaling pathways with epidermal growth receptor 
(EGFR) and MAPK pathways that are the main signaling pathways for cell 
proliferation induction (107-110). Ov-GRN-1 triggers the MAPK pathway (101) 
which is consistent with the initiation of CCA in people with chronic O. viverrini 
infection [99].  
 
Thirdly, Ov-GRN-1 induces gene expression of STK11 (liver kinase B1), which is 
involved in wound healing by triggering inflammatory pathways and chemotaxis 
regulation (111, 112).  
 
The wound healing properties of Ov-GRN-1 has potential in the treatment of diabetic 
ulcers where the normal tissue repair mechanisms are overwhelmed and topical 
treatment is required for a short term. There are staggering statistics related to 
diabetes, with estimates of 280 Australians developing the disease every day and 
predictions that 3.3 million Australians will have type 2 diabetes by 2031 (113). More 
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than 8% of diabetic deaths are related to diabetic ulcers, (reviewed in (113)) making 
the need for more effective wound healing treatments of critical importance. 
 
Despite the potential of Ov-GRN-1, complications might arise in its development as a 
wound healing agent because it is difficult to produce in substantial quantities (114). 
An approach that might be effective in developing more viable wound healing agents 
based on Ov-GRN-1, involves using chemical synthesis to make truncated forms of 
the full-length protein. Minimising proteins can enhance their potential in drug design 
by improving stability and making them cheaper to manufacture (115). Furthermore, 
smaller peptides are less likely to be immunogenic than larger proteins. The 
background to the granulin family and details of the truncation studies on granulins 
are given in 1.4 and is taken from a published review on “Folding of Granulin 
Domains” (116). 
1.4 Granulins 
Granulins were initially identified in the granules of human leukocytes (117) and are 
now known to occur in a wide range of organisms (118) with examples in particular 
species of oyster (119), insects (120), parasites (101), ascidians (121), mollusks (122) 
and plants (123). They are involved in several physiological functions and disease 
processes (124, 125) such as cell growth modulatory effects (125-127), wound repair 
(114, 128), inflammation (129) and tumour growth (130-132). We have recently 
shown that a granulin from a liver fluke, and peptides engineered based on this 
protein, have potent wound healing properties in a mouse model (128). The peptides 
in particular have significant potential in the development of new therapeutics for 
wound healing in conditions such as diabetes, which is often associated with chronic 
wounds.  
 
The precursor proteins of granulins either have a single granulin domain, or multiple 
domains. The precursor protein of human granulin is progranulin (PGRN) (126), also 
known as proepithelin (133, 134), PC-cell-derived growth factor (135) and acrogranin 
(136). PGRN comprises a signal peptide and tandem repeats of seven-and-a-half 
granulin motifs in the order P-G-F-B-A-C-D-E, where P is the half-motif and A-G are 
full repeats (129, 137, 138). The full repeats have also been referred to as 1-7, in the 
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order they occur in the precursor protein, as shown in Figure 1-2A. The numerical 
nomenclature will be used in this review. The precursor protein is proteolytically 
processed by elastase into individual granulin modules, which each have masses in 
the 6 kDa range, after secretion from the cell (137, 138). PGRN has similar activities 
to granulin including roles in cellular proliferation (134), controlling embryogenesis 
(139), tissue repair (140), cancer (141, 142) and inflammation (129, 137, 143).  
 
Granulins have a conserved cysteine framework comprising four pairs of cysteine 
residues flanked by two separated cysteine residues at both the N and C terminal 
regions (129), as shown in Figure 1-2B.  
 
 
Figure 1-2 (A) The order of the granulin motifs in human PGRN. (Β) Granulin 
cysteine framework. Granulins comprise 12 cysteine residues, with four cysteine 
pairs and two separated cysteine residues at the N- and C-terminal regions. The 
disulfide bonds shown in the figure are based on the connectivity determined for carp 
granulin-1 (144).  
 
 
Despite the conserved cysteine framework, there is limited sequence conservation 
amongst the granulin family and consequently there is variation in the structures and 
biological activities. The three-dimensional structures and folding properties of 
granulins from carp, human and a liver fluke have been studied. This review provides 
an overview of these studies and the insight gained on the structure-function 
relationships for these peptides. Understanding the structure-function relationships is 
likely to useful for developing lead molecules for conditions such as wound healing. 
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1.4.1 Granulin structure  
1.4.1.1 Three-dimensional structure of carp granulin-1  
The first three-dimensional structure determined in the granulin family was of carp 
granulin-1, and used native material isolated from extracts of spleen and head kidney 
of Cyprinus carpio (144, 145). The structure, determined using NMR spectroscopy, 
comprises four β-hairpins (I-IV) that are cross-linked by six disulfide bonds resulting 
in a ladder-shaped arrangement of the disulfide bonds (144). Residues 1-11 (I), 14-28 
(II), 31-43 (III) and 46-57 (IV) are involved in forming the four β-hairpins (I-IV). 
The structures are relatively well defined with an RMSD over the backbone atoms of 
0.52 ± 0.2 Å (144). 
 
Carp granulin-1 appears to be highly stable to thermal denaturation as there were no 
changes in the NMR spectra following a heating and cooling cycle (144). This 
stability is likely to be associated with hydrophobic interactions involving the side 
chains of Val 1, His 3 and Ile 9, as well as interactions between the side chains of Ile 
2, Trp 24 and the two disulfide bridges Cys I-Cys III and Cys II-Cys V, which link 
the first two β-hairpins together (144). The side chain of Trp 24 also interacts with 
the side chains of Asp 5, Thr 8 and Leu 18, which is likely to be contributing to the 
stability (146). 
1.4.1.2  Three-dimensional structures and activities of human granulins 
The seven full-length human granulin modules (1-7) have each been expressed 
recombinantly as thioredoxin fusion proteins using an E. coli strain that promotes 
formation of disulfide bonds (147). Enterokinase was used to cleave the fusion 
proteins to yield the individual modules. The disulfide isomers present in the 
recombinant granulin modules were analysed using reversed-phase HPLC, mass 
spectrometry and NMR spectroscopy (147). Three of the seven peptides (GRN-2, 
GRN-4 and GRN-5) displayed relatively sharp peaks on HPLC and significant 
dispersion in the amide region of NMR spectra. By contrast GRN-3 and GRN-7 did 
not display significant dispersion in the NMR spectra, indicating a lack of well-
defined structure. The fractions from GRN-1 and GRN-6 were not spectrally 
homogeneous. GRN-1 contains only ten cysteine residues rather than the twelve 
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present in the majority of granulins (147). It would be of interest to further 
characterize the folding of this peptide to determine the influence of a reduced 
number of disulfide bonds on structure.  
 
Given the significant dispersion in the amide region for GRN-2, GRN-4 and GRN-5, 
isomers were purified by RP-HPLC and analysed using two-dimensional NMR 
spectroscopy (147). A single peak from GRN-4 was purified, whereas two peaks 
were purified for GRN-5 and GRN-2. All of the purified forms were full-length, with 
the exception of one of the fractions from GRN-2, which had a molecular weight of 
approximately half that of the full-length peptide (147). The GRN-5 peaks had the 
same mass and appeared to be different disulfide bond isomers. Analysis of the NOEs 
(Nuclear Overhauser Enhancement) in the NMR data indicated that Cys I-Cys III and 
Cys II-Cys V formed disulfide bonds in GRN-2, GRN-4 and GRN-5, consistent with 
the carp granulin-1 structure, but did not allow definitive elucidation of the other 
disulfide bonds. Similarly, proteolytic cleavage and partial reduction approaches did 
not provide evidence for the complete disulfide connectivity (147).  
 
The three-dimensional structures of GRN-2, GRN-4 and GRN-5 were determined 
using the disulfide connectivity elucidated for carp granulin-1 and indicated the 
presence of two well-defined β-hairpins in the N-terminal region but the C-terminal 
regions were more disordered (147). Despite the well-defined N-terminal region, the 
first hairpin was less well defined than the second hairpin (147). The three-
dimensional structure of GRN-4 is shown in Figure 1-3, highlighting the well-defined 
N-terminal region in contrast to the C-terminal region. The root mean square 
deviation (RMSD) for GRN-4 is 7.0 ± 1.9 Å over the backbone atoms, which is 
significantly higher than that observed for carp granulin-1, highlighting the disorder 
present in the C-terminal region of GRN-4.  
 
In addition to the structural variation, there was also significant variation in the 
bioactivity of the GRN peptides. GRN-4 displayed inhibition of the growth of a 
breast cancer cell line, whereas GRN-2 showed stimulatory activity (147). The poorly 
folded isomers, which were present in GRN-1, GRN-3, GRN-6 and GRN-7, generally 
had weak activity (148). The differences in structure and activity across the human 
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granulin peptides indicate that the sequence diversity has a significant impact on the 
structure-function relationships. The role of the disulfide bonds in structure and 
activity has been further evaluated for GRN-3 using experimental and computational 
approaches (148, 149). Structural analysis of fully reduced GRN-3 indicated the 
peptide was disordered (149).  
 
 
 
Figure 1-3 Three-dimensional structure of full-length human GRN-4. (A) An 
overlay of the ten lowest energy structures of full-length GRN-4 (PDB code 2JYE). 
The disulfide bonds are shown in red. (B) Ribbon representation of the secondary 
structure present in a single structure of GRN-4 (PDB code 2JYE).  
 
 
This is perhaps not surprising given the role of disulfide bonds in stabilizing the 
structures of small peptides. Intriguingly though, the fully reduced GRN-3 had 
biological activity, as it was able to trigger an inflammatory response in SY-SH5Y 
human neuroblastoma cells by activation of NF-κB, in a dose dependent manner 
(149). It appears a well-defined structure is not necessary for this bioactivity, but 
further study on the structure-function relationships are required to understand the 
important structural features. 
 
Computational analysis of the structures of PGRN and the human granulin domains 
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indicates the presence of disorder, and in particular there appears to be disorder 
between the granulin domains (148). It has been suggested that this disorder is 
associated with facilitating the cleavage of the granulin domains from the precursor 
protein (148). In addition, it has been suggested that the predicted disordered regions 
surrounding individual GRNs in PGRN could provide a binding site for specific 
protein disulfide isomerases to impart correct disulfide bonding in PGRN (148). 
Highly flexible/disordered regions have also been suggested to be involved in the 
multi-functionality of granulin modules, since the plasticity in disordered 
conformations can facilitate interaction with other proteins (148). 
 
GRN-3 showed the greatest disorder in the computational analysis (148) , consistent 
with the original study by Ghag et al, 2016 which showed that GRN-3 had limited 
dispersion in the amide region of the NMR spectra (149). However, the disorder 
predicted by the computational analysis in the Ghag et al, 2017 study was not 
unequivocally confirmed by experimental analysis, as the circular dichroism (CD) 
spectroscopy and NMR data were inconsistent (148). The CD data indicated a lack of 
structure whereas the NMR data showed the oxidized peptide was more structured 
than the fully reduced peptide (148). Although there is evidence that GRN-3 might 
not be well structured in solution, it was shown to be highly thermally stable (146, 
150). The interplay between structure and stability is unclear in this case, but an 
experimental structure, not presently available, is likely to provide insight into the 
disorder/flexibility present in GRN-3. 
1.4.2  Truncation of granulin peptides 
1.4.2.1  Carp granulin-1 
Following on from the elucidation of the three-dimensional structure of carp 
granulin-1, its folding has been explored to determine if the N-terminal region can 
fold independently. The rational for these studies was based on the N-terminal region 
of carp granulin-1 resembling a disulfide β-cross motif and the two hydrophobic 
clusters that appear to stabilize the first two β-hairpins (146).  
 
A 30-residue peptide corresponding to the N-terminal fragment of the carp granulin 
protein (CG1 1-30) with Cys IV and Cys VI, the disulfide connecting the N-terminal 
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to the C-terminal domain of the full-length protein, replaced with serine residues has 
been chemically synthesised (see Figure 1-4A) (151). The peptide was oxidized in a 
single step reaction to form two disulfide bonds and, based on NMR and mass 
spectrometry data, the disulfide bond connectivity was determined to be Cys I-Cys III 
and Cys II-Cys V, and is identical to full-length carp granulin-1. The three-
dimensional structure is also consistent with the structure present in the full-length 
protein, as CG1 1-30 contains two β-hairpins as shown in Figure 1-4(B-C). These 
results indicate that the N-terminal region of carp granulin-1 can fold independently, 
and that only two disulfide bonds are required to allow formation of the native-like 
structure (151). 
 
A smaller peptide, termed CG1 3-30 and corresponding to residues 3-30 of carp 
granulin-1, has also been synthesised and structurally characterised (151). A 
comparison of the Cα, Cβ and Hα chemical shifts of CG1 1-30 and CG1 3-30 showed 
significant differences in the N-terminal region of the two peptides (151). Consistent 
with the observed chemical shift differences, the structures also differ with CG1 3-30 
only containing one β-hairpin in contrast to the two β-hairpins of CG1 1-30 (Figure 
1-4D-E). Furthermore, the structures of CG1 3-30 are less well defined than the CG1 
1-30 structures. The structural differences are thought to result from differences in the 
hydrophobic interactions present in the two peptides. The first two residues in CG1 1-
30 are involved in hydrophobic clusters and it appears that these residues have a 
critical role in folding (151). 
 
The lack of structural definition for the first β-hairpin in CG1 3-30 was consistent 
with the lack of slowly exchange amide protons observed for residues 1-14, indicating 
that this region is not stabilized by hydrogen bonds (151). In contrast, H/D exchange 
experiments indicated the presence of a number of slowly exchanging amide protons 
for residues 15-25 that correspond to the second β-hairpin region in CG 1-30 (151). 
Therefore, it is likely that this region is stabilized by hydrogen bonds, as expected for 
β-sheet structure (151).  
 
Overall, the analysis of the truncated carp granuln-1 peptides suggested that although 
the N-terminal region can fold independently with only two disulfide bonds, 
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removing the first two residues prevents formation of the first β-hairpin, most likely 
as a result of disrupting hydrophobic interactions (151). Consequently, it appears that 
the disulfide bonds alone are not sufficient for the conformational stability of the β-
hairpin stack in carp granulin-1 N-terminal truncated peptides.  
 
 
 
Figure 1-4 Sequence and three-dimensional structure of truncated carp 
granulin-1.  (A) Sequences of N-terminal truncated analogues of carp granulin-1 
from residues 1-30 and 3-30. Cys IV and Cys VI were replaced with serine residues; 
the cysteines are highlighted in red, and the substitutions are in bold letters. (Β) 
Superposition of the ten lowest energy structures of CG1 1-30 (PDB code 1I8X) over 
the backbone atoms. (C) The ribbon representation of the secondary structure present 
in CG1 1-30. (D) Superposition of the ten lowest energy structure of CG1 3-30 (PDB 
code 1I8Y). (E) The ribbon representation of the secondary structure present in CG1 
3-30. Figure generated using MOLMOL (152). 
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1.4.2.2 Truncation of a human granulin – GRN-4  
As mentioned in section 1.4.1.2, full length human GRN-4 has a β-hairpin structure 
similar to the N-terminus of carp granulin-1, but significant structural disorder in the 
C-terminal region (147). However, the amino-terminal domain of GRN-4 has a 
distinctly more flexible conformation in solution than its carp granulin-1 homologue 
as a consequence of low sequence identity  (50%) (146, 147). GRN-4 lacks several 
hydrophobic and turn-stabilizing residues that are predicted to contribute to the 
conformational stability of carp granulin-1 and its N-terminal subdomain (153).  
 
Based on the structural differences between GRN-4 and carp granulin-1, truncated, 
hybrid GRN-4 peptides have been designed and synthesized (153). These truncated 
peptides included incorporation of the hydrophobic cap of carp granulin-1 into GRN-
4 by replacing residues Asp 1, Lys 3 and Ser 9 with the corresponding residues, Val 
1, His 3, and Ile 9, and replacement of Gln 20 of GRN-4 with Pro 20, the 
corresponding residue in carp granulin-1 as shown in Figure 1-5A (153). The latter 
change was made in an attempt to stabilise the β-turn linking the two antiparallel 
strands of the second β-hairpin (153).  
 
Disulfide bond mapping and proteolytic digestion experiments showed that the 
disulfide bond pairing in the hybrid peptides was identical to that found in carp 
granulin-1 N-terminal fragment (146, 153).  Despite containing the native-like 
disulfide connectivity, the majority of the hybrid peptides did not display the regular 
secondary structure present in the native peptide. Only the hybrid peptide that 
incorporated the hydrophobic cap with Pro 20 resulted in a well-defined structure 
similar to the carp granulin-1 truncated peptide, as shown in Figure 1-5B (153). 
These findings emphasize that both hydrophobic and turn-stabilizing interactions are 
important for deriving the correct disulfide pairing alongside the structural integrity 
of the stack of two β-hairpins in GRN-4. 
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Figure 1-5 (A) The sequence of the 30-residue amino terminal sub-domain of 
GRN-4.  Residues D1, K3, S9 and Q20 were replaced with V1, H3, I9 and P20, 
respectively, in the hybrid peptide. The SH groups of Cys IV and Cys VI were 
protected by S-acetamidomethyl in the hybrid peptide. (B) Three-dimensional 
structure of hybrid truncated GRN-4 peptide (PDB code 1G26). The side chains of 
replaced amino acids are highlighted. The Cys IV and Cys VI ACM protecting 
groups were left unmodified. Figure generated using MOLMOL (152).  
 
 
1.4.2.3 Truncation of human progranulin 
Truncation studies have also been carried out on human PGRN. An engineered 
protein, termed Atsttrin, has been recombinantly expressed in bacteria containing 
partial segments of GRN 2, 4 and 5 and linker regions between the segments (154). 
The full-length protein exerts anti-inflammatory effects via binding to tumor necrosis 
factor receptors (TNFRs) and inhibits the TNFα-TNFR interaction (154). Although 
this interaction has been questioned it has been confirmed by several groups (155). 
PGRN has been reported to have potential for treating TNFα-mediated pathologies 
and conditions such as rheumatoid arthritis (154-156). Interestingly, Atsttrin showed 
even better anti-inflammatory effects with higher binding affinity to TNFR and a 
longer half-life (~120 hours) compared to PGRN (~40 hours) (154).  
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The PGRN-TNFR interaction appears to be highly dependent on PGRN folding, as 
the PGRN-TNFR interaction was abolished by treating PGRN with the reducing 
agent DTT (157). Given that Atsttrin also has anti-inflammatory activity suggests that 
it is folded in a similar way but no three-dimensional structural data has been 
reported. Atsttrin contains an uneven number of cysteine residues (17) suggesting that 
the oxidative folding could be complicated. This complexity appears to be reflected 
in the purification, as the reverse phase HPLC trace of Atsttrin varies among batches 
from the same expression clone and consequently, variable bioactivity results were 
observed (157, 158). It is of interest to determine the disulfide bond connectivity in 
Atsttrin to provide insight into the structure-function relationships of this complex 
truncated form of human progranulin.  
1.4.2.4 The liver fluke granulin Ov-GRN-1  
The parasitic liver-fluke granulin, Ov-GRN-1, isolated from the ES products of the 
carcinogenic flatworm liver fluke Opisthorchis viverrini has significant sequence 
differences to human granulins (114, 128). The full-length Ov-GRN-1 structure has 
not yet been determined due to the difficulty in generating sufficient quantities of 
recombinant refolded protein (128). However, recent synthesis and characterization 
of a series of truncated analogues from the N-terminal region of the full-length 
protein has provided insight into the structure of the full-length Ov-GRN-1 protein 
(128). 
 
Three analogues were synthesized from the N-terminal region of the full-length Ov-
GRN-1 protein, comprising four cysteine residues as shown in Figure 1-6A. Cys IV 
and Cys VI (where present) were replaced with alanine residues. The peptides were 
synthesized using selective protection of the cysteine residues to form the two native-
like disulfide bonds (Cys I-Cys III, Cys II-Cys V) (128).  
 
The activities of the truncated Ov-GRN-1 peptides were tested in a cell proliferation 
assay and a mouse wound healing model (128). The most active peptide in the cell 
assay was the three-disulfide bond-containing peptide. Interestingly, a truncated 
version of carp granulin-1 was not active in this cell assay, again highlighting the 
importance of sequence in the bioactivity of granulins (159).  
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Figure 1-6 Sequence and three-dimensional structures of the liver fluke Ov-
GRN-1 truncated analogues. (A) Sequences show Cys IV and Cys VI were replaced 
with alanine residues; the cysteines are highlighted in red, and the substitutions are in 
bold letters. (B) The structures of Ov-GRN12-34 (PDB code 5UJH) and (C) Ov-GRN12-
35_3s (PDB code 5UJG) in ribbon format showing the secondary structure present in 
two of the Ov-GRN-1 truncated analogues. Figure generated using MOLMOL (152). 
 
 
All of the Ov-GRN-1 peptides were found to significantly improve the rate of wound 
healing in the mouse wound healing model at similar potency to the full-length 
protein (128). There was no significant difference in the potency of the peptides in 
the mouse model (128). Furthermore, the peptides also had similar bioactivity to 
Regranex, a form of recombinant platelet-derived growth factor currently used in the 
clinic for treating wounds (160, 161). This finding highlight the potential of the 
granulin peptides in the development of novel wound healing agents. This potential is 
based in part on the ease of synthesis of these peptides (compared to recombinant 
growth factors) and their stability, which is likely to facilitate the delivery methods. 
The comparable bioactivities of Ov-GRN-1 peptides and the full-length protein, 
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despite the differences in structure, indicates that the precise structure is not critical 
for the bioactivity. 
1.4.3 Related proteins – from plants to cone snails 
The β-stack structure present in N-terminal region of granulins has also been found in 
other proteins including in the C-termini of some plant cysteine proteases (123). The 
C-terminal region of these plant proteases have a similar cysteine pattern to granulin 
but otherwise there is limited sequence similarity (123). A peptide derived from rice 
oryzain β has been synthesized and the structure determined using NMR 
spectroscopy (123). The region synthesized is similar in size to the truncated carp 
granulin-1 and has the cysteine residues equivalent to Cys IV and VI in the granulins 
replaced with serine residues, to prevent formation of a non-native disulfide bond 
(123). This peptide formed the Cys I-Cys III and Cys II-Cys V connectivity present in 
the granulins and displayed the β-stack structure as shown in Figure 1-7A. The 
structural similarity with carp granulin-1 and the independent folding of this 
structural motif in a plant cysteine protease suggests that this motif could be 
conserved across a wide range of proteins.  
 
Chemical shift analysis of the two-disulfide bond-containing Ov-GRN-1 peptides 
indicated a lack of β-sheet structure, which was confirmed by determination of the 
three-dimensional structures as shown for one of the analogues in Figure 1-6B (128). 
By contrast, the three-dimensional structure of the three-disulfide bond peptide has a 
β-hairpin similar to that present in the truncated form of carp granulin-1 (Figure 1-4 
D-E). In addition to the two native-like disulfide bonds (Cys I-Cys III, Cys II-Cys V), 
this peptide also contains a non-native bond between Cys IV and Cys VI, which 
appears to stabilize the β-hairpin structure (128).  
 
In support of the hypothesis that the granulin structure might be wide spread, a 
peptide was recently found in cone snail venom with structural similarity to the N-
terminal region of granulins. The peptide, MiXXVIIA, contains 33 residues, 
including eight cysteine residues, but does not have the same cysteine framework or 
any sequence homology as the granulins (162). However, following determination of 
the structure of MiXXVIIA a database search indicated structural similarity with the 
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N- terminal region of human granulin-4, as shown in Figure 1-7B. Based on this 
structural similarity the cell proliferation activity of MiXXVIIA was explored and 
was found to promote cell proliferation, albeit at lower potency to Ov-GRN-1 (128, 
162). Cell proliferation effects are unusual for cone snail venom peptides as the 
majority of these peptides target ion channels or receptors (163). Therefore, the 
unexpected finding of structural similarity between granulins and a venom peptide 
led to the discovery of unexpected bioactivity. It should be noted that it appears 
unlikely that the function of MiXXVIIA in the venom is related to the cell 
proliferation activity, but no other bioactivity has yet been found for this peptide. 
 
 
 
Figure 1-7 Three-dimensional structures of peptides with granulin-like 
structures.  (A) A region from the rice oryzain β (PDB code 1FWO). (B) Structure 
of the conotoxin MiXXVIIA showing the two β-hairpins, which are cross linked by 
two disulfide bonds shown in red. Figure generated using MOLMOL (152). 
 
 
1.4.4 Conclusions 
The biological functions of granulins are varied and their structure-function 
relationships are complex. Although only a limited number of granulin structures 
have been determined, they show significant diversity. The N-terminal region appears 
to be well defined in several granulins, but the hybrid studies on GRN-4 and carp 
granulin-1 have shown the important role that the N-terminal residues play in the 
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formation of structure (128, 153). The differences in the N-terminal sequences might 
explain, in part, the fact that some of the human granulins did not fold into well-
defined structures (147). 
 
To date, only carp granulin-1 displays a well-defined C-terminal region (144). The 
lack of definition in the C-terminal region of human granulins prevented the 
definitive elucidation of the disulfide connectivity (147). It should be noted that the 
carp granulin-1 structure is the only structure that has been determined from native 
material and it is possible that the recombinant peptides are different to those present 
in the native protein. Nonetheless, the lack of certainly in the connectivity of human 
granulins, along with the non-native disulfide bond in Ov-GRN-1(128), which 
apparently stabilizes the β-hairpin structure, poses the intriguing question of whether 
the disulfide connectivity is conserved throughout the granulin family.  
The differences in the activities of the human granulins, even for peptides that 
displayed similar, well-defined conformations, illustrates that it is not clear what 
effect (if any) structure has on bioactivity. Further structure-function studies are 
required to enhance our understanding of the roles that structural elements in 
granulins play in different functions, and potentially provide insight into their 
mechanism of action. 
1.5 Scope of the thesis 
This thesis entitled “Structure-function relationships of disulfide-rich peptides” 
focused on two peptides: Chlorotoxin and Ov-GRN-1. The overall aim was to provide 
insight into the important features for bioactivity for these interesting disulfide-rich 
peptides and whether this information could be used to design novel drug leads. The 
majority of the chapters are based on published manuscripts or manuscripts to be 
published, therefore each of the experimental chapters comprise all s including a 
separate introduction and references. 
 
Chapter 1 provides a background to the two major components of this work and 
highlights the significance of the studies. Section 1.4 from Chapter 1 has been 
published with the title of “Folding of Granulin Domains” in the Journal of Peptide 
Science (116). 
	 29	
 
Chapter 2 expands the knowledge of the structure-function relationships of the 
scorpion venom peptide, chlorotoxin. It is generally believed that disulfide bonds 
have an important role in both the structure and function of disulfide rich peptides. 
However, reduced chlorotoxin still has some bioactivity and this chapter explored the 
hypothesis that a small, unstructured region of chlorotoxin might be contributing to 
this bioactivity. This study has been published in the Journal of Frontiers in 
Pharmacology (164). 
 
Chapters 3-5 focused on elucidation of the structure function relationships and 
potential of truncated versions of Ov-GRN-1, as the low yield in recombinant 
expression limits its potential of the full-length protein as a drug lead. Chapter 3 
focused on downsizing Ov-GRN-1 and investigating the folding, structure and 
bioactivity features of the minimized analogues. Ultimately, Ov-GRN-1 was 
successfully tailored into a 24-residue peptide, Ov-GRN12-35_3s, and the outcome was 
published in the Journal of Medicinal Chemistry (128).  
 
Moving forward to further optimize the truncated Ov-GRN-1 peptides, Chapter 4 
investigated the role of proline residues in adopting multiple conformations, folding 
yield and the structure of Ov-GRN12-35_3s. This study, published in Journal of 
Medicinal Chemistry, led to identification of a more potent analogue, GRNP4A, which 
surpasses the currently available biologic product in the market for healing diabetic 
ulcers, Regranex  (165).  
 
Chapter 5 focused on expanding the knowledge of structure-function relationships of 
granulins.  In particular, determining whether the folding properties evident for the N-
terminal region of Ov-GRN-1 are unique to this parasite protein, and whether the C-
terminal region can also fold independently and have bioactivity. This study is being 
prepared for publication. 
 
Chapter 6 provides a summary of the findings from this thesis as well as the gaps in 
the knowledge in these fields and the future directions that could be taken. 
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2.1 Abstract  
Chlorotoxin was originally isolated from the venom of the Israeli scorpion Leiurus 
quinquestriatus, and has potential as a tumour imaging agent based on its selective 
binding to tumour cells. Several targets have been suggested for chlorotoxin including 
voltage-gated chloride channels, and it has been shown to have anti-angiogenic 
activity and inhibit cell migration. The structure of chlorotoxin is stabilized by four 
disulfide bonds and contains β-sheet and helical structure. Interestingly, the reduced 
form has previously been shown to inhibit cell migration to the same extent as the 
wild type, but structural analysis indicates that the reduced form of the peptide does 
not maintain the native secondary structure and appears unstructured in solution. This 
lack of structure suggests that a short stretch of amino acids might be responsible for 
the bioactivity. To explore this hypothesis we have synthesised fragments of 
chlorotoxin without disulfide bonds. As expected for such small peptides, NMR 
analysis indicated that the peptides were unstructured in solution. However, the 
peptide corresponding to the eight C-terminal residues, inhibited cell migration, in 
contrast to the other fragments. Our results suggest that the C-terminal region plays a 
critical role in the bioactivity of chlorotoxin. 
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2.2 Introduction  
One of the most well studied scorpion venom peptides is chlorotoxin (CTX), which 
was originally purified from the venom of the Israeli scorpion Leiurus quinquestriatus 
(1). Chlorotoxin contains 36 amino acids with four disulfide bonds at the core of its 
well-defined structure. The tertiary structure, as shown in Figure 2-1, comprises a β-
hairpin and an α-helix (2, 3). The disulfide connectivity is CI–CIV, CII–CVI, CIII–CVII 
and CV–CVIII (Figure 2- 1). 
 
		
Figure 2-1 Schematic three-dimensional structure of chlorotoxin (PDB code 
5L1C). Each structural element represents the four fragments and are color coded. 
The sequences for the fragments are given below the structure.  
 
 
Chlorotoxin selectively binds to glioma cells and other embryologically related cells 
and derived tumors of neuroectodermal origin (4, 5).  In contrast, more than fifteen 
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normal human tissues have been shown to be negative for chlorotoxin binding (5). 
The selective binding of chlorotoxin to tumor cells bodes well for its application in 
cancer therapy as a tumor optical imaging contrast agent, particularly for brain cancer 
(6-10). Radiolabeled chlorotoxin successfully passed human clinical trial phases I and 
II (11-13) and FDA approval has been granted to progress to phase III, under the 
name TM-601 (14).   
 
Chlorotoxin is known to inhibit migration and invasion of tumor cells through 
mechanisms that potentially involve multiple pathways (4, 5, 8, 15). The molecular 
targets identified for chlorotoxin are all involved in malignant cell migration and 
invasion, including voltage-gated chloride channels (ClC-3), annexin-2 and matrix 
metalloproteinase-2 (MMP-2) (16-19). It has been shown chlorotoxin can effectively 
block the ClC-3 voltage-gated chloride channel (1, 20), which is selectively expressed 
in glioma cells, (17, 21, 22). ClC-3 is involved in cell cytoskeleton rearrangements 
and consequently cell shape and movements during cell migration (4, 23, 24). 
Furthermore, it has been shown that chlorotoxin also interacts with a cell surface 
protein complex composed of MMP-2, membrane type-I MMP (MT1-MMP), a 
transmembrane inhibitor of metalloproteinase-2, αvβ3 integrin, and other proteins (18, 
25, 26). 
 
Direct binding of chlorotoxin with molecular targets has not been experimentally 
characterized but a recent computational study predicted the binding of chlorotoxin 
with MMP-2 (27). The model proposed in this study suggests that the β-sheet of 
chlorotoxin interacts in a region between the collagen binding domain and catalytic 
domain of the MMP-2, whereas the α-helix of chlorotoxin does not appear to be 
involved in the interaction (27).  
  
The three-dimensional structure of disulfide-rich toxins, such as the scorpion venom 
peptides leiurotoxin-I and charybdotoxin (28, 29), is generally critical for bioactivity. 
However, a recent study suggests this is not the case for chlorotoxin. A reduced form 
of chlorotoxin, with the cysteine residues mutated to aminobutyric acid, maintains 
inhibitory effects on HUVEC cell migration compared to the wild-type peptide, but 
does not have regular secondary structure (8). This lack of structure suggests that a 
	 47	
short stretch of amino acids might be responsible for the bioactivity. Determining the 
minimal sequence of chlorotoxin with bioactivity is likely to enhance the 
understanding of the structure-function relationships. We have synthesised four 
fragments of chlorotoxin, containing 7-11 residues, with the cysteine residues 
replaced with alanine residues to prevent disulfide bond formation, and analysed the 
structure, in vitro binding and bioactivity.  
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2.3 Experimental section 
2.3.1 Peptide synthesis, purification and characterization 
Chlorotoxin (CTX) was purchased from Iris Biotech GmbH (Marktredwitz, 
Germany). Chlorotoxin fragments were chemically synthesised using standard 
stepwise Fmoc solid-phase peptide synthesis methods on the rink amide resin 
(Anaspec, Fremont, CA, USA) using an automated PS3 bench top peptide synthesiser 
(Protein Technologies, Tuscon, AZ, USA). Peptides were deprotected and cleaved 
from the resin using the following cleavage cocktail: 95%TFA:2.5%TIPS:2.5%H2O 
(v/v/v). The peptide was then precipitated and washed several times with cold diethyl 
ether, dissolved in 50% acetonitrile:50% H2O, lyophilised and stored as lyophilized 
powder. Crude peptide mixtures were purified by reversed-phase HPLC (RP-HPLC) 
on a C18 preparative column (Phenomenex Jupiter 250 x 21.2 mm, 10 µm, 300 Å). 
The peptides were eluted with a 1% gradient from 1% to 60% of solvent Β in solvent 
A over 60 min at the flow rate of 5 ml/min (Solvent A: 0.05%TFA/water, Solvent B: 
0.05% TFA in 90% acetonitrile/water). The purified fractions were characterised by a 
SCIEX 5800 MALDI TOF/TOF mass spectrometer (SCIEX, Foster city, CA, USA).  
2.3.2 NMR spectroscopy and structure analysis 
Samples were prepared from lyophilised peptides at a concentration of 0.2 mM in 
90%H2O:10%D2O with 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) as a 
reference. All NMR spectra were recorded on a 600 MHz AVANCE III NMR 
spectrometer (Bruker, Karlsruhe, Germany). 2D 1H-1H TOCSY, 1H-1H NOESY, 1H-
15N HSQC, and 1H-13C HSQC spectra were collected at 290 K and used for amino 
acid assignment. All spectra were recorded with an interscan delay of 1 s. NOESY 
spectra were acquired with mixing times of 200 ms, and TOCSY spectra were 
acquired with isotropic mixing periods of 80 ms. All spectra were assigned using 
CCPNMR (30) based on the approach described by Wüthrich (31) . 
2.3.3 Serum stability assay 
 The serum stability of the peptides was tested using human male serum (Sigma, 
USA), as previously described (32). All peptides were tested at a final concentration 
of 6.6 µM after dilution from a stock solution at 200 µM. The serum was centrifuged 
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at 17000 g for 10 min to remove the lipid component, and the supernatant was 
incubated at 37°C for 15 min before the assay. Each peptide was incubated in serum 
or phosphate-buffered saline (PBS) at 37°C, and 40 µL triplicate aliquots were taken 
at 0 h, 3 h, 8 h, and 24 h. The aliquots of serum were quenched with 40 µL of 6 M 
urea and incubated for 10 min at 4°C. Then, each aliquot was quenched with 40 µL of 
20% trichloroacetic acid (TCA) and incubated for another 10 min at 4°C to precipitate 
serum proteins. Finally, samples were centrifuged at 17000 g for 10 min, and 90 µL 
of the supernatant was analysed on Reverse Phase HPLC using a Phenomenex Jupiter 
Proteo C12 analytical column (150 x 2.00 mm, 4 µm, 90 Å; Phenomenex, Torrance, 
CA, USA) and a linear gradient of solvent B (90% acetonitrile/10% H2O, 0.045% 
trifluoroacetic acid (TFA)) at a flow rate of 0.4 mL/min using an Agilent 1260 
Infinity system (Agilent Technologies, Hanover, Germany). The control samples 
contained equivalent amounts of the peptides in PBS and subjected to the same 
treatment procedure. The percentage recovery of peptides was detected by a 
wavelength UV detector set to 214 nm. 
 
The stability at each time point was calculated as the area of the serum-treated peptide 
peak on the RP-HPLC at 214 nm as a percentage of the area of zero hour serum-
treated peptides (33). 
2.3.4 Mammalian cell culture 
The U-87 MG (ATCC® HTB-14), human primary glioblastoma astrocytoma cell line was 
grown and maintained in modified Minimum Essential Medium (MEM) (Life 
Technologies) at 37°C and 5% CO2. The growth medium was supplemented to a final 
concentration of 10% fetal bovine serum (FBS) (Gibco, Scotland), 15 mM HEPES, 1x 
penicillin-streptomycin solution, 1 mM sodium pyruvate and 2 mM L-glutamine. 
 
The 1BR.3.GN (ECACC 90020509), human skin normal fibroblast cell line was 
purchased from the European Collection of Authenticated Cell Cultures (ECACC). 
1BR.3.GN cells were grown and maintained in DMEM/F12 (Life Technologies, 
Australia) containing 1× GlutaMAX, 1x penicillin-streptomycin solution, and 
supplemented with FBS at 37°C and 5% CO2.  
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2.3.5 Cytotoxicity assay 
The 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)2H-tetrazolium-5-carboxanilide (XTT) 
colorimetry assay was performed to determine whether chlorotoxin at the applied 
concentration was toxic to the U-87 cell line (34). Cells were seeded in 96-well 
microplates (7.5 ×103 cells/well) and incubated at 37°C for 24 h. The culture media 
were then replaced with 150µL of treatment at two final concentrations of 5 and 60 
µM. The treatment were in either media supplemented with 10% FBS or media 
supplemented with 0.5% FBS, 1x ITS-G and 1% BSA. DMSO (50% v/v) was used as 
a control for cell death (35). Cells then were incubated at 37°C for 24 h. The media 
was removed after 24 hours and the cells were incubated with 50 µL XTT (1.0 mg/ml 
in media without phenol red and 0.025 mM phenazine methosulfate (Sigma, USA)) 
for 3.5 hour. Absorbance (A) was measured at 450 nm wavelength, 650 nm used as 
reference wavelength in a plate reader (Polarstar Optima, Germany). Cell viability 
was calculated as percentage of control cells using the equation: (A450 − A650) of 
treated cells × 100 / (A450 − A650) of control cells. 
 
The experiments were repeated three times in pentaplicates and statistical significance 
of the observed difference was determined using one-way ANOVA with Dunnett’s 
multiple comparison tests using the GraphPad Prism v7 software (GraphPad Software 
Inc., USA). 
2.3.6 Peptide biotinylation  
Chlorotoxin fragments were biotinylated on the resin to be detected by streptavidin-
APC for the binding assay according to the following protocol. The assembled 
peptide on the resin (0.1 mmol) was washed with DMF. Biotin (Sigma, USA) was 
coupled to the N-terminal amide using HCTU/DIPEA activation in DMSO:DMF 
(1:1), overnight. The resin was washed with DMSO:DMF (1:1) twice to remove 
excess biotin and washed  further with DMF (2x) and DCM (2x) and allowed to dry 
before proceeding to cleavage step. The biotinylated peptide was cleaved from the 
resin as previously mentioned. The mono-labelled peptides were then purified using 
preparative RP-HPLC and characterised using a SCIEX 5800 MALDI TOF/TOF 
mass spectrometer (SCIEX, Foster City, CA, USA) and analytical RP-HPLC.  
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The chlorotoxin biotinylation was performed as described previously (36). Briefly, 
1mg/ml chlorotoxin (Iris, Germany) solution was prepared in phosphate buffer (pH 
8.0) and incubated with 27.5 µl of 10 mM NHS-Biotin (Sigma, USA) in DMSO (10 
molar excess). The final concentration of the organic solvent was kept <20% in the 
reaction buffer. After 6 h incubation at room temperature, excess biotin was removed 
by passing the reaction solution through Phenomenex Strata C8 unit (55 µm, 70 A°). 
The collected sample was characterized using TripleTOF® 6600 Quadrupole Time-
Of-Flight (QTOF) mass analyser (SCIEX, Foster City, CA, USA) and analytical RP-
HPLC.  
2.3.7 Cell surface binding and internalization assay  
Flow cytometric analysis was performed to investigate binding of chlorotoxin and 
fragments to U-87 MG and 1BR.3.GN cells. For cell surface binding analysis, cells 
were detached from adherent culture using StemProTM AccutaseTM Cell Dissociation 
reagents (Gibco, USA), washed and resuspended in media supplemented with 0.5% 
FBS, 1x ITS-G and 0.1% BSA. After adjusting the cell density to 106 cells per mL, 
100 µL of the cell suspension was placed in round-bottom 96-well plate. For each 
concentration of chlorotoxin and fragments duplicate wells received treatments of 
either 5 or 50 µM chlorotoxin or chlorotoxin fragments for 30 min at 4°C. 
Biotinylated anti-mouse/human CD44 antibody (BioLegend) was used as control 
positive in all sets of experiments (37).  
 
Following the incubation cells were washed three times with PBS and centrifuged at 
400 g for 3 min to remove the unbound peptides. APC-conjugated streptavidin (BD 
Pharmingen, USA) was added at a concentration of 6.5 µg/mL to each well and 
incubated for further 30 min on ice. Incubation was followed by two further washes in 
PBS and stained cells were then analysed on a BD FACS Canto II flow cytometer 
(BD Bioscience, USA). Data analysis was performed using FlowJo software (Tree 
Star, v. 8.8.4.).  
 
To investigate whether chlorotoxin fragments internalize into cells via the same 
thermodynamic pathway as chlorotoxin, cells were incubated with chlorotoxin 
fragments at a concentration of 50 µM in 0.5% media supplemented with 1x ITS-G 
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and 0.1% BSA for 30 min at 37°C, with 5% CO2. Then cells were washed with PBS 
and fixed using 1x fixation/permeabilization buffer (eBioscience, USA). Cells were 
washed and permeabilized using 1x permeabilization buffer (eBioscience, USA) for 
10 min. Cells then were stained with APC-streptavidin at 4°C for 30 min. Samples 
were washed twice with PBS and subsequently analysed on BD FACS Canto II flow 
cytometer (BD Bioscience, USA) and data were analysed as described above. 
2.3.8 Cell migration/invasion assay 
Migration assays were performed using CytoSelect cell migration assay kit (8 µm, 
Fluorometric format, Cell Biolabs, USA) according to the manufacturer's instructions. 
Briefly, cells were serum-starved overnight, then harvested using StemProTM 
AccutaseTM Cell Dissociation reagents and resuspended in media supplemented with 
1x ITS-G and 1% BSA at 106 cells/ml. Aliquots of 100 µL of cells were then pre-
incubated with chlorotoxin or fragments (at two concentrations of 5 and 50 µM) for 
30 min at room temperature. Then cells were added to the each insert (upper 
chamber), and 150 µL media supplemented with or without 10% FBS 
(chemoattractants) was added to each well (lower chamber). The plate was incubated 
at 37°C for 16 h to allow cell migration through the polycarbonate membrane pores in 
response to chemoattractant (10% FBS) and subsequently lysed and detected by 
CyQuant® GR dye. Fluorescence measurement was performed using a fluorescence 
plate reader (Polarstar Optima, Germany) with a 485/520 nm filter (at an extinction of 
480 nm and an emission of 520 nm). The percentage inhibition of migration in each 
treatment was calculated relative to that of the untreated cells. Statistical analyses 
using one-way ANOVA were performed for comparing treatments against control 
cells followed by Dunnett’s using the GraphPad Prism software. 
 
The invasion assay was performed using CytoSelect cell invasion assay kit (8 µm, 
Fluorometric format, Cell Biolabs, USA) using the same protocol. The cells were 
allowed to pass through a polycarbonate membrane bearing 8 µm sized pores with a 
thin layer of basement membrane for 24 h. Cells that had invaded to the other side of 
the inserts were lysed and detected by CyQuant® GR dye. The percentage inhibition 
of invasion in each treatment was calculated relative to that of the untreated cells. 
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Statistical analyses using one-way ANOVA were performed for comparing treatments 
against control cells followed by Dunnett’s using the GraphPad Prism software. 
2.3.9 Protein array analysis of chlorotoxin 
Chlorotoxin used for the protein array analysis was chemically synthesised using 
Fmoc chemistry with 2-chlorotrityl resin and oxidised using 0.1 M ammonium 
bicarbonate pH 8 and 1mM reduced glutathione, with stirring overnight at room 
temperature. The peptide was biotinylated using a 20-fold excess of EZ-Link® Sulfo-
NHS-LC-biotin (ThermoFisher Scientific), according to the manufacturer’s 
instructions. To ensure that successful labelling of chlorotoxin was achieved, the 
sample was analysed utilising an SCIEX 5800 MALDI TOF/TOF mass spectrometer 
(SCIEX, Foster city, CA, USA), followed by purification of labelled chlorotoxin (to 
remove excess non-reacted and hydrolyzed biotin reagent from the solution) via 
HPLC. The purified sample was dried and resuspended in 100 µL of 1.0% PBS (pH 
7.2) in order to achieve a required final concentration of 10 µg. Protein-protein 
interactions among biotinylated chlorotoxin and more than 9000 human proteins were 
then investigated employing a ProtoArray® Human Protein Microarray v5.0 Protein-
Protein Interaction (PPI) kit (Invitrogen™) and significant interactions detected 
employing a GenePix® microarray scanner (Molecular Devices), according to the 
manufacturer’s instructions. 
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2.4 Results 
2.4.1 Design and synthesis of chlorotoxin fragments 
To determine the minimal sequence requirements of chlorotoxin to elicit cellular 
effects, four chlorotoxin fragments (CTX-1, -2, -3, -4) were chemically synthesised 
using Fmoc solid-phase peptide synthesis. The sequences of the full-length 
chlorotoxin and synthetic fragments, and the location of the fragments in the 
chlorotoxin structure are shown in Figure 2-1. The crude peptides were purified using 
RP-HPLC and mass analysis carried out using MALDI TOF/TOF mass spectrometry. 
2.4.2 Structural analysis with NMR spectroscopy 
The structures of the purified peptides were analysed using NMR spectroscopy. The 
one-dimensional spectra of the chlorotoxin fragments did not have significant 
dispersion in the amide region. Further analysis of the TOCSY and NOESY spectra 
for the individual fragments allowed assignment of the resonances and analysis of the 
secondary shifts, which indicated that the peptides had shifts close to random coil, 
consistent with the peptides being unstructured in solution (Figure 2-2).  
 
	
Figure 2-2 Secondary shifts of chlorotoxin and chlorotoxin fragments. The 
secondary shifts were obtained by subtracting random coil shifts from the αH shifts 
(38).  Secondary shifts for chlorotoxin residues are shown in black (39). The 
secondary shifts for CTX-1, 2, 3 and 4 are shown in green, red, blue and orange 
respectively. The sequence for chlorotoxin is given below the graph. The cysteine 
residues were replaced with alanine residues in the chlorotoxin fragments. (#: could 
not be assigned).  
 
2.4.2.1 Serum stability assay 
The stability of the chlorotoxin peptide fragments in human serum was assessed using 
RP-HPLC, and the degradation profiles are shown in Figure 2-3. CTX-1 and -2 
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degraded more slowly than CTX-4. The latter peptide had less than 10% peptide 
remaining after 3 hours, whereas CTX-1 had more than 18% remaining at the 8 h time 
point and could be detected up to 24 hours. The serum stability could not be measured 
accurately for CTX-3 peptide, using the same column as that used for the other 
fragments, because of the hydrophilic nature of this peptide. Chlorotoxin has been 
previously shown to be highly stable in serum with only 10% degradation after 24 
hour incubation with human serum at 37°C using the same protocol (35, 39). 
 
Due to low serum stability of chlorotoxin fragments, the cell assays were designed to 
minimize the exposure of the peptides to serum media (FBS). Prior to the cell assays, 
cells were pre-treated with chlorotoxin or chlorotoxin fragments in 0.5-1% media 
supplemented with 1x ITS-G and 0.1% BSA which were used to ensure cells remain 
healthy and viable over the course of the 30 min treatment (40). It has been previously 
shown that, chlorotoxin achieves the maximum cellular level at a concentration of 10 
µM within 30 min of incubation with cells under physiological conditions (37°C, 5% 
CO2) (7). Chlorotoxin has been shown to significantly label cells (19), block chloride 
channel (23), inhibit endothelial cell migration (8), and induce biochemical changes in 
U87-MG cells (41) over 30 min incubation with cells. Thus, 30 minutes pre-treatment 
appears to be the optimum treatment time for chlorotoxin and fragments, in this study.  
 
 
Figure 2-3 Stability of the peptides in human serum. The amount of peptide 
remaining was calculated by comparing the area of the elution peak of peptides 
incubated in human serum and that of peptides that had not been incubated. The 
experiments were performed in triplicates. All data are represented as mean ± SEM. 
Chlorotoxin has been previously shown to be highly stable in serum with only 10% 
degradation after 24 hour incubation with human serum, using the same protocol (35, 
39). 
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2.4.2.2 Cytotoxicity assay 
The cytotoxicity of chlorotoxin and the chlorotoxin fragments was investigated using 
an XTT assay on the U-87 MG cell line. Cells were incubated with either 5 or 60 µM 
peptide. These concentrations are comparable to those used in the subsequent cell 
assays. The XTT assays were carried out in media (10%), and also in media 
supplemented with 0.5% FBS, 1x ITS-G and 1% BSA. The chlorotoxin fragments 
were not cytotoxic to U87-MG cells under either media condition or peptide 
concentration, with cell viability after a 24 h incubation period higher than 90% for all 
peptides tested (Figure 2-4).  
  
These results are consistent with previous study that showed chlorotoxin is not toxic 
on U87-MG and HUVECs cells at concentrations up to 10 µM and 200 µM, 
respectively (8, 42). 
 
 
 
 
	
	
Figure 2-4 Cell viability assay of chlorotoxin and fragments treated U87-MG 
cells for 24 hours. Chlorotoxin and fragments were added in media supplemented 
with 0.5% FBS, 1x ITS-G and 1% BSA. Cell viability was determined by XTT assay. 
Controls with media and DMSO at 50% (v/v) were used to establish 100 and 0% of 
cell survival, respectively. The experiments were repeated three times in 
pentaplicates. Data are shown as mean ± SEM. 
	 57	
2.4.2.3 Peptide biotinylation  
Peptides were labelled with biotin to allow detection using flow cytometry. The 
chlorotoxin fragments were biotinylated on resin, resulting in a single biotin moiety 
attached to the N-terminus. Following incubation with biotin, the peptides were 
purified using RP-HPLC to remove excess biotin. By contrast, chlorotoxin was 
biotinylated in solution. The mass spectrometry analysis indicated the presence of 
chlorotoxin species with one, two, three and four biotin moieties attached, consistent 
with the four biotinylation sites. Excess biotin was removed from the sample using 
RP-HPLC but it was not possible to purify the individual species and therefore the 
mixture was used in the subsequent experiments. 
2.4.2.4 Cell surface binding/endocytosis assay  
To evaluate the interaction of chlorotoxin fragments with U87-MG cells, a cell line 
previously shown to bind to chlorotoxin, in vitro binding assays were carried out with 
the biotinylated peptides and binding detected by flow cytometry using APC-
conjugated streptavidin as shown in Figure 2-5A. As expected, native chlorotoxin 
demonstrated a significant level of APC fluorescence and surface binding to cells 
when compared to control-treated cells (Figure 2-5A). Further analysis of the relative 
binding efficiency of the four fragments revealed that while CTX-1, CTX-2 and CTX-
4 did not display any significant binding to the surface of cells, CTX-3 did 
significantly bind to the surface of both U87-MG and 1BR.3.GN cell lines in a dose 
dependent manner (Figure 2-5A and B).  
 
These studies were done at 4°C. A direct comparison of the peptides with chlorotoxin 
is difficult, given the differences in the number of biotin moieties present in the full-
length peptide and the fragments, which will affect the signal intensity.  
 
We next assessed whether the peptide fragments were being internalized and 
interacting with a target within the cell. Analysis of the internalization of the 
fragments into the U87-MG cells at 37°C, indicated that while CTX-1 and CTX-2 do 
not appear to be internalized into either the tumor cell line (U87-MG) or normal cell 
line (1BR.3.GN), CTX-3 and CTX-4 appeared to be binding internally to U87-MG 
cells (Figure 2-6A and B).  
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Figure 2-5 In vitro cell surface binding of chlorotoxin fragments. (A) 
Representative flow cytometric histogram of in vitro U87-MG cell surface binding of 
biotinylated chlorotoxin fragments detected by APC labelled streptavidin. Cells were 
treated with 50 µM chlorotoxin or fragments at 4°C for 30 min. Grey shaded 
histograms represent cells treated with APC-streptavidin alone. (B) Mean 
fluorescence intensity (MFI) of in vitro cell surface binding of chlorotoxin fragments 
(50 µM) to U87-MG and 1BR.3.GN cell line. The experiments were performed three 
times in duplicates. Data are presented as mean ± SEM. The statistical analysis was 
performed using an ANOVA Dunnett’s multiple comparison test by comparison of 
chlorotoxin fragments with control cells (****P<0.0001.). The data was normalised 
to account for differences in cell number and expressed as percent of maximum cell 
number for each sample (% of Max).  
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Figure 2-6 In vitro cell internalization of chlorotoxin fragments. (A) 
Representative flow cytometric histogram of in vitro U87-MG cell internalization of 
biotinylated chlorotoxin fragments detected by APC labelled streptavidin. Cells were 
treated with 50 µM chlorotoxin fragments at 37°C for 30 min. Grey shaded 
histograms represent cells treated with APC-streptavidin alone. (B) Mean 
fluorescence intensity (MFI) of in vitro cell internalization of chlorotoxin fragments 
(50 µM) to U87-MG and 1BR.3.GN cell line. The experiments were performed two 
times in quadruplicates. Data are presented as mean ± SEM. The statistical analysis 
was performed using an ANOVA Dunnett’s multiple comparison test by comparison 
of chlorotoxin fragments with control cells (** P<0.01, *** P<0.001 ****P<0.0001.).  
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Interestingly, only CTX-3 showed any evidence of fluorescence signal when exposed 
to 1BR.3.GN cells, however it is not clear whether this binding was on the surface of 
the cell or internal (Figure 2-6B). Given that CTX-4 appeared to bind internally to 
U87-MG cells, but not 1BR.3.GN cells suggests that this intracellular interaction may 
be specific to the glioblastoma cell line. Chlorotoxin has been previously shown not 
to bind to human fibroblasts. (5). 
2.4.2.5 Migration and invasion assay 
The inhibitory effects of chlorotoxin and the chlorotoxin fragments on migration and 
invasion of U87-MG cells were analysed and the results summarised in Figure 2-7. 
chlorotoxin significantly inhibited U87-MG cell migration with inhibitory effects of 
32.9% (P<0.01) and 34.6% (P<0.001) compared to control cells at 5 and 50 µM, 
respectively (Figure 2-7A). Only CTX-4 inhibited U87-MG cell migration at a 
concentration of 50 µM (20.4%, P<0.05).  
 
Chlorotoxin also significantly inhibited U87-MG cell invasion by 37% (P<0.05) and 
36.7% (P<0.05) at 5 and 50 µM (Figure 2-7B), respectively, consistent with previous 
studies (18, 19, 23). None of the chlorotoxin fragments significantly inhibited U87-
MG cells invasion even at the highest concentration tested (50 µM).  
 
2.4.2.6 Protein array analysis of chlorotoxin 
Protein-protein interactions among biotinylated chlorotoxin and more than 9000 
human proteins were investigated employing a ProtoArray® Human Protein 
Microarray v5.0 Protein-Protein Interaction (PPI) kit (Invitrogen™) and monitored 
with a GenePix® microarray scanner (Molecular Devices). Of the more than 9000 
possible interactions tested herein, 104 (ca. 1.0%) were significant (Z-score of > 3), 
while four of the top nine, including interactions between chlorotoxin and cortactin 
(CTTN; Z-score 32.27), polo-like kinase 1 (PLK1; Z-score 11.20), homeobox protein 
HOXB6 (Z-score 10.47) and XTP3-transactivated protein A (XTP3TPA; Z-score 
6.21825), are relevant to the present investigation as these proteins have been shown 
to be involved in cancer.  
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Figure 2-7 The migration and invasion assay. Cells were pre-incubated with 
chlorotoxin and fragments at 5 and 50 µM and then were used for migration/invasion 
assay. (A) The effect of chlorotoxin and fragments on U87-MG cell migration. (B) 
The effect of chlorotoxin and fragments on U87-MG cell invasion. The percentage 
inhibition of migration/invasion in each treatment was calculated relative to that of 
the untreated well. The data was expressed as mean ± SEM. Data were analyzed by 
one-way ANOVA against peptide control. * P<0.05, ** P<0.01.  
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2.5 Discussion 
Given the potential of chlorotoxin as a therapeutic it is of significant interest to 
understand the structural features important for function, as this information is likely 
to facilitate the development of chlorotoxin as a therapeutic. Numerous studies have 
analyzed the binding of chlorotoxin and conjugates to cells but there is still limited 
information on the structure-function relationships and target interaction. 
 
The chlorotoxin fragments synthesized in the current study showed limited stability in 
human serum and did not display regular secondary structure in solution. 
Interestingly, CTX-2 was the most stable of the peptides tested in human serum and is 
also the longest peptide, which might explain the enhanced stability. The lack of 
structure in solution is expected for such small peptides and is consistent with the 
previous study, which showed that the disulfide bonds in chlorotoxin are critical for 
the three-dimensional structure (8).  
 
The C-terminal fragments of chlorotoxin (CTX-3 and CTX-4) displayed interesting 
properties in the cellular assays. CTX-3 showed cell surface binding and cell 
internalization, whereas CTX-4 was internalized into cells and was the only fragment 
to inhibit U87-MG cell migration at the highest concentration tested (50 µM). Despite 
the effect of CTX-4 on cell migration it did not inhibit cell invasion.  
 
The cell surface binding and internalization of chlorotoxin is critical to its potential as 
a tumor imaging agent and our current results suggest that residues 22 to 28, present 
in CTX-3, might be involved with this process. However, given that CTX-3 binds to 
both a tumor cell line and a normal cell line, in contrast to previous studies on 
chlorotoxin, it appears likely that this region is not sufficient by itself to account for 
the selective binding to tumor cells. It is possible the cell surface binding observed for 
CTX-3 is non-specific membrane binding mediated by the presence of the high 
proportion of positively charged (2 lysine and 1 arginine) residues within a seven-
residue peptide as reported for other highly charged peptides (43, 44). Although no 
cell surface binding was observed for CTX-4, it was the only fragment that appeared 
to be specifically internalized into the glioma cells at 37°C. The differences between 
CTX-3 and CTX-4 suggest they might have different internalization mechanisms.  
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Our results, whereby CTX-4 only inhibits migration and not invasion, indicates that it 
might inhibit the ClC-3 channel, which is involved in cell migration, independently 
from the MMP2 macromolecular complex, which is involved in cell invasion. The 
other possibility is that CTX-4 inhibits U87-MG cell migration through another 
pathway, which does not necessarily involve the macromolecular complex. Annexin 
A2, which is identified as another chlorotoxin target, is involved in cell migration in a 
series of glioma cells including U87-MG cells (19, 45). Therefore, it is possible that 
CTX-4 inhibits U87-MG cell migration through an annexin A2 interaction. However, 
more research, including mutagenesis studies, are required to investigate CTX-4 
binding to the targets previously suggested for chlorotoxin. Additional studies 
involving the synthesis of over-lapping peptide fragments might also provide further 
insight into the structure-function relationships. 
 
The recently proposed model of MMP-2 interacting with chlorotoxin (27) shows that 
residues 29-36 (which correspond to CTX-4) are directly involved in the interaction 
with MMP-2 (27), Neither of the cysteine residues (C33 and C35) in this region 
interact with MMP-2, therefore it is highly likely that replacing cysteines with alanine 
in our study would not make a significant difference in CTX-4 binding and 
bioactivity. Furthermore, a recent study has used chlorotoxin as inspiration to design 
blood-brain barrier shuttles. MiniCTX3, contains residues 28-32 of chlorotoxin and a 
lactam bridge, and was able to transport nanoparticles across endothelial cell (35). 
These studies highlight the potential importance of the C-terminal region of 
chlorotoxin in cellular interactions and support our current findings.  
 
Although several biological targets for chlorotoxin have been proposed, direct binding 
has not been reported. Here we used protein array technology to identify another 
possible target for chlorotoxin. Chlorotoxin bound most strongly to cortactin, which 
was initially identified as a substrate of the Src nonreceptor tyrosine kinase but its 
overexpression has now been linked to invasive cancers, including melanoma, 
colorectal cancer and glioblastoma, making it an important biomarker for invasive 
cancers (46). Cortactin localizes to invasive protrusions in cells including invadopodia 
and has been shown to associate with MMP-2 using co-immunoprecipitation studies 
(47). Similarly to annexin A2, it has been suggested that a transient interaction 
between cortactin and complexes containing MMPs might exist (47). Given 
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chlorotoxin can penetrate cells via clathrin-mediated endocytosis, it is possible that it 
can interact with cortactin intracellularly, or alternatively as part of a MMP-2 
complex that is subsequently internalised (7). The importance of intracellular 
targeting of cortactin has been shown with a cell permeable peptide that binds 
cortactin, and inhibits the invasion of a range of cancers including glioblastomas (48). 
Our cell internalization assay provides supports for the possibility that CTX-4 can 
bind an intracellular target that is specific to tumor cells compared to normal cells. It 
would be of interest to determine if CTX-4 can also bind to cortactin.  
 
Overall, this study provides insight into understanding the important sequence 
requirements for chlorotoxin bioactivity, and indicates that a small region of 
chlorotoxin, which is not structured in solution, can have an influence on cell 
migration, albeit at relatively high concentrations. This result might explain the 
bioactivity previously observed for the reduced form of chlorotoxin (8). We also 
provide evidence that fragments of chlorotoxin are involved in cell binding and/or 
internalisation. Further study is required to determine if these fragments can bind to 
the biological targets previously suggested for chlorotoxin. 
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2.7 Non-standard abbreviations 
Human Umbilical Vein Endothelial Cells (HUVEC); Minimum Essential Medium 
(MEM); Fetal Bovine Serum (FBS); 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES); Reversed-phase HPLC (RP-HPLC); Matrix assisted laser 
desorption/ionisation - time of flight mass spectrometry (MALDI TOF/TOF MS); 
Nuclear Magnetic Resonance (NMR); Total Correlated Spectroscopy (TOCSY); 
Nuclear Overhauser Spectroscopy (NOESY); heteronuclear single quantum 
correlation experiment (HSQC); trichloroacetic acid (TCA); 2,3-Bis(2-methoxy-4-
nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt (XTT); Insulin-
Transferrin-Selenium (ITS-G); Dimethyl sulfoxide (DMSO); 2-(6-Chloro-1-H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU); 
Ethyldiisopropylamine (DIPEA); Time-of-flight mass spectrometry (QTOF); Bovine 
serum albumin (BSA); allophycocyanin (APC); Phosphate-buffered saline (PBS); 
chlorotxin (CTX); trifluoroacetic acid (TFA); N -hydroxy-succinimide (NHS); MMP 
matrix metalloproteinase-2(MMP-2); 4,4-dimethyl-4-silapentane-1-sulfonic acid 
(DSS); Analysis Of Variance (ANOVA); European Collection of Authenticated Cell 
Cultures (ECACC). 
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Chapter 3. Development of a Potent 
Wound Healing Agent Based on the 
Liver Fluke Granulin Structural Fold 
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3.1 Abstract 
Granulins are a family of protein growth factors that are involved in cell proliferation. 
An orthologue of granulin from the human parasitic liver fluke Opisthorchis viverrini, 
known as Ov-GRN-1, induces angiogenesis and accelerates wound repair. 
Recombinant Ov-GRN-1 production is complex, and poses an obstacle for clinical 
development.  To identify the bioactive region(s) of Ov-GRN-1, four truncated N-
terminal analogues were synthesized and characterized structurally using NMR 
spectroscopy. Peptides that contained only two native disulfide bonds lack the 
characteristic granulin β-hairpin structure. Remarkably, the introduction of a non-
native disulfide bond was critical for formation of β-hairpin structure.  Despite this 
structural difference, both two and three disulfide-bonded peptides drove proliferation 
of a human cholangiocyte cell line and demonstrated potent wound healing in mice.  
Peptides derived from Ov-GRN-1 are leads for novel wound healing therapeutics, as 
they are likely less immunogenic than the full-length protein and more convenient to 
produce. 
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3.2 Introduction 
Granulins are a family of protein growth factors involved in a wide range of 
physiological functions and disease processes including embryogenesis, wound 
repair, inflammation and tumour growth (1). The human parasitic liver fluke 
Opisthorchis viverrini secretes a granulin family member called Ov-GRN-1, which 
was originally isolated from the excretory/secretory (ES) products of the carcinogenic 
trematode (2, 3). Ov-GRN-1 was the first growth factor described from a pathogen to 
cause proliferation of both human and murine cells (4, 5). We have shown that 
picomolar concentrations of recombinant Ov-GRN-1 induce angiogenesis and 
accelerate wound repair in mice upon topical administration, findings that indicate 
that liver fluke granulin might be developed as a treatment for wounds (6). 
 
An understanding of the structure-activity relationship for Ov-GRN-1 would enable 
design of the most efficacious form of this granulin for healing wounds. The three-
dimensional structure of Ov-GRN-1 has not been experimentally determined, but 
structures for granulins of several species have been reported. The initial granulin 
structure determined was that of carp granulin-1; this comprises four β-hairpins cross-
linked together by six disulfide bonds in a ladder-shaped arrangement of the disulfide 
bonds (7). Despite the well-defined structure observed for carp granulin-1, the 
structure-function relationships of granulins are complex and appear to be highly 
dependent on the primary sequence. This is particularly evident with the human 
granulins. The precursor protein of mammalian granulin (progranulin, PGRN) 
contains seven-and-a-half granulin domains that are approximately 6 kDa in 
molecular mass and are proteolytically processed into individual granulin modules 
after secretion of PGRN from the cell (1). The “half-granulin” unit, termed 
paragranulin, contains only six cysteine residues (8).  
 
The seven human granulin modules have been expressed individually and the 
structures analyzed by NMR spectroscopy (9). Three contain relatively well-defined 
three-dimensional structures in solution (A, C and F), whereas the others are mainly 
mixtures of poorly structured disulfide isomers (9). The structure of human granulin 
A includes a β-hairpin structure similar to carp granulin-1 but there is significant 
structural disorder in the C-terminal region. Of the well folded human granulin 
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modules, granulin A demonstrates potent inhibition of proliferation of a breast cancer 
cell line, while by contrast, human granulin F stimulates cell proliferation (9). The 
poorly folded peptides exhibit weak or no inhibitory or activity. It should be noted, 
however, that the limited activity may be due to the absence of key signaling 
pathways in the target cells, and/or that the production of the recombinant peptides in 
bacteria induced incomplete/incorrect folding. To date, the range of granulin activities 
and binding partners is broad, and seemingly organ- and co-factor-dependent (10-13).  
 
Structural analysis with NMR spectroscopy has shown that the N-terminal regions of 
carp granulin-1 and human granulin A can fold independently of the C-terminal 
regions (14, 15). Truncated analogues of these two granulins containing only two-
disulfide bonds, have β-hairpin structures, as shown for a 30-residue N-terminal 
domain of carp granulin-1 (Figure 3-1). In the current study we synthesized truncated 
versions of Ov-GRN-1 to determine if this region can fold independently, and to 
determine if the N-terminal region contributes to cell proliferation and wound healing. 
We show for the first time that the N-terminal region of Ov-GRN-1 displays novel 
folding properties, and notably from a drug design perspective, peptides derived from 
the N-terminus are as potent as the full-length protein and Regranex, a clinically used 
wound-healing agent, in healing cutaneous wounds in laboratory mice. 
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Figure 3-1 Three-dimensional structure of a 30 residue N-terminal domain of 
carp granulin-1. (A) PDB code 1QGM, the β-strands are shown as purple arrows and 
the disulfide bonds in yellow ball and stick format. The image was generated using 
MolMol. (B) The disulfide connectivity in the full length carp granulin-1 protein(7). 
Cysteines are designated with sequential roman numerals I-XII. The two bonds in the 
truncated carp granulin-1 are highlighted in yellow. 
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3.3 Experimental section 
3.3.1 Peptide synthesis and purification 
Truncated granulin peptides were synthesised using manual solid-phase peptide 
synthesis using fluorenylmethyloxycarbonyl (FMOC) chemistry. Peptides were 
assembled on 2-chlorotrityl chloride resin (Auspep, Australia). Amino acids were 
activated using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU-Iris Germany) in peptide grade dimethylformamide 
(DMF -Auspep, Australia). Peptides were cleaved using a mixture of 95% TFA/2.5% 
TIPS/2.5% H2O. The TFA was removed by evaporation with nitrogen and ice-cold 
diethyl ether was added to the residue. Ether was removed by filtration and the 
peptide was dissolved in 40% acetonitrile/water mixture containing 0.1% 
trifluoroacetic acid (TFA) and subsequently freeze-dried. The resulting crude peptides 
were purified with reverse phase high performance liquid chromatography (RP-
HPLC) on a C18 preparative column (Phenomenex Jupiter 10µm C18 300Å 250x21.2 
mm).  Gradients of 1%/min of 0%-80% solvent B (90% acetonitrile in 0.045% TFA 
in H2O) and solvent A (aqueous 0.045% TFA in H2O) were used and the eluent was 
monitored at 215 and 280 nm. Peptides were oxidised by stirring a solution of the 
peptide in 100 mM ammonium bicarbonate (pH 8.2) containing 5 mM reduced 
glutathione and left overnight at room temperature and purified using RP-HPLC on a 
C18 preparative column (Phenomenex Jupiter 10µm C18 300Å 250x21.2 mm). The 
purity of the peptides was assessed using analytical RP-HPLC and all peptides had 
≥95% purity.  
 
To confirm the disulfide connectivity of the truncated peptides, Ov-GRN12-34 was 
synthesised with selective protection of the cysteine residues. Cys1 and Cys14 were 
side-chain protected with ACM groups and Cys8 and Cys23 with (Trt) protecting 
groups. Following cleavage and purification of the crude peptide the disulfide bond 
between Cys8 and Cys23 was formed in 100 mM ammonium bicarbonate and the 
peptide was purified using the procedure described above. The S-ACM groups were 
subsequently removed by stirring 2 mg of peptide in 0.5 mL TFA, 10 uL anisole and 
25 mg silver trifluoromethanesulfonate at 4ºC for 1.5 h. Cold ether (10 mL) was 
added to the mixture and the precipitate collected by centrifugation. The precipitate 
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was washed twice with ether and oxidized, without further purification, overnight 
using a solution of 50% DMSO in 0.5 M HCl. The solution was diluted 15 times with 
water and the fully folded peptide was purified by HPLC using 1% ACN gradient on 
a C-18 preparative column (Phenomenex Jupiter 10µm C18 300Å 250x21.2 mm). 
 
3.3.2 Auto-induction of recombinant protein expression in E. coli 
Ov-grn-1 pET41a or Escherichia coli thioredoxin (trx) cDNAs contained within the 
pET32a (Novagen) plasmid were transfected into BL21 E. coli cells (Life 
Technologies) and used to create recombinant proteins with auto-induction as 
described (5, 16). Briefly, ZYM-5052 culture media were supplemented with 100 µM 
Fe(III)Cl3 and 100 µg/L kanamycin to produce recombinant protein (rOv-GRN-1) or 
50 µg/L ampicillin to produce TRX. Two hundred (200) ml of inoculated media in a 
one-litre baffled Erlenmeyer flask was incubated overnight at 37°C at 300 rpm 
rotation to induce expression with auto-induction. 
3.3.3 Recombinant protein purification 
Purification of rOv-GRN-1 was achieved using an AKTA10 purification system at 
4°C (GE Healthcare) (4). The BL21 E. coli pellet was lysed with 3 freeze/thaw cycles 
followed by sonication on ice with a Q4000 unit (Qsonix). Twenty (20) g of the 
resulting insoluble pellet was solubilized in 400 ml urea-containing nickel binding 
buffer (8 M urea/300 mM NaCl/50 mM imidazole/50 mM sodium phosphate pH 8 
[Sigma]) at 4°C for 24 h with slow agitation. The 0.22 µM filtered supernatant was 
passed over 2 × 5 ml Histrap IMAC nickel columns (GE Healthcare) and washed with 
increasing imidazole concentrations (two column volumes [CV] at 50 mM/5 CV at 
100 mM) and eluted with 500 mM imidazole in binding buffer. The control TRX 
protein was expressed in the same fashion but under native conditions (without 
chaotropic agents) and purified with Histrap IMAC Nickel columns (4). 
3.3.4 Protein refolding and purification 
Refolding of urea-denatured rOv-GRN-1 was performed with 28 mL of G10 
Sephadex (GE) resin on a XK16/20 column (GE) as described (4). A 120 ml 
Superdex 30 XK16/60 column (GE) was used to fractionate 3 ml of refolded rOv-
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GRN-1 into 150 mM NaCl, 50 mM sodium phosphate, pH 6, at a flow rate of 
1 ml/min. Fractions containing rOv-GRN-1 monomer eluting at a size equivalent of 
~1 kDa (based on the fold of granulin proteins despite a denatured molecular size of 
10.4 kDa) were pooled. Protein concentration was determined by a combination of 
microplate Bradford assay (Biorad) and absorbance at 280 nm. 
3.3.5 NMR spectroscopy and structure determination 
Purified peptides were dissolved in 90%H2O/10% D2O to provide a ~0.2 mM stock. 
2D 1H-1H TOCSY, 1H-1H NOESY, 1H-1H DQF-COSY, 1H-15N HSQC, and 1H-13C 
HSQC spectra were acquired at 290 K using a 600 MHz AVANCE III NMR 
spectrometer (Bruker, Karlsruhe, Germany) equipped with a cryogenically cooled 
probe. Spectra were recorded with an interscan delay of 1 s. NOESY spectra were 
acquired with a mixing time of 200 ms, and TOCSY spectra were acquired with an 
isotropic mixing period of 80 ms. All spectra were assigned using CCPNMR (17) 
based on the approach described by Wüthrich (18) The αH secondary shifts were 
determined by subtracting the random coil 1H NMR chemical shifts of Wishart  from 
experimental αH chemical shifts (19). 
 
The three-dimensional structures of Ov-GRN12-34 and Ov-GRN12-35_3s were 
determined. The 2D NOESY spectra were automatically assigned and an ensemble of 
structures calculated using the program CYANA (20). Torsion-angle restraints 
predicted using TALOS+ were used in the structure calculations. Disulfide-bond 
connectivities (Cys1-Cys14, Cys8-Cys23) were included in the calculations for Ov-
GRN12-34 because these bonds were confirmed by selective protection of the cysteine 
residues. Selective protection of the cysteine residues was not used for Ov-GRN12-35_3s 
in an attempt to isolate the most energetically favourable form. Consequently, the 
structures were calculated with the 15 possible disulfide connectivities. An analysis of 
the CYANA target functions was carried out to determine the most likely 
connectivity. Structures were visualised using MOLMOL (21). 
3.3.6 Mammalian cell culture 
The non-malignant cholangiocyte cell line H69 is a SV40-transformed human bile 
duct epithelial cell line derived from human liver, kindly provided by Dr. Gregory J. 
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Gores, Mayo Clinic, Rochester, Minnesota. H69 cells (4, 22, 23) were maintained in 
T75 cm2 vented flasks (Corning) as monolayers as described (24) with minor 
modifications. Cells were maintained with regular splitting using 0.25% trypsin (Life 
Technologies) every 2–5 days in complete media [RPMI (Sigma) with growth factor-
supplemented specialist complete media (23) [DMEM/F12 with high glucose, 10% 
FCS, 1×antibiotic/antimycotic, 25 µg/ml adenine, 5 µg/ml insulin, 1 µg/ml 
epinephrine, 8.3 µg/ml holo-transferrin, 0.62 µg/ml, hydrocortisone, 13.6 ng/ml T3 
and 10 ng/ml EGF – Life Technologies]. Low nutrient media for cell proliferation 
assays was 5% complete media, i.e. 0.5% FCS and 1/20th of the growth factor 
concentrations listed above for complete media. The identities (human-derived) of the 
cell line were confirmed with single tandem repeat (STR) analysis in January 2015 
(15/15 positive loci across 2 alleles) and mycoplasma free at the DNA Diagnostics 
Centre (DDC)–medical (U.S.A.), accredited/certified by CAP, ISO/IEC 17025:2005 
through ACLASS. 
3.3.7 Cell proliferation monitoring in real time using xCELLigence 
Cells were seeded at 1,500 cells/well in 180 µl complete media (above) in E-plates 
(ACEA Biosciences) and grown overnight while monitored with an xCELLigence SP 
system (ACEA Biosciences) which monitors cellular events in real time by measuring 
electrical impedance across interdigitated gold micro-electrodes integrated into the 
base of tissue culture plates (25). Cells were washed three times with PBS prior to 
addition of 180 µl of low nutrient media (above) and incubated for a minimum of 6 h 
before further treatment.  Treatments were prepared at 10× concentration and added to 
each well in a total volume of 20 µl. The xCELLigence system recorded cell indexes 
at intervals of one hour for 5-6 days following treatment. Readings for the cell index 
were normalized prior to treatment and cell proliferation ratios represent the relative 
numbers of cells compared to control cells at day 4.  Dose response curves for each 
peptide were generated from 3-6 independent experiments each with 4-6 replicates. 
Comparisons of induction of cell proliferation in response to treatments were 
accomplished using two-way ANOVA test with Dunnett’s multiple comparison 
correction, using GraphPad Prism 6.02.  
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3.3.8 Mouse wounding assay 
These studies were conducted with the approval of the James Cook University Small 
Animal Ethics Committee, applications A1806 and A2204, as described (6). Briefly, 
female 11-12 week old BALB/c mice weighing 19-23 g were sourced from the 
Australian ARC (Animal Resources Centre) and randomly allocated into groups of 4-
5 mice. Mice were anesthetized (intraperitoneal xylazine 16 mg/kg; ketamine 80 
mg/kg), after which a skin-deep wound on the crown of the head was inflicted using a 
5 mm biopsy punch (Zivic instruments). Betadine liquid antiseptic (Sanofi) was 
applied followed by application of 50 µl that contained either 71 pmoles of Regranex 
(treatment of 71 pmoles equals 1 µg per 0.25 cm2 wound, as recommended by 
manufacturer Smith and Nephew), 56 pmoles of rOv-GRN-1, Ov-GRN-1 peptides, 
control peptide (EADRKYDEVARKLAMVEADL), TRX or PBS suspended in 1.5% 
methylcellulose (Sigma). Wounds were photographed daily and after blinding 
treatment groups the area of the lesion was measured with ImageJ software and 
plotted as percent of wound closure from original wound images. Wound healing 
rates were compared with two-way ANOVA test with Dunnett’s correction for 
multiple comparisons, using GraphPad prism 6.02. Each mouse wounding study was 
conducted at least twice to provide reproducibility. 
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3.4 Results 
3.4.1 Design and synthesis of truncated Ov-GRN-1 peptides 
To determine if the N-terminal region of Ov-GRN-1 can fold independently several 
truncated peptides were designed and synthesized using FMOC chemistry. The 
sequences of the synthetic peptides are shown in Figure 3-2A.  
 
Ov-GRN1-35, Ov-GRN8-38 and Ov-GRN12-34 all contain four cysteine residues 
equivalent to Cys I, Cys II, Cys III and Cys V in the full-length protein (for the 
remainder of the report, Roman numerals refer to the numbering present in the full 
length protein). Cys IV and Cys VI were predicted to form disulfide bonds with Cys 
VII and Cys IX respectively, based on the three-dimensional structure of carp 
granulin-1(7). In the truncated analogues Cys IV and Cys VI were replaced with 
alanine residues to prevent disulfide bond formation between these residues. Selective 
protection of the cysteine residues was used to direct the folding to form the predicted 
disulfide connectivity (i.e. Cys I-Cys III and Cys II-Cys V).  
 
Ov-GRN-1 contains an extended N-terminal tail (11 residues prior to the first cysteine 
residue) not present in the majority of granulins, and these residues were included in 
Ov-GRN1-35 to determine if they play a role in the bioactivity. The N-terminus was 
truncated and the C-terminus extended in Ov-GRN8-38 to provide an analogue with a 
similar number of residues to the carp granulin-1 truncated peptide. Ov-GRN12-34 is 
the minimal sequence that contains the four cysteine residues (Cys I, Cys II, Cys III 
and Cys V) and was designed to determine if the N- and C-terminal regions are 
required for folding and activity.  
 
An additional peptide was synthesised (Ov-GRN12-35_3s) with a truncated N-terminus 
but containing the first six cysteines of Ov-GRN-1 (the “3s” refers to the presence of 
three-disulfide bonds in the peptide). This peptide is analogous to mammalian 
paragranulin (above) in terms of the cysteine residues. It was synthesized without 
selective protection of the cysteine residues and the major conformation was purified 
for analysis of its structure and activity.  
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Figure 3-2 Sequences and secondary shifts of the Ov-GRN-1 truncated 
analogues. (A) Sequences show Cys IV and Cys VI were replaced with alanine 
residues; the cysteines are highlighted in red and the substitutions are shown in blue. 
The N-terminal 30 residues of carp granulin-1 is also provided, with Cys IV and VI 
replaced with alanine residues. (B) Secondary shifts of Ov-GRN-1 peptides with four 
cysteine residues (Ov-GRN1-35, Ov-GRN8-38 and Ov-GRN12-34). The secondary shifts 
were derived by subtracting random coil shifts (19) from the αH shifts. The similarity 
in the secondary shifts for the conserved residues indicates that the overall fold is the 
same in the three peptides. Color scheme is retained in Figures (3-2)-(3-5).  Both 
panels: black connecting lines represent disulfide bond connectivity. 
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3.4.2 Structural analysis with NMR spectroscopy 
NMR spectroscopy was employed to analyse the structure of the peptides. The one-
dimensional spectra of Ov-GRN1-35, Ov-GRN8-38 and Ov-GRN12-34 have limited 
dispersion in the amide regions consistent with a lack of β-sheet structures despite 
formation of the two native disulfide bonds. Two-dimensional spectra (TOCSY and 
NOESY) were used to assign the resonances, and the secondary shifts were 
determined by subtracting random coil shifts (19) from the αH shifts. The secondary 
shifts are similar over the equivalent residues for these three peptides, as shown in 
Figure 3-2B, indicating that the structures were similar and consequently, that the 
differences in the N- and C-termini of these peptides did not influence the overall 
fold. Furthermore, the secondary shifts were consistent with a lack of β-sheet 
structure as they are primarily negative and β-sheet structures are characterised by 
positive secondary shifts. The three-dimensional structure of Ov-GRN12-34 was 
determined using NMR spectroscopy, as shown in Figure 3-3. In contrast to the 
characteristic granulin fold, the structure comprised turns and a region of 310 helix. 
The structure statistics are provided in Table 3-1.  
 
In contrast to the two-disulfide bond-containing Ov-GRN-1 peptides, Ov-GRN12-35_3s, 
with three-disulfide bonds has more dispersion in the amide region in the one-
dimensional NMR spectrum.  Furthermore, additional peaks were present in the 
spectra, likely due to isomerisation of the proline residues. Despite these additional 
peaks, the major conformation was fully assigned, and the secondary shifts were 
similar to the truncated carp granulin-1(14) (Figure 3-3B), which indicates the 
similarity of the overall structures. Truncated carp granulin-1, comprising residues 1-
30, has previously been synthesised with Cys IV and Cys VI replaced with serine 
residues, and was shown to form a β-sheet structure(14). Here we synthesised carp 
granulin1-30 with Cys IV and Cys VI replaced with alanine residues to be consistent 
with the truncated peptides of Ov-GRN-1. Only minor variations were evident 
between the published (14) chemical shifts of carp granulin-1 with the serine 
substitutions and the peptide with the alanine substitutions (Figure 3-4), indicating 
that the overall fold is still maintained. 
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Figure 3-3 Structural analysis of Ov-GRN12-34 and Ov-GRN12-35_3s. (A) Secondary 
shifts of Ov-GRN12-34 and Ov-GRN12-35_3s compared to carp granulin1-30. The 
secondary shifts were derived by subtracting random coil shifts (19) from the αH 
shifts. Ov-GRN12-34 has significantly different secondary shifts compared to Ov-
GRN12-35_3s and carp1-30, and lacks positive shifts indicating a lack of β-sheet 
structure. Despite the differences in sequence the trends for the secondary shifts 
between Ov-GRN12-35_3s and carp1-30 are similar indicating that the β-sheet present in 
carp granulin-1 is also present in Ov-GRN12-35_3s (black arrows). (B) The structures of 
Ov-GRN12-34 and Ov-GRN12-35_3s were determined using NMR spectroscopy and 
confirms that Ov-GRN12-34 does not contain β-sheet structure but Ov-GRN12-35_3s does 
(blue arrows). Disulfide bonds are shown as yellow ball and stick representations and 
the structure of carp1-30 are shown for comparison. The side-chains of residues Ser17 
and Ser27 are highlighted on the carp1-30 structure, to indicate the Cys-Ser substituted 
sites of Cys IV and Cys VI.  Based on this structure it appears likely that Cys IV and 
Cys VI of carp1-30 could form a disulfide bond, consistent with the likely connectivity 
in Ov-GRN12-35_3s. 
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Table 3-1 Structural statistics for the Ov-GRN-1 peptides ensemble  
 
 Ov-GRN12-34 Ov-GRN12-35_3s 
Experimental restraints   
Interproton distance restraints 252 113 
   Intraresidue 78 46 
   Sequential 139 52 
   Medium range (i-j < 5) 21 4 
   Long range (i-j ≥5) 14 44 
Disulfide-bond restraints 6 9 
Dihedral-angle restraints 14 10 
   
R.m.s. deviations from mean coordinate 
structure (Å) 
  
Backbone atoms  0.32 ± 0.15 0.65 ± 0.2* 
All heavy atoms  0.93 ± 0.27 1.65 ± 0.33* 
   
Ramachandran Statistics   
% in most favoured region 71.4 78.2 
% in additionally allowed region 28.6 21.8 
• RMSD for residues 12-24. 
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Figure 3-4 Chemical shift comparison between the published shifts of a 
truncated form of carp granulin (14) and the mutant with C17A and C27A 
mutations. 
 
To confirm if the structure of Ov-GRN12-35_3s was similar to carp granulin1-30, three-
dimensional structures were calculated using CYANA. Structures were initially 
calculated without disulfide bond restraints. In these structures a β-hairpin was 
present from residues 14-23, but residues 1-8 were not defined. The lack of definition 
for residues 1-8 prevented an analysis of the sulfur-sulfur distances providing insight  
 
into the most likely connectivity. Therefore, an alternative approach was used 
whereby the structures were calculated with the 15 possible disulfide bond 
connectivities. This approach has previously been used for disulfide-rich peptides 
such as the cyclotides to analyse the disulfide bond connectivities (26, 27). The 
CYANA target functions for the 15 connectivities for Ov-GRN12-35_3s are shown in 
Table 3-2. The connectivity with the lowest CYANA target function was Cys I-Cys 
III, Cys II-Cys V and Cys IV-Cys VI. The three-dimensional structure of Ov-GRN12-
35_3s with this connectivity is shown in Figure 3-3A and the structure statistics 
provided in Table 3-2. The most well defined region of the molecule was the β-
hairpin between residues 14-23. The N-terminal region, encompassing Cys I and Cys 
II displayed marked structural disorder. 
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Table 3-2  CYANA target functions for the 15 possible disulfide bond 
connectivities present in Ov-GRN12-35_3s.  
	
Set Number Disulfide bonds 
connectivity 
Average Target Function ± SD 
1 1-14, 8-23,15-24 *0.016  ± 0.003 
2 1-14, 8-24, 15-23 3.08 ± 0.18 
3 1-14, 8-15, 23-24 3.59 ± 0.15 
4 1-8, 14-23, 15-24 3.72 ± 0.02 
5 1-8, 14-15, 23-24 5.71 ± 0.32  
6 1-8, 14-24, 15-23 5.21 ± 0.25 
7 1-15, 8-14, 23-24 3.31 ± 0.04 
8 1-15, 8-23, 14-24 1.58 ± 0.37 
9 1-15, 8-24, 14-23 1.28 ± 0.2 
10 1-23, 8-14, 15-24 *0.018 ± 0.01 
11 1-23, 8-15, 14-24 0.32 ± 0.05 
12 1-23, 8-24, 14-15 2.53 ± 0.23 
13 1-24, 8-14, 15-23 2.61 ± 0.11 
14 1-24, 8-15, 14-23 1.18 ± 0.12 
15 1-24, 8-23, 14-15 2.49 ± 0.29 
*The two connectivities with the lowest target functions are highlighted with an 
asterisk. The connectivity corresponding to Set Number 1 has the lowest target 
function indicating that the distance and angle restraints satisfy this connectivity 
better than the other connectivities, and it is therefore the most likely connectivity 
present in Ov-GRN12-35_3s. 
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3.4.3 Cell proliferation  
The influence of the Ov-GRN-1 peptides on proliferation of H69 cholangiocytes in 
real time was assessed using xCELLigence technology and dose response curves were 
determined for the peptides. Ov-GRN12-35_3s at a final concentration of 2 µM resulted 
in a 41% increase in cell growth compared to control peptide (P<0.0001) (Figure 3-
5A). A dose response curve similar to that obtained for Ov-GRN-1 was observed with 
Ov-GRN12-35_3s treatment, characterized by significantly increased cell proliferation at 
final concentrations of ≥15 nM (P<0.05). The two-disulfide bonded Ov-GRN-1 
peptides were less potent at nanomolar concentrations, but at 2 µM promoted 
significant cell proliferation (14-25% above peptide control; P<0.01) with dose 
response curves typified by Ov-GRN12-34 (Figure 3-5A). No cell cytotoxicity was 
observed for any of the peptides tested at concentrations up to 2 µM.  
 
The cell proliferation observed for the Ov-GRN peptides is in contrast to carp 
granulin1-30 that induced minimal cell proliferation (non-significant) at all 
concentrations tested, and maximum proliferation of 9% over peptide controls at 32 
nM. The response at 400 nM of all the Ov-GRN peptides (Figure 3-5B) highlights the 
enhanced potency of the three-disulfide bonded peptide (Ov-GRN12-35_3s) compared to 
the two-disulfide bonded peptides. Ov-GRN12-35_3s promoted a highly significant 
(P<0.0001) increase in cell proliferation (26% over peptide controls) compared to the 
remaining peptides that induced minimal proliferation, of which the most potent was 
Ov-GRN1-35 (9% non-significant increase over peptide control). 
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Figure 3-5 Liver fluke granulin peptides induce cell proliferation.  (A) 
Opisthorchis viverrini granulin peptides but not carp granulin1-30 induced proliferation 
of H69 human cholangiocytes at a range of concentrations as monitored using 
xCELLigence. Only selected treatments are graphed to aid visualization. Variable 
slope dose response lines of best fit show proliferation four days after a single 
application of treatment. Ov-GRN12-35_3s potency characterized by significantly 
increased cell proliferation observed at final concentrations of ≥15 nM (P<0.05). 
Black arrow denotes 400-483 nM concentration used in panel B. (B) Mean 
proliferation at 400 nM of all Ov-GRN-1 synthesized peptides and 483 nM Ov-GRN-
1 protein from panel A. ns = not significant, **** P<0.0001. Both Panels: 2-way 
ANOVA test with Dunnett’s correction for multiple comparisons was used to 
compare treatments with relevant treatment controls (Ov-GRN-1 protein relative to 
thioredoxin expression matched recombinant protein control and peptides relative to 
peptide control (20-residue peptide derived from tropomyosin). Mean values from 4-6 
replicates pooled from 2-4 experiments with SEM bars shown either above or below 
for clarity.  
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3.4.4 Mouse wound healing model 
The truncated Ov-GRN-1 peptides formulated with methylcellulose were tested in a 
mouse model of wound healing. All Ov-GRN-1 peptides exhibited potent activity 
(Figure 3-5A, B) when applied topically compared to control peptide in 
methycellulose. The Ov-GRN-1 peptides, Ov-GRN-1 protein and Regranex 
significantly improved healing compared to peptide control on days 2-4 (P<0.05). As 
wounds closed, differences among treatments waned and significant differences were 
unapparent beyond day 4. Regranex and the various granulin peptides showed near 
identical best-fit curves and intact Ov-GRN-1 was the only compound tested here that 
provided significant improvement over Regranex on days 3 and 4 (P<0.05; Figure 3-
6B). 
 
	
Figure 3-6 Mouse wound healing activity of Ov-GRN-1 and peptides. (A+B) 
Wound healing outcomes from treatments with 56 pmoles of recombinant Ov-GRN-1, 
Ov-GRN-1 peptides, unrelated peptide, thioredoxin (TRX) protein controls and 71 
pmoles Regranex in 1.5% methylcellulose gel applied daily in 50 µl volume from 
days 0-4 to a ~0.2 cm2 wound arising from biopsy punch to the scalp between the 
ears. To aid visualisation, data were split across two graphs with the Ov-GRN-1 and 
peptide control groups shown in both panels. No significant differences between the 
unrelated peptide control, PBS, or TRX protein control were noted at any time point. 
Black arrows denote the day 4 time point used in panel C. (C) Wound healing relative 
to PBS vehicle control from day 4. All panels: mean healing rates of 2-6 biological 
replicates of groups of 4-5 animals plotted with SEM bars. Groups have been 
marginally shifted left or right to aid viewing. Repeated measure 2-way ANOVA test 
with Dunnett’s correction for multiple comparisons compare each group against each 
other group.  Significance against peptide/protein control signified by **** = 
P<0.0001, *** = P<0.001, ** = P<0.01, * = P<0.05, ns=not significant.  Significant 
treatments against Regranex signified by # = P<0.05.  Color of asterisk or hash 
represents the relevant group.  The colors and symbols are maintained across Figures 
(3-2)-(3-5). 
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Significant differences were not observed between the various negative control 
groups formulated with methylcellulose, including PBS vehicle control, peptide 
control, and thioredoxin (TRX) recombinant protein control.  
	
When healing at day 4 (Figure 3-6C, Figure 3-7) was evaluated relative to PBS 
vehicle from each biological replicate, treatment of wounds with Ov-GRN-1 protein 
and peptides significantly accelerated wound healing compared to controls (P<0.01 at 
day 4: 26-41% over PBS). Although the Ov-GRN-1 protein, Ov-GRN1-35 and Ov-
GRN12-34 (37-41% over PBS) provided improved healing compared to Regranex 
(29% over PBS), none of these comparisons reached significance at the day 4 time 
point. 
 
 
 
	
	
	
Figure 3-7 Mouse wound healing day 4 images.  Representative images from mouse 
wound healing study presented in Figure 3-6.  Wound healing outcomes from 
treatments with 56 pmoles of recombinant Ov-GRN-1, Ov-GRN-1 peptides, unrelated 
peptide, thioredoxin (TRX) protein controls and 71 pmoles Regranex in 1.5% 
methylcellulose gel applied daily in 50 µl volume from days 0-4 to a ~0.2 cm2 wound 
arising from biopsy punch to the scalp between the ears.  The treatment colors are 
maintained across Figures (3-2)-(3-5). 
	 91	
3.5 Discussion 
Elucidating the structure-activity relationships of granulins has been challenging 
given the sequence and structural variations in this protein family. Regions with 
bioactivity are poorly understood, and uncertainty remains about potential receptors 
for this growth factor (28, 29).  
 
Ov-GRN-1 appears to have distinct folding pathways compared to other granulins. 
The N-terminal region of Ov-GRN-1, comprising two native disulfide bonds (Cys I-
Cys III and Cys II-V), does not fold independently into a native-like β-hairpin 
structure, in contrast to carp granulin-1 and human granulin A. It is noteworthy that 
the introduction of a third, non-native disulfide bond in Ov-GRN12-35_3s results in a β-
hairpin structure similar to that present in the carp granulin-1 and human granulin A 
peptides (14, 15). The disulfide bond connectivity of Ov-GRN12-35_3s appears to 
comprise the two native disulfide bonds (Cys I-Cys III and Cys II-V) in addition to 
the Cys IV-Cys VI disulfide bond. If the bond pairs are conserved across species (7, 
9), the latter bond is predicted not to be present in the full length Ov-GRN-1, as Cys 
IV is predicted to bond to Cys VII and Cys VI to Cys IX.  
 
The paragranulin (half-granulin) domain of mammal progranulin contains the 
equivalent six cysteine residues present in Ov-GRN12-35_3s and is biologically active 
(30), which suggests that Ov-GRN12-35_3s potentially contains the same disulfide 
connectivity. Carp granulin1-30 peptide might accommodate this Cys I-Cys III, Cys II-
Cys V, Cys IV-Cys VI connectivity (14). Although carp granulin1-30 peptide contains 
only the two native disulfide bonds (Cys I-Cys III and Cys  II-Cys V), analysis of the 
structure indicates that the side-chains of the serine residues, which replace Cys IV 
and Cys VI, are in close proximity, and suggest that it is feasible for these cysteine 
residues to form a disulfide bond.  
 
The disulfide connectivity in Ov-GRN12-35_3s has implications for the structure of full-
length Ov-GRN-1, which has not been experimentally determined because sufficient 
quantities of correctly folded recombinant material remain unavailable. Therefore, the 
disulfide connectivity of the native protein has not been shown to conform to the 
connectivity originally shown for carp granulin-1 (7). It is conceivable that the protein 
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contains a disulfide domain comprising the first six cysteine residues (equivalent to 
that seen in Ov-GRN12-35_3s), and a second domain containing the last six cysteine 
residues. Without the structure of the full-length protein and a comparison to the 
native protein secreted by the parasite, this remains speculation. However, previous 
reports revealed ambiguity in the disulfide connectivity of granulins (15). The 
structures of human granulin A and F have well-defined N-terminal regions, but 
disordered C-terminal regions prevented characterisation of all the disulfide bonds. 
Furthermore, chemical analysis of the disulfide connectivity of human granulin A was 
inconclusive (15).  
 
In addition to providing insight into the folding of Ov-GRN-1, the current study 
revealed that the N-terminal region contributes to the bioactivity and the β-hairpin of 
Ov-GRN12-35_3s further enhanced cell proliferation activity. However, the β-hairpin 
structure is far from the complete story in regard to proliferative activity, as the carp 
granulin1-30 peptide contains dual β-hairpins and in contrast to the Ov-GRN-1 
peptides, showed no substantial proliferation at the eight concentrations tested (10 nM 
- 2 µM). A comparison of the sequences of carp granulin-1 with Ov-GRN-1 reveals 
that there are only two conserved non-cysteine residues between Cys I and Cys VI. 
This lack of conservation in the loop sequences likely accounts for the differences in 
both folding and bioactivity. 
 
Despite the lack of native structure, the two-disulfide bond containing Ov-GRN-1 
peptides promoted cell proliferation at high concentrations (>800 nM) and stimulated 
significant healing of cutaneous wounds in mice. Ov-GRN12-35_3s was the most potent 
peptide in the cell proliferation assay, but was no more active in vivo than the other 
Ov-GRN-1 peptides. If the β-hairpin of Ov-GRN12-35_3s is involved in wound healing 
in vivo we did not observe a difference in mice. Cell proliferation activity may be cell 
line-specific, or alternatively the concentrations tested in mouse wound repair were 
not optimal. In either case, the activity observed in mice may be of greater biological 
and therapeutic consequence than findings from the in vitro analysis. In the future, we 
envision exploring a range of cells from diverse organs and tissues and investigation 
of mice that exhibit deficits in wound healing in order to increase our understanding 
of the role of Ov-GRN-1 structure-activity relationships. 
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To conclude, structural analysis with NMR spectroscopy suggested that Ov-GRN-1 
exhibits unique folding properties compared with other granulins, presumably 
resulting from primary sequence. We have identified a bioactive region of Ov-GRN-1, 
which is likely to be less immunogenic and more readily produced than the full-length 
recombinant protein. Peptides and derivatives of liver fluke granulin that maintain the 
bioactivity represent a key advance towards identification of a novel therapies for 
treatment of wounds.   
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Chapter 4.  Structural Variants of a 
Liver Fluke Derived Granulin 
Peptide Potently Stimulate Wound 
Healing 
 
 
 
	 98	
4.1 Abstract 
Granulins are a family of growth factors involved in cell proliferation. The liver-fluke 
granulin, Ov-GRN-1, isolated from a carcinogenic liver fluke Opisthorchis viverrini, 
can significantly accelerate wound repair in vivo and in vitro. However, it is difficult 
to express Ov-GRN-1 in recombinant form at high yield, impeding its utility as a drug 
lead.  Previously we reported that a truncated analogue (Ov-GRN12-35_3s) promotes 
healing of cutaneous wounds in mice. NMR analysis of this analogue indicates the 
presence of multiple conformations, most likely as a result of proline cis/trans 
isomerisation. To further investigate whether the proline residues are involved in 
adopting the multiple confirmations we have synthesised analogues involving 
mutation of the proline residues. We have shown that the proline residues have a 
significant influence on the structure, activity and folding of Ov-GRN12-35_3s. These 
results provide insight into improving the oxidative folding yield and bioactivity of 
Ov-GRN12-35_3s, and might facilitate the development of a novel wound healing agent.  
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4.2 Introduction 
Granulins are a large family of disulfide-rich proteins with diverse biological 
functions (1, 2) including wound healing (3), cell growth and proliferation modulation 
(1) and angiogenesis (4, 5). There is limited sequence conservation amongst the 
granulin domains but the majority contain twelve cysteine residues, with a conserved 
framework (6, 7), as shown in Figure 4-1A. The most well studied granulin in terms 
of structure is carp granulin-1, which has a β-hairpin stack stapled together with the 
six disulfide bonds (8), that are critical for maintaining structure (9). Despite the 
conserved cysteine framework, the structure-function relationships are complex with 
some granulin domains displaying cell proliferation activity and some having 
inhibitory effects on cell growth (10-12), and the effects on biological pathways also 
appears to vary (13).  
 
The liver-fluke granulin, Ov-GRN-1, isolated from Opisthorchis viverrini, displays 
potent wound healing activity in vivo (14-16), but low yields in the recombinant 
expression have limited its development as a therapeutic (17). Elucidating the 
structure-function relationships has also been impacted by the difficulties in 
producing significant quantifies for study. However, we have recently shown that 
truncated analogues of Ov-GRN-1 represent functional mimetics (18) with potential 
in treating chronic wounds where the normal tissue repair mechanisms are 
overwhelmed, such as diabetic ulcers (19, 20). 
 
Our truncated analogues of Ov-GRN-1 provide insight into the folding and the 
bioactive region, but uncertainty remains regarding the principal features for 
secondary structure formation and structural stability (21, 22). For instance, the 
peptide (Ov-GRN12-35_3s) corresponding to residues 12-35 in Ov-GRN-1, comprises 
only one β-hairpin in contrast to a truncated form of carp granulin-1 (18, 23, 24). 
Intriguingly, this peptide contains a non-native disulfide bond based on the predicted 
connectivity as shown in Figure 4-1B. The role of this bond in secondary structure 
stabilisation is not fully understood. In addition, Ov-GRN12-35_3s displays evidence of 
additional conformations in the NMR spectra. To determine if these additional 
conformations are the result of proline cis/trans isomerisation, in the current study we 
have mutated the proline residues and examined the effects on structure, folding and 
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activity. Determining the most structurally stable and potent analogue is expected to 
facilitate the development of Ov-GRN-1 derived peptides as novel wound healing 
agents.  
 
 
 
 
 
	
Figure 4-1 Conserved cysteine framework in the granulin family. Disulfide bond 
connectivity in full-length carp granulin-1 (A), and the synthetic N-terminal Ov-GRN-
1 peptide (Ov-GRN12-35_3s) (B). A non-native disulfide bond marked in red is 
predicted to be present in Ov-GRN12-35_3s (18). C = cysteine residues sequentially 
numbered with Roman numerals, --- represents non-cysteine amino acids, solid black 
lines connecting cysteine residues represent disulfide bonds. 
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4.3 Experimental section 
4.3.1 Peptide synthesis, purification and characterisation   
Granulin analogues were synthesised by a stepwise solid phase peptide synthesis 
procedure on a Protein Technologies PS3 synthesiser. The Fmoc amino acid 
derivatives (Auspep, Australia) were activated using HCTU (Iris, Germany) and 
coupled on the 2-chlorotrityl chloride resin with DIPEA/DMF. The peptide was 
cleaved from the resin using the following cleavage cocktail: 
95%TFA:2.5%TIPS:2.5%H2O (v/v/v). The peptide was then precipitated with ice-
cold diethyl ether and the ether evaporated off with a stream of nitrogen gas. 
Precipitated peptide was dissolved in 50%acetonitrile:50% H2O:0.1%TFA (v/v/v) and 
subsequently lyophilised. The resulting crude peptides were purified by reversed-
phase HPLC using a C18 preparative column (Phenomenex Jupiter 250 x 21.2 mm, 10 
µm, 300 Å), a flow rate of 5 mL/min, and a 1% gradient (0-60%B) of solvent A 
(95.95%H2O:0.05% TFA (v/v)) and solvent B (90%acetonitrile:10%H2O:0.05%TFA 
(v/v/v)).  The eluents were monitored at 214 and 280 nm and the mass determined 
using a 5800 MALDI TOF/TOF mass spectrometer (SCIEX, Foster city, CA). Based 
on analytical RP-HPLC the purified peptides had ≥95% purity.  
4.3.2 Disulfide formation  
Disulfide bonds were formed by overnight air oxidation of 0.1 mg/ml peptide in 0.1 
M ammonium bicarbonate (pH 8-8.2) containing 5 mM reduced glutathione at room 
temperature for 24 h. The solution was acidified, filtered and purified on a C18 
preparative column using RP-HPLC and the peptide mass was analysed using a 5800 
MALDI TOF/TOF spectrometer (SCIEX, Foster city, CA).   
4.3.3 NMR spectroscopy and structure analysis 
Samples were prepared from lyophilised peptide at concentrations of approximately 
0.2 mM in 90%H2O:10%D2O. All NMR spectra were recorded on a 600 MHz 
AVANCE III NMR spectrometer (Bruker, Karlsruhe, Germany). 2D 1H-1H TOCSY, 
1H-1H NOESY, 1H-1H DQF-COSY, 1H-15N HSQC, and 1H-13C HSQC at 290 K were 
used for assignment. All spectra were recorded with an interscan delay of 1 s. 
NOESY spectra were acquired with mixing times of 200 ms, and TOCSY spectra 
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were acquired with isotropic mixing periods of 80 ms. All spectra were assigned 
using CCPNMR (25) based on the approach described in Wüthrich et al (26). The αH 
secondary shifts were determined by subtracting random coil 1H NMR chemical shifts 
(27) from the experimental αH chemical shifts. The 2D NOESY spectra were 
assigned and an ensemble of structures calculated using the program CYANA (28). A 
total of 100 initial structures were calculated using the CYANA program. Torsion-
angle restraints predicted using TALOS N were used in the structure calculations 
(29). Structures were visualised using MOLMOL (30). 
4.3.4 Mammalian cell culture 
The 1BR.3.GN (ECACC 90020509), human skin normal fibroblast cell line was 
obtained from European Collection of Authenticated Cell Cultures (ECACC). 
1BR.3.GN cells were grown and maintained in DMEM/F12 (Life Technologies) 
containing 1× antibiotic/antimycotic and 1× GlutaMAX, supplemented with 10% fetal 
bovine serum (FBS) (Gibco, Scotland) at 37°C and 5% CO2. Cell proliferation assays 
were performed with DMEM/F12 media supplemented with 10% FBS. 
 
The H69 non-malignant cholangiocyte cell line was obtained from Dr. Gregory J. 
Gores, Mayo Clinic, Rochester, Minnesota (18). H69 cells were cultured and 
maintained as previously described (18) in DMEM/F12 (Life Technologies) 
containing 1× antibiotic/antimycotic and 15 mM HEPES, supplemented with 10% 
fetal bovine serum (FBS) (Gibco, Scotland) at 37°C and 5% CO2. Cell proliferation 
assays were performed with modified DMEM/F12 media supplemented with 0.5% 
FBS and particular hormone and growth factors in defined concentration ranges 
reported (18).  
4.3.5 Cell proliferation monitoring in real time using xCELLigence  
Analysis of cell proliferation was performed in real time using an xCELLigence SP 
system (ACEA Biosciences) as described previously (18). 1BR.3.GN cells were 
plated into a 96-well xCELLigence E-plate (ACEA Biosciences) at a density of 7500 
cells/well; then placed in the xCELLigence system with 5% CO2 at 37°C and 
monitored overnight (31). The complete media was subsequently replaced with 150 
µL of starvation media (DMEM/F12 media supplemented with 0.5% FBS) and 
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incubated overnight. Treatments in 10% media were added to each well in a total 
volume of 20 µL to provide 200 nM or 500 nM final concentrations and the cell index 
(CI) was monitored with the real time cell analysis software (RTCA, ACEA 
biosciences). At control peptide treatment peak cell number (peak CI) the cell 
proliferation rate was calculated as the relative number of treated cells compared to 
control cells (~120 hours in culture). H69 Cell proliferation was performed as 
described previously (18). GraphPad Prism 6.02 was used for comparing treatments 
against peptide controls with one-way ANOVA followed by Holm-Sidak’s multiple 
comparison tests. Treatments were measured with 3-6 biological replicates from 2 
independent experiments. 
4.3.6 Mouse wounding assay  
These studies were conducted with the approval of the James Cook University Small 
Animal Ethics Committee, applications A2204, as described previously (14). Briefly, 
female 11-12 week old BALB/c mice weighing 19-23 g were sourced from the 
Australian ARC (Animal Resources Centre) and randomly allocated into groups of 4 
mice and fur removed on the crown of the head with small animal electric shaver. 
Mice were anesthetized with 3% isoflurane/air mix (Provet), after which a skin-deep 
wound on the crown of the head was created using a 5 mm diameter circular biopsy 
punch and surgical scissors (Zivic instruments). Betadine liquid antiseptic (Sanofi) 
was applied followed by application of 50 µL that contained either 71 pmoles of 
Regranex (32, 33) (treatment of 71 pmoles equals ~1 µg per 0.2 cm2 wound, as 
recommended by manufacturer Smith and Nephew), 56 pmoles of rOv-GRN-1 (15), 
50 pmoles Ov-GRN-1 peptides, or control peptide 
(EADRKYDEVARKLAMVEADL) (18), E.coli thioredoxin protein expression 
control (TRX) or PBS vehicle control suspended in 1.5% methylcellulose (Sigma). 
Wounds were photographed daily and treatments applied daily up until 4 days post 
wounding.  Groups were blinded and the area of the lesion was measured with ImageJ 
software and plotted as percent of wound closure from original wound images. 
Wound healing rates of treatments were compared against controls and other 
treatments with one-way ANOVA test with Holm-Sidak’s correction for multiple 
comparisons, using GraphPad prism 6.02. Wound healing assays in mice were 
performed in duplicat. 
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4.4 Results  
4.4.1 Design and synthesis of Ov-GRN12-35_3s mutants 
To determine which proline residues are involved in adopting multiple conformations, 
three single mutants (GRNP2A, GRNP4A, GRNP10A) of Ov-GRN12-35_3s, in which each 
mutant has one of the three prolines changed to an alanine residue were chemically 
synthesised. An analogue with all proline residues replaced with alanine residues was 
also synthesised and termed GRN3Ala. The sequences of the synthetic Ov-GRN-1 
truncated peptides are given in Table 4-1. 
 
All peptides were chemically synthesised using Fmoc solid phase peptide synthesis. 
The crude peptides were purified using RP-HPLC and mass analysis carried out using 
MALDI mass spectrometry. The peptides were oxidised to form the disulfide bonds in 
0.1 M ammonium bicarbonate and 5 mM glutathione at room temperature for 24 
hours. Glutathione was used as a disulfide bond shuffling reagent and generally 
improved the yield of the correctly folded forms (results not shown). 
 
 
 
Table 4-1 Sequences of Ov-GRN-1 peptides 
	
Peptide Sequence 
 
Ov-GRN12-35_3s 
 
1    5     10    15    20   
CPDPVYTCRPGQTCCRGLHGYGCC 
  
GRNP2A CADPVYTCRPGQTCCRGLHGYGCC 
GRNP4A CPDAVYTCRPGQTCCRGLHGYGCC 
GRNP10A CPDPVYTCRAGQTCCRGLHGYGCC 
GRN3Ala CADAVYTCRAGQTCCRGLHGYGCC 
All Ov-GRN-1 truncated peptides contain the first six cysteine residues (bold) in the 
full-length protein.  Prolines at positions 2, 4 and 10 are underlined and numbered in 
the native first sequence and subsequent variant sequences show proline to alanine 
variations underlined in bold. 
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A relatively sharp, early eluting peak was presented for the majority of the peptides. 
To describe the efficacy of the folding, the relative folding yield of this early eluting 
peak is given in Table 4-2. Relative folding yield is taken to mean the fraction of the 
integrated HPLC peak corresponding to the early eluting peak (natively folded 
species), relative to the total integrated HPLC area corresponding to all folding 
species in a given HPLC chromatogram (22, 34). For all peptides, with the exception 
of GRNP10A, the major early eluting peaks were isolated from each reaction for further 
characterisation.  
The large number of peaks present in the folding reaction of GRNP10A, even following 
a 48-hour oxidation period, prevented the purification of a single major disulfide 
isomer. The yield of this early eluting peak is significantly higher in the GRN3Ala 
mutant (relative oxidative folding yield of 42.6%) compared to the other peptides. 
 
 
 
Table 4-2 Oxidative folding yields for the granulin peptides  
 
Peptide Yield (%) 
Ov-GRN12-35_3s 23.0 
 
GRNP2A 33.0 
GRNP4A 31.0 
GRNP10A 20.0 
GRN3Ala 43.0 
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4.4.2 Structural analysis with NMR spectroscopy 
The structures of the purified or partially purified fractions for the Ov-GRN12-35_3s 
analogues were analysed using NMR spectroscopy. The one-dimensional spectra of 
all peptides have significant dispersion in the amide region consistent with the 
presence of β-sheet structure. Analysis of the TOCSY (Total Correlated 
Spectroscopy) and NOESY (Nuclear Overhauser Effect Spectroscopy) spectra for the 
individual proline mutants indicates the presence of multiple conformations most 
likely as a result of isomerisation of the proline residues. By contrast, the GRN3Ala 
peptide did not appear to have multiple conformations as shown in Figure 4-2. 
 
 
	
 
Figure 4-2 Regions of the TOCSY spectra of Ov-GRN12-35_3s and GRN3Ala. Spectra 
were recorded at 0.2 mM, 290 K. Assigned residues are shown with their residue 
name and number. Additional peaks not seen in GRN3Ala (right) resulting from 
multiple confirmations in Ov-GRN12-35_3s are boxed (left). 
	
	
 
 
Two-dimensional spectra (TOCSY and NOESY) were used to assign the major 
conformations, and the secondary shifts were determined by subtracting random coil 
shifts from the experimental αH shifts (27). The consecutive positive secondary shifts 
in Figure 4-3, particularly for residues 12-15, are consistent with the presence of β-
sheet structure. The secondary shifts are generally similar over the equivalent residues 
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for all proline mutants compared to the N-terminal Ov-GRN-1 peptide, Ov-GRN12-
35_3s, indicating that the overall structures are similar.  
 
 
 
	
 
Figure 4-3 Secondary shifts of Ov-GRN12-35_3s engineered peptides.  The secondary 
shifts were derived by subtracting random coil shifts from the αH shifts (27). The 
consecutive positive shifts for residues 11-14 is indicative of β-sheet. The trends for 
the secondary shifts are similar compared to Ov-GRN12-35_3s indicating that the β-sheet 
present in Ov-GRN12-35_3s is maintained in the proline mutant analogues. 
 
	
 
GRN3Ala was chosen for full structural analysis because of the efficient folding, lack 
of conformational heterogeneity and to determine the influence of the proline residues 
on the overall fold. The family of structures was calculated using CYANA (28). The 
disulfide bonding pattern of Ov-GRN12-35_3s was previously predicted to be Cys I-Cys 
III, Cys II-Cys V and Cys IV-Cys VI (18), and this connectivity was used in the 
structure calculations of GRN3Ala. Preliminary structures were calculated based on 
NOE (Nuclear Overhauser Effect) and dihedral angle restraint data. Hydrogen bond 
restraints were subsequently included for bonds that were predicted to occur in the 
preliminary structures and were consistent with the slowly exchanging amide protons.  
A family of 20 structures with the lowest CYANA target functions were chosen to 
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represent the structures of GRN3Ala. The structure statistics for the final ensemble of 
structures is given in Table 4-3.  
 
The structures are well defined with an RMSD of 0.78 Å over the backbone atoms of 
all residues. Analysis of the secondary structure using MOLMOL indicates an α-helix 
from residues 4 to 11 and a β-hairpin involving residues 14 to 23. The β-hairpin in 
GRN3Ala is consistent with the structure of Ov-GRN12-35_3s, but the N-terminal α-helix 
represents a significant structural change (Figure 4-4). 
 
 
 
 
Table 4-3 Structural statistics for GRN3Ala 
	
Experimental restraints  
Interproton distance restraints  
Intraresidue, |i-j|=0  85 
Sequential, |i-j|=1 84 
Medium range, 1 <|i-j| < 5 10 
Dihedral-angle restraints 28 
R.m.s. deviations from mean coordinate structure (Å) 
Backbone atoms (all) 0.78 ± 0.27 
All heavy atoms (all) 1.69 ± 0.32 
Ramachandran (%)  
Residues in most favoured regions 95.9% 
Residues in additionally allowed regions 4.1% 
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Figure 4-4 Three-dimensional structure of Ov-GRN12-35_3s (A) and GRN3Ala (B). 
The structures were determined based on NMR spectroscopy data with cysteines 
numbered with Roman numerals joined by disulfide bonds in yellow, β-sheet 
represented as arrows, and α-helix shown as a pink/aqua coil. The side-chains of Pro 
2, Pro 4 and Pro 10 are highlighted (dark blue) on the Ov-GRN12-35_3s structure (PDB 
ID code: 5UJH). The proline residues were replaced with alanine residues (dark blue) 
in GRN3Ala (PDB ID code: 6E1L; the coordinates are provided as supporting 
information).  
	
4.4.3 Cell proliferation monitoring in real time using xCELLigence  
In addition to structural studies, to gain insight into the structure-function 
relationships of Ov-GRN12-35_3s, the proline mutants were tested in an in vitro cell 
proliferation assay (17, 22). GRNP10A was not tested because a single isomer could 
not be purified. The rates of cell proliferation of H69 human bile duct (cholangiocyte) 
and 1BR.3.GN human fibroblast skin cells, in the presence of peptides or controls, 
were measured using xCELLigence technology as shown in Figure 4-5. The 
individual proline mutants significantly increased H69 cell proliferation compared to 
the negative control peptide (20 residue peptide from tropomyosin). The proliferation 
rates of GRNP2A, P4A were 131% (P<0.0001) and 141% (P<0.0001), respectively, 
relative to the control peptide (Figure 4-5A). GRN3Ala did not induce H69 significant 
cell proliferation at concentrations up to 1 µM (data not shown).  
 
In contrast to the H69 proliferation, GRN3Ala substantially promoted proliferation in 
1BR.3.GN cells in a dose dependant manner by 12% (P<0.01) and 26% (P<0.01) at 
200 nM and 500 nM, respectively. GRNP4A also promoted cell proliferation in a dose 
dependant manner with these cells, with proliferation rates relative to the control 
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peptide of 108% (P<0.05) at 200 nM, and 125% (P<0.01) at 500 nM. By contrast, 
GRNP2A was not active at 200 nM but 500 nM promoted significant cell proliferation 
(16% above peptide control (P<0.001) (Figure 4-5B).  It should be noted the 
1BR.3.GN cells showed substantially less proliferation than the H69 cells. The 
differences in media in addition to the cell-type are likely to contribute to this 
difference. 
 
 
Figure 4-5 Granulin peptide variants stimulated in vitro cell proliferation (A) The 
H69 cells in low nutrient media (0.5% FBS) were treated with 200 nM peptide for 48 
h (2 days). (Β) Human fibroblast 1BR.3.GN cells were grown in complete media 
(10% FBS) and the various peptides were assessed for stimulation of proliferation at 
200 nM and 500 nM at peak cell index (~120 hours/5 days).  The proliferation rates 
relative to peptide controls are plotted as mean ± SEM bars. Data were analyzed by 
one-way ANOVA against peptide control. Not significant = ns, * P<0.05, ** P<0.01, 
*** P<0.001 ****P<0.0001.  
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4.4.4 Mouse wounding assay 
The peptides GRNP2A, GRNP4A and GRN3Ala were also tested in a mouse wound 
healing assay using the procedures previously reported (18). The results are shown in 
Figure 4-6 and highlight that both GRNP4A (142.8%, P<0.0001) and recombinant Ov-
GRN-1 (127.1%, P<0.0001) stimulated more marked resolution of the cutaneous 
lesions on the scalp of the mice than GRN3Ala (125.1%, P<0.001) and Ov-GRN12-35_3s 
(119.1%, P<0.05). GRNP4A promoted a significant (P<0.05) increase in wound 
healing by 21% compared to the Regranex treatment. GRNP2A (116%) did not 
significantly influence wound healing compared to the control peptide.   
 
 
 
 
	
Figure 4-6	 Granulin peptides stimulated mouse wound healing. The average 
wound healing rate relative to the peptide control treatment is shown after four days 
of 56 pmol of various granulin treatments or 76 pmol of Regranex are shown. 
Relative to the peptide negative control the full-length granulin protein (Ov-GRN-1) 
and Regranex stimulate wound healing by 27% and 22% respectively.  Data were 
analyzed by one-way ANOVA from duplicated experiments with 4 female balb/c 
mice per group.  Compared against peptide control: Not significant = ns, * P<0.05, 
*** P<0.001 ****P<0.0001.  Compared against Regranex  # = P<0.05.  
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4.5 Discussion  
Chronic wounds are a substantial problem affecting 1-2% of people globally and 
costing ~USD $50 billion to treat annually (35, 36). Better treatments are needed 
desperately, especially for diabetics who suffer from a disproportionally high rate of 
chronic wounds (36). Regranex (recombinant human platelet-derived growth factor) 
is the only FDA approved treatment for chronic wounds, but increased malignancies 
were observed in patients (37). Ov-GRN-1 has potential in the development of a novel 
wound-healing agent, but there is still limited information on the structure-function 
relationships. Here we show mutation of the proline residues in Ov-GRN12-35_3s can 
improve folding yield and wound healing properties. 
Mutation of the individual proline residues did not disrupt the overall fold of Ov-
GRN12-35_3s, but multiple conformations were still present based on the presence of 
additional peaks in the NMR spectra. By contrast, when all three proline residues 
were mutated to alanine residues a single set of peaks corresponding to a single 
conformation were observed in the NMR spectra. These results indicate that all three 
proline residues are involved with cis/trans isomerisation to some extent.  
Cis/trans isomerisation can be a rate-determining step in the folding of proteins (38, 
39), and appears to be influencing the folding of Ov-GRN12-35_3s. Removal of proline 
2 and proline 4 in GRNP2A and GRNP4A respectively, improved the oxidative folding 
yields relative to Ov-GRN12-35_3s. By contrast, mutation of proline 10 with an alanine 
residue did not improve the folding yield. Prevention of cis/trans isomerisation by 
removal of all three proline residues resulted in the highest folding yield (Table 4-2). 
These results indicate that the proline residues, which have a much higher propensity 
to form cis peptide bonds than other residues (40), are generally detrimental to the 
folding under the current conditions (41). Further study is required to determine the 
influence of the proline residues on folding in vivo.   
Our findings conform with earlier reports that revealed that folding of human granulin 
modules is strongly influenced by sequence variations (10). In mammals, granulins 
are expressed as progranulin, which contains seven-and-a-half granulin modules (7, 
42). The folding profiles of recombinant versions of the seven full-length granulin 
modules vary markedly, based on HPLC analysis (10). Analysis of the structures with 
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NMR spectroscopy indicate that GRN-2, GRN-4 and GRN-5 display defined 
structures (10). By contrast, GRN-3 and -7 did not display significant dispersion in 
the NMR spectra, and GRN-6 and -1, exhibit multiple signals in the NMR spectra for 
unique protons (10). Although the folding and structures vary amongst the different 
human granulin domains, the sequences responsible for these different conformations 
have not been defined (21). Sequence alignment (Table 4-4) of Ov-GRN12-35_3s with 
human granulins and carp granulin-1 shows that GRN-3 and -2 both contain a proline 
residue immediately following the first cysteine in the sequence, consistent with 
proline 2 in Ov-GRN12-35_3s. GRN-3 does not have a predominant, sharp peak in the 
HPLC profile of the folding reaction, but GRN-2 does (10). Although mutation of 
proline 2 in Ov-GRN12-35_3s had an influence on the folding profile, the varying results 
for GRN-3 and GRN-2 suggest that this proline alone does not have a general 
influence on folding of granulin domains.  
 
Sequence alignment of human granulin domains and carp granulin-1 also shows in all 
but two sequences (hGRN-1 and -7) there is a highly conserved proline residue 
immediately after the second cysteine in the granulin cysteine framework (Table 4-4).  
 
Ov-GRN-1 does not contain this conserved “CP” sequence but rather contains a 
“CRP” sequence where the proline is equivalent to residue 10 in Ov-GRN12-35_3s. 
When this proline was mutated to an alanine residue in GRNP10A, the folding profile 
did not contain one major isomer in contrast to the other mutants, indicating that this 
residue is important in the folding of Ov-GRN12-35_3s. 
 
In addition to the influence on folding, mutation of the proline residues also 
influenced biological activity. The single point mutants of Ov-GRN12-35_3s 
significantly accelerated the proliferation of H69 human cholangiocytes to a similar 
extent to native Ov-GRN12-35_3s, whereas GRN3Ala did not enhance the rate of 
proliferation. By contrast, GRNP4A and GRN3Ala significantly accelerated the 
proliferation of fibroblasts at the low concentration, whereas GRNP2A did not. The 
results from the in vivo wound healing study correlate with the fibroblast cell assay 
results. For example, GRN3Ala is not active on H69 cells but is active on fibroblasts 
and in the in vivo wound-healing assay. Conversely, GRNP2A induced proliferation of 
cholangiocytes, but only showed this effect on fibroblast cells at the highest 
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concentration tested and was not significantly active in the in vivo wound-healing 
assay.  
 
 
 
Table 4-4 Sequence alignment of human granulins.  
 
UniProt Entry Peptide N-terminal six cysteine core sequence B8XSI4 
 
Ov-GRN12-35_3s CPDPVYTCRP-GQTCCRGLHG-YG-CC 
P28799 
 
*hGRN-1(G)	 CQVDAH-C-SAGHSCIFTVSGTSS-CC 
P28799 
 
hGRN-2(F) CPDSQFEC-PDFSTCCVMVDGSWG-CC 
P28799 
 
hGRN-3(B)  CPDARSRC-PDGSTCCELPSGKYG-CC 
P28799 
 
hGRN-4(A) CDMEVS-C-PDGYTCCRLQSGAWG-CC 
P28799 
 
hGRN-5(C)  CDNVSS-C-PSSDTCCQLTSGEWG-CC 
P28799 
 
hGRN-6(D) CDQHTS-C-PVGQTCCPSLGGSWA-CC 
P28799 
   
 
hGRN-7(E) CGEGHF-C-HDNQTCCRDNQG-WA-CC 
P28799 
 
 
paraGRN CPDGQF-C—PVA--CCLDPGGASYSCC 
P81013 
 
carp granulin-1 CDAATI-C-PDGTTCCLSPYGVWY-CC 
Cysteine residues are marked in bold and the proline residues equivalent to proline 10 
in Ov-GRN12-35_3s are underlined in each sequence. hGRN-n(X) designates the 
individual human granulin domains from human progranulin with the two commonly 
used numbered (n) and alphabetized (X) designations. *hGRN-1(G) is an unusual 5 
cysteine N-terminal variant (10 cysteine residues rather than 12 in the full GRN 
domain). 
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The consistency between the mouse wound healing assay and the fibroblast cell 
assays is not unexpected given the role of fibroblasts in wound healing of the skin 
(43-46). Fibroblast numbers peak 3 days post-injury and migrate into the wound to 
initiate the proliferative phase differentiation (47). This is followed by deposition of 
new matrix proteins to restore structure and function to the injured tissue (44). 
Additionally, the complete 10% FBS media used with the fibroblasts is likely a closer 
approximation of the in vivo conditions encountered by cells than the low nutrient 
media used with the cholangiocytes. 
 
The limited activity of GRNP2A in the fibroblast cell assay and the in vivo wound-
healing assay, suggests that proline 2 plays an important role in the function of this 
protein. However, GRN3Ala, which also lacks proline 2 and has a well-defined α-helix 
at the N-terminal region, is active in the fibroblast cells and the in vivo model. 
Collectively, these results suggest that the structure-function relationships for the 
granulin peptides are complex.  
 
The lack of activity of GRN3Ala on the H69 epithelial cells compared to fibroblasts is 
of interest. There are many functional similarities between tumorigenesis and wound 
healing (44, 48). Inflammation, collagen and matrix deposition and angiogenesis are 
involved in both processes. While wound healing is usually a self-limiting process, 
rapid cellular division occurs and when uncontrolled, cell division can result in 
tumour formation (44, 48, 49). Developing a wound healing treatment with a growth 
factor can be effective but understanding the signalling pathways involved is an 
important step to limiting unwanted tumour stimulation, as seen with Regranex (37). 
Our next step to develop these peptides as potential healing stimulating treatments is 
to explore the underlying mechanism of action and uncover the binding 
partner/receptor(s) for Ov-GRN-1 and underlying signal transduction pathways. 
Nevertheless, this result might have significant implications for different 
receptor/mechanisms being involved in proliferation of cholangiocytes and the wound 
healing properties of Ov-GRN-1 and derivative peptides. 
 
An area that can be explored to further the understand of the granulin peptide wound 
healing processes is mathematical models that break down healing steps based upon 
healing rates (50). Separating healing phases allows more detailed analysis and 
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statistical refinement.  However, our data does not match the latest Cogan et al model 
that uses a 2-phase piecewise linear fit of initial stasis followed by a healing period 
(51). But as models adapt to a range of wound methodologies, we expect our future 
analysis will increasingly explore the use of these approaches. 
 
The in vivo model used in the current study represents a normal (acute) wound 
healing process, which includes four phases: coagulation/inflammatory phase, 
proliferative phase, matrix remodelling and scar formation. Diabetic ulcers are 
classified as chronic wounds, which fail to progress through the wound healing phases 
in a timely manner (52, 53). In particular, the proliferative phase, which involves 
fibroblast cell proliferation and angiogenesis, is impaired in diabetic patients (52). 
Thus the prolonged inflammatory phase and persistent infections exacerbate the 
healing progress in diabetic ulcers (52, 53). Given the influence of the granulin 
peptides on the proliferation of fibroblasts we speculate that the granulin peptides will 
also be efficacious in diabetic wound healing models, but this remains to be 
determined.  
4.6 Conclusions 
Overall, our results highlight the importance of the proline residues in the structure, 
folding and function of Ov-GRN12-35_3s. GRN3Ala had the highest folding yield and 
was a potent stimulator of healing in mice.  GRNP4A was the most potent peptide for 
healing wounds in vivo, and was significantly more potent than Regranex, a growth 
factor approved for human clinical use for this indication (32). The enhanced wound 
healing potency and improved folding yields of these proline mutants suggest they 
might be good candidates for further development as wound healing agents.  
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4.8 Supporting information 
PDB ID Code for GRN3Ala: 6E1L  
 
4.9 Non-standard abbreviations 
HCTU, (2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate); DIPEA, Ethyldiisopropylamine; TOCSY, Total Correlated 
Spectroscopy; USD, United States Dollar; ECACC, European Collection of 
Authenticated Cell Cultures; DMEM/F12, Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; 
FBS, Fetal Bovine Serum; CI, Cell Index; ARC, Animal Resources Centre; TRX, 
thioredoxin; RP-HPLC, Reverse phase HPLC; D2O, Deuterium Oxide; DQF-COSY, 
Double-quantum filtered correlation spectroscopy;  ANOVA, ANalysis Of Variance . 
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Chapter 5. Distinct Structural and 
Biological Differences Between the N- 
and C-terminal Regions of Granulins 
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5.1 Abstract 
Granulins are a family of growth factor proteins, which generally contain six disulfide 
bonds and are found in most organisms. We have recently shown that the N-terminal 
half of Ov-GRN-1, a granulin derived from the parasitic human liver fluke 
Opisthorchis viverrini, can fold independently and has potent wound healing activity. 
This peptide contains three disulfide bonds, including a bond not present in full-length 
carp granulin-1, the prototypic granulin family member. Here we show using 
structure-based design, chemical peptide synthesis and folding analysis that the N-
terminal half of the human granulin A protein also folds independently with three 
disulfide bonds, despite significant sequence differences to the Ov-GRN-1 peptide. 
This result indicates that accommodation of a non-native disufide bond might be a 
general phenomenon in the granulin family. We also show for the first time that the 
equivalent C-terminal half of Ov-GRN-1 does not fold into a well-defined structure, 
but still displays some cell proliferation activity. Our results indicate that well-defined 
structures are not critical for granulin bioactivity 
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5.2 Introduction 
Ov-GRN-1 is a disulfide-rich protein isolated from the excretory/secretory 
products of the liver fluke Opisthorchis viverrini. Ov-GRN-1 belongs to the 
granulin protein family (3-5) and is involved in a range of processes including 
wound healing (6-9), angiogenesis (10) and carcinogenesis (3, 11). The 
granulin protein family contains a highly conserved cysteine-rich motif, which 
forms six disulfide bonds (Figure 5-1A) and a series of antiparallel β-sheets (4, 
12-15). The structure of full-length human granulin A (also referred to as 
hGRN-4(12)) is shown in Figure 5-1B (16).  
 
 
Figure 5-1 Granulin cysteine framework and structure. (A) Schematic 
representation of the highly conserved cysteine framework and disulfide bond pairing 
present in the granulin family; the cysteine residues are numbered using Roman 
numerals (I-XII). (Β) The three-dimensional structure of full-length hGRN A (PDB 
ID: 2JYE). 
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Granulin proteins are found in a wide variety of organisms and possess distinct 
variations in the structures (12, 17). For example, the carp and zebrafish 
granulins display relatively well defined structures (15, 18), whereas several of 
the human granulins have a well-defined stack of two β-hairpins in the N-
terminal region, and structural disorder in the C-terminal region (16). The 
folding pathways involved in formation of the disulfide-rich structures are 
unknown, but it has been shown that peptides corresponding to the N-terminal 
region of carp granulin-1 and a human granulin A analogue fold autonomously 
with two disulfide bonds (19-21). Furthermore, we have recently shown that the 
N-terminal half of Ov-GRN-1 can also fold independently (7). This peptide 
contains three disulfide bonds, including a bond not present in the full-length, 
well-defined carp granulin-1 and zebrafish granulin AaE peptides (15, 18). 
Despite containing a non-native disulfide bond, this peptide displays a well-
defined structure, potent cell proliferation and in vivo wound healing properties 
(6, 7). 
 
It is not clear if the folding properties of the Ov-GRN-1 N-terminal peptide are 
unique to the parasite protein, or whether granulins from other sources can also 
fold independently with the first six cysteine residues present. There is 
significant sequence variation amongst granulin peptides, making accurate 
prediction of different folding properties difficult. Furthermore, there is no 
information available on the folding and structural properties of granulin 
peptides containing just the C-terminal region.  
 
In the current study we have analysed the folding of the N-terminal region of 
human granulin A, the most abundant of the human granulins (22), and show 
that it can form a well-defined structure incorporating a non-native disulfide 
bond. We also show that the C-terminal region of Ov-GRN-1 truncated peptide 
does not fold independently, in contrast to the N-terminal region, but still 
displays bioactivity, albeit with lower potency than the proline mutants of Ov-
GRN-1 previously studied (6) .  
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5.3 Experimental section 
5.3.1 Peptide synthesis, purification and characterisation 
Truncated granulin peptides were synthesised on a Protein Technologies PS3 
synthesiser, using 2-chlorotrityl-chloride resin. The Fmoc amino acid 
derivatives (Auspep, Australia) were activated using HCTU (Iris, Germany) 
and coupled on the resin with DIPEA/DMF by stepwise solid-phase peptide 
synthesis chemistry. Peptides were cleaved from the solid support by treatment 
with a mixture of TFA:TIPS:H2O at ratios of 95%:2.5%:2.5% (v/v), followed 
by purging with nitrogen to evaporate TFA. Peptides were then precipitated in 
ice-cold diethyl ether and dissolved in 50% acetonitrile:50% H2O:0.1% TFA 
(v/v) and subsequently lyophilised. The crude peptides were purified by 
reversed-phase HPLC (RP-HPLC) on a Phenomenex Jupiter C18 preparative 
column (300 Å, 10 µm, 250 x 21.2 mm), using a gradient of 0-60% solvent Β 
(Solvent A: 99.95% H2O:0.05% TFA; Solvent Β: 90% acetonitrile:10% 
H2O:0.045% TFA) over 60 minutes. The collected fractions were characterised 
using a SCIEX 5800 MALDI TOF/TOF mass spectrometer (SCIEX, Foster 
city, CA) and then lyophilized. 
5.3.2 Disulfide bond formation 
Disulfide bonds were formed as described previously (6, 7). Reduced peptide 
(0.1 mg/mL) was dissolved in 0.1 M ammonium bicarbonate (pH 8-8.2) 
containing 5mM reduced glutathione at room temperature for up to 72 h. The 
presence of disulfide-bonded species was examined by removing aliquots from 
the folding mixture at selected time points and analysing them with analytical 
RP-HPLC using a Phenomenex Jupiter 4 µm Proteo column (150 x 2.00 mm, 
90 Å). When the oxidation was completed, the oxidation solution was acidified 
with TFA and loaded on a C18 preparative column with a flow rate of 5 
mL/min. The separation method was as follows: a gradient of 0-50% solvent Β 
over 50 min. Fractions were collected and the peptide mass was analysed using 
a SCIEX 5800 MALDI TOF/TOF spectrometer.   
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5.3.3 NMR spectroscopy  
Lyophilised peptide was dissolved in 90%H2O:10% D2O at a concentration of 
approximately 0.2 mM. All NMR spectra were acquired on a Bruker 600 MHz 
AVANCE III NMR spectrometer (Bruker, Karlsruhe, Germany). 2D 1H-1H 
TOCSY, 1H-1H NOESY, 1H-1H DQF-COSY, collected at 290 K were used for 
sequence-specific assignments and structure calculations. 1H-15N HSQC and 
1H-13C HSQC spectra were acquired for nitrogen and carbon chemical shifts 
respectively. Two-dimensional homonuclear NOESY and TOCSY spectra were 
acquired with a mixing time of 200 ms and a spin lock time of 80 ms 
respectively. All spectra were processed using Bruker TopSpin (Version 
3.5pl7) and assigned using CCPNMR analysis 2.1 based on the approach 
described in Wüthrich et al (23).  
 
5.3.4 Structure calculations 
The three-dimensional structures of hGRNA4-28_3s were calculated using the 
CYANA program, based on automated assignment of the NOEs (24). Torsion-
angle restraints predicted by TALOS-N were used in the structure calculations 
(25). An ensemble of 100 structures was calculated and the 20 structures with 
the lowest target function chosen to represent the structures of hGRNA4-28_3s. 
Structures were visualised using MOLMOL and the root-mean-square 
derivation (RMSD) values were assessed (26). The αH secondary shifts were 
determined by subtracting random coil 1H NMR chemical shifts from the 
experimental αH chemical shifts (27).  
 
5.3.5 Mammalian cell culture 
The human skin normal fibroblast cell line, 1BR.3.GN (ECACC 90020509), 
was purchased from European Collection of Authenticated Cell Cultures 
(ECACC). The 1BR.3.GN fibroblasts were grown and maintained in 
DMEM/F12 (Life Technologies) containing 1× antibiotic/antimycotic and 1× 
GlutaMAX, supplemented with 10% fetal bovine serum (FBS) (Gibco, 
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Scotland) at 37°C and 5% CO2. Cell proliferation assays were performed with 
DMEM/F12 media supplemented with 10% FBS. 
5.3.6 Cell proliferation monitoring in real time using xCELLigence 
An xCELLigence Real Time Cell Analyzer – Single Plate (RTCA SP) 
instrument (ACEA Biosciences) was used to evaluate cell proliferation as 
described previously (6, 7). Briefly, 1BR.3.GN cells (7,500 cells/well) were 
seeded into a 96-well xCELLigence E-plate (ACEA Biosciences). The E-plate 
was placed into the xCELLigence station and incubated at 37°C with 5% CO2 
and monitored overnight. The complete media was subsequently aspirated and 
replaced with 150 µL of starvation media (DMEM/F12 media supplemented 
with 0.5% FBS) and incubated overnight. Treatments in 10% media were added 
to each well in a total volume of 150 µL to provide 200 nM or 1 µM final 
concentrations in quadruplicate. Cells treated with a 20-residue peptide from 
tropomyosin (EADRKYDEVARKLAMVEADL) served as the negative 
control peptide (6, 7). Cell proliferation was monitored every 1 h for 7 days. 
The cell index (CI) was normalized to CI of the time-point when the treatments 
were added to the cells. The cell proliferation rate was calculated as CI for the 
treated cells compared to CI for peptide control cells (~100-120 hours in 
culture). Cell proliferation rates were compared between treatment and control 
wells, and statistical analyses were conducted using one-way ANOVA 
followed by Holm-Sidak’s correction for multiple comparisons, using 
GraphPad prism 6.02. 
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5.4 Results 
5.4.1 Design and synthesis of granulin peptide analogues 
Three granulin peptide analogues were synthesised to provide insight into the 
structure-function relationships of granulin peptides. The sequences of the 
synthetic truncated peptides are provided in Table 5-1. To determine if the N-
terminal region of human granulin A can fold in a similar way to the Ov-GRN-
1 peptides, a 24-residue peptide, termed hGRNA4-28_3s, was chemically 
synthesised. The design of this peptide is equivalent to the three-disulfide, 24-
residue Ov-GRN-1 peptide analogue we previously synthesised (Ov-GRN12-
35_3s) (7). 
 
Two additional Ov-GRN-1-derived peptides were also synthesised. One peptide 
corresponded to residues 9 to 35 (Ov-GRN9-35_3s) and was synthesised to 
determine if the additional three residues, compared to Ov-GRN12-35_3s (the 
prefix Ov has been added to the Ov-GRN-1 derived peptides to distinguish 
them from the human granulin peptide), stabilize the β-hairpin at the N-
terminus. The second peptide corresponded to residues 39-66 (Ov -GRN39-66_3s) 
and spans the region encompassing cysteine VII to cysteine XII. All peptides 
were synthesised using Fmoc solid-phase peptide synthesis on 2-chlorotrityl 
resin. The disulfide bonds were formed by air oxidation in 0.1 M ammonium 
bicarbonate and 5 mM glutathione at room temperature.  
 
The analytical RP-HPLC traces of the oxidation reactions for hGRNA4-28_3s and 
Ov-GRN9-35_3s both contain a relatively sharp peak that eluted earlier than the 
other peaks (Figure 5-2). The folding profiles are consistent with previous 
studies on granulin peptides and indicate that the early eluting peak is likely to 
have a well-folded structure (6, 16, 18, 20, 21). The relative folding yield was 
calculated based on the area of early eluting peak relative to the total peak area. 
hGRNA4-28_3s  had a better folding yield (57%) compared to Ov-GRN9-35_3s 
(43%). The early eluting peaks for these two peptides were purified to 
homogeneity by semi-preparative RP-HPLC. 
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Hyphen (-) indicates a sequence gap. Cysteine residues are shown in bold. The sequences of the peptides synthesised in the 
current study are highlighted in blue.  *Residues 20-84 of the Ov-GRN-1 sequence are shown in this table, (…) indicates the 
sequence that is not presented here.  #The sequences of the previously studied hybrid hGRNA(1), Ov-GRN12_35_3s(1, 2) and carp 
granulin-1, are cited accordingly and presented in this table just for comparison purposes. The replaced residues in hybrid 
hGRNA, relative to the wild type sequence, are underlined (1-5). 
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Figure 5-2 HPLC analysis of the oxidation reaction of granulin N-terminal 
truncated analogues, Ov-GRN9-35_3s and hGRNA4-28_3s. Analytical HPLC was 
carried out using reversed phase HPLC with a Phenomenex Jupiter Proteo C12 
analytical column. 
 
 
By contrast, the RP-HPLC trace for the oxidation of the C-terminal fragment of 
Ov-GRN-1, Ov -GRN39-66_3s, does not contain a sharp, early eluting peak. 
Analysis of the fractions collected from the preparative RP-HPLC using a 
SCIEX 5800 MALDI TOF/TOF MS spectrometer shows that a mixture of fully 
oxidised and partially oxidised products are present in the oxidation solution 
following a 82 hour oxidation time (Figure 5-3). The purified fraction obtained 
for fully oxidised Ov-GRN39-66_3s was a mixture of poorly resolved isomers, 
which could not be purified to homogeneity. 
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Figure 5-3 HPLC and mass analysis of the Ov-GRN39-66_3s oxidation reaction. The 
oxidation mixture was fractionated using a C18 preparative RP-HPLC column 
following 82 hours of oxidation. The masses of different Ov-GRN39-66_3s disulfide 
bond isomers eluting at different time points are shown in boxes A and B.  (A) Box A 
shows the ((M + H)+ charged ion at (m/z)= 2851.7808), which corresponds to fully 
oxidised Ov-GRN39-66_3s. (B) Box B shows the ((M + H)+ charged ion at (m/z)= 
2853.7397), which corresponds to the partially oxidised Ov-GRN39-66_3s with 2 
disulfide bonds. The non-symmetric isotope pattern in box Β indicates the presence of 
some traces of fully oxidised product from adjacent peaks.   
 
 
 
5.4.2 Structural analysis with NMR spectroscopy  
The structures of the purified or partially purified fractions of truncated peptides 
in solution were analysed using NMR spectroscopy. One-dimensional proton 
NMR spectra of hGRNA4-28_3s and Ov-GRN9-35_3s showed large chemical shift 
dispersion in the amide region (Figure 5-4), consistent with peptides containing 
β-sheet structure. By contrast, the NMR spectrum of Ov-GRN39-66_3s (Figure 5-
4), has limited dispersion in the amide region, and broad peaks consistent with 
an unstructured peptide. 
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Figure 5-4 One-dimensional proton NMR spectra for granulin N-terminal 
truncated analogues. Spectra are shown from 6 to 10.5 ppm; This region contains 
primarily the amide protons. Ov-GRN9-35_3s, and hGRNA4-28_3s have significant 
chemical shift dispersion in this region compared to the limited dispersion for Ov-
GRN39-66_3s. 
 
 
Secondary shift analysis suggested that the overall structure for hGRNA4-28_3s 
and Ov-GRN9-35_3s is similar to the previously studied peptide, Ov-GRN12-35_3s 
(Figure 5-5).  The hGRNA4-28_3s three-dimensional structure was calculated 
using distance and dihedral angle restraints derived from one- and two-
dimensional homonuclear 1H NMR experiments. The refinement statistics are 
given in Table 5-2. As illustrated in Figure 5-6, hGRNA4-28_3s looks similar in 
conformation to Ov-GRN12-35_3s, in agreement with the secondary Hα chemical 
shift analysis. Comparison of the 20 lowest energy structures for hGRNA4-28_3s 
and Ov-GRN12-35_3s indicates that the peptides share a β-hairpin structure at the 
C-terminal region. D2O exchange experiments indicated that hGRNA4-28_3s has 
12 slowly exchanging amide protons, whereas the previously studied Ov-
GRN12-35_3s peptide had eight slowly exchanging amide protons, indicating that 
hGRNA4-28_3s might have a more stable structure. 
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Figure 5-5 αH Secondary-shift comparison for truncated granulin analogues. 
The αH secondary shifts were calculated by subtracting the random coil 1H NMR 
chemical shifts previously reported by Wishart et al. (27) from the experimental αH 
chemical shifts. The color used for each peptide is shown at top of the diagram. The 
sequences of Ov-GRN12-35_3s (green), Ov-GRN9-35_3s (red), and hGRNA4-28_3s (blue) 
are given at the bottom of the diagram. 
	
	
	
	
	
	
	
Table 5-2 Structural statistics for hGRNA4-28_3s 
 
 
  
Experimental restraints  
Interproton distance restraints  
           Intraresidue, |i-j|=0 37 
           Sequential, |i-j|=1 34 
          Medium range, 1 <|i-j| < 5 4 
          Long range, |i-j| >=5 17 
Disulfide-bond restraints 3 
Dihedral-angle restraints 32 
Hydrogen bond restraints (3 restraints per bond) 9 
R.m.s. deviations from mean coordinate structure (Å)  
Backbone atoms 1.57 ± 0.52 
All heavy atoms 2.51 ± 0.75 
Ramachandran Statistics  
% in most favoured region 87.8 
% Residues in additionally allowed regions 12.2 
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Figure 5-6  A comparison of the three-dimensional structure of (A) hGRNA4-28_3s 
(PDB ID: 6NUG) and (Β) Ov-GRN12-35_3s (PDB ID: 5UJG). Ribbon representations 
are of the lowest energy structures from ensembles of 20 structures. Disulfide bonds 
are shown as yellow sticks and only the backbone atoms are displayed. The figure 
was prepared using MOLMOL (26). 
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5.4.3 Cell proliferation monitoring in real time using xCELLigence  
The effect of the truncated granulin analogues on the growth of 1BR.3.GN 
fibroblasts was evaluated using an xCELLigence system. 1BR.3.GN is a human 
fibroblast skin cell line derived from a transformed normal fibroblast. Cells were 
cultured with two concentrations of the peptides, 200 nM and 1 µM (Figure 5-
7).  Ov-GRN9-35_3s showed an effect on cell proliferation with an increase in cell 
number by 114% (P<0.01) and 117% (P<0.001) at 200 nM and 1 µM, 
respectively. Cells cultured in the presence of 1 µM Ov-GRN39-66_3s had 
increased cell survival (121%, P<0.0001) compared to the control peptide. No 
significant effect on cell growth was observed at 200 nM (Figure 5-7). 
Although the Ov-GRN-1 truncated peptides had cell proliferation activity, 
hGRNA4-28_3s did not promote significant growth of 1BR.3.GN cells at 
concentrations up to 1 µM. 
 
 
 
Figure 5-7  xCELLigence fibroblasts cell proliferation assay. Fibroblast cells were 
treated with peptides at 200 nM (black) and 1 µM (white). Cell index was measured 
after 60-72 hour post treatment. Data represent mean ± SEM of three independent 
experiments. Data were analyzed by one-way ANOVA against peptide control (Not 
significant = ns, ** P<0.01, *** P<0.001). 
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5.5 Discussion 
Insight into the structure-activity relationships of granulin proteins is just 
beginning to emerge, but studies have already highlighted the complexity 
associated with this family. Here we show that the Ov-GRN-1 N-terminal and 
C-terminal regions have distinct folding properties and that regular secondary 
structure is not critical for enhancing the rate of cell proliferation. 
Understanding the processes involved in granulin folding and bioactivity is 
likely to facilitate the development of novel wound healing agents based on the 
granulin scaffold.  
 
We have shown that a 24-residue peptide from the N-terminal region of human 
granulin A, containing half of the highly conserved cysteine motif, can fold 
independently into a well-defined structure with a β-hairpin as the main 
element of secondary structure. This peptide contains a non-native disulfide 
bond (Cys IV to VI), analogous to our previous studies on a truncated form of 
Ov-GRN-1 (Ov-GRN12-35_3s) (7). The structures of hGRNA4-28_3s and Ov-
GRN12-35_3s are similar despite the sequence differences (the peptides have 42% 
sequence identity), suggesting that independent folding of the first six cysteine 
residues in the granulin scaffold might be a common feature. 
 
It is not readily apparent why the N-terminal region of granulins would fold 
independently incorporating a non-native disulfide bond, as most granulin 
modules are expressed as 12 cysteine-containing proteins and appear to form a 
laddered arrangement of the disulfide bonds where Cys IV is bonded to Cys VII 
and Cys VI is bonded to Cys IX (refer to Figure 5-1A for disulfide bond 
connectivity) (16, 18, 28). However, this unusual folding property might be 
related to the paragranulin modules that contain only six cysteine residues (12, 
16, 28), and which based on our results are also likely to contain the Cys IV to 
Cys VI bond. 
 
Although hGRNA4-28_3s displayed a well-defined structure, its effect on 
fibroblast cell proliferation was not statistically significant at concentrations up 
to 1 µM. This lack of bioactivity might not be surprising given that rat 
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epithelin-1, a protein with a very similar sequence to hGRN A, does not induce 
fibroblast proliferation (29) and hGRN A inhibits the growth of several human 
cancer cells via an apoptotic pathway (16, 28-32) rather than promoting cell 
growth. The low sequence similarity between hGRNA4-28_3s and Ov-GRN9-35_3s, 
indicates that the Ov-GRN-1 cell proliferation activity is related to the peptide 
sequence. 
 
Previous studies have shown that a human granulin A peptide containing only 
two disulfide bonds (Cys I-Cys III and Cys II-Cys V) does not form a well-
defined structure, in contrast to carp granulin-1 and plant-like granulin 
truncated analogues (7, 16, 20, 21, 33). Hydrophobic interactions have a critical 
contribution to stabilization of the overall fold of carp granulin-1 and plant 
granulin-like analogues (20, 21, 33). Based on the importance of these 
interactions a fragment of hGRNA (residues 1-30) containing four substitutions 
was designed and shown to contain a β-hairpin structure. The sequence of this 
hybrid peptide is given in Table 5-1 (16). Interestingly, superposition of the 
backbone atoms of hGRNA4-28_3s and the previously studied hybrid hGRNA 
peptide (19) shows the overall fold is very similar (Figure 5-8). Therefore, these 
findings suggest that forming a non-native disulfide bond effectively 
compensates for the lack of structure in a truncated version of hGRNA, in a 
similar manner to the hydrophobic substitutions (16). 
 
In addition to the relatively minor substitutions in hGRNA having a significant 
influence on folding and structure (19), it has previously been shown that minor 
changes in the carp granulin-1 sequence can have an effect on structure.  
Analysis of carp granulin-1 peptides containing residues 1-30 and residues 3-30 
showed that the former had a more well defined structure than the latter (20, 
21). By contrast, in the current study we show that addition of three N-terminal 
residues to a truncated Ov-GRN-1 peptide did not influence the overall fold 
based on secondary structure analysis (Figure 5-5) adding to the complexity of 
the structure-function relationships of granulin peptides. 
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Figure 5-8 Superposition of the structures of the hGRNA4-28_3s and the hybrid 
hGRNA N-terminal truncated peptides. The β-hairpins are shown as arrows, and 
for hGRNA4-28_3s (PDB ID: 6NUG) it is shown in cyan, and for hybrid hGRNA (PDB: 
1G26) (19)  in dark blue. Disulfide bonds are shown as yellow sticks and cysteine 
residues are labelled using Roman numerals. The cysteine residues involved in 
forming the non-native disulfide bond (IV-VI) in hGRNA4-28_3s are labelled with red 
letters. The figure was prepared using MOLMOL (26). 
 
 
 
No folding or bioactivity studies have previously been reported on the C-
terminal regions of granulins. We show for the first time that the C-terminal 
region of Ov-GRN-1, comprising the second half of the 12 cysteine motif (Ov-
GRN39-66_3s), does not fold into one major isomer following an extended 
oxidation time of 82 hours. It is possible that the non-native disulfide bond 
interferes with the correct folding in the C-terminal truncated analogue, unlike 
the N-terminal analogues. In addition, the highly-conserved cysteine spacing is 
also inverted in the C-terminal half of the molecule compared to the N-terminal 
region, as shown for Ov-GRN-1 in Table 5-1, and this is likely to influence the 
folding.  
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Although Ov-GRN39-66_3s could not be purified to homogeneity, a fraction that 
was fully-oxidised was analysed in the fibroblast proliferation assay and 
displayed a similar level of activity to Ov-GRN9-35_3s. This result indicates that 
the structure might not be critical for the cell proliferation bioactivity of Ov-
GRN-1. Furthermore, there is limited sequence homology between the two 
halves of Ov-GRN-1 and further study is required to determine residues 
important for bioactivity. Our results for the C-terminal region of Ov-GRN-1 
are consistent with previous studies on human granulin B, which indicate that 
this protein is intrinsically disordered but significantly induces NF-κB 
activation in SY-SH5Y human neuroblastoma cells in a dose-dependent manner 
(34). 
 
Overall, this study has shown that a non-native disulfide bond has an important 
role in stabilising a well-defined structure in the N-terminal region of truncated 
granulin peptides. Furthermore, Ov-GRN-1-induced cell proliferation does not 
appear to be dependent on structure alone, but rather on the unique peptide 
sequence. However, the mechanism of action of granulin peptides has yet to be 
established, and it is possible that upon binding to a biological target, structure 
might be induced.  
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5.7 Non-standard abbreviations  
HCTU, (2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate); DIPEA, Ethyldiisopropylamine; TOCSY, Total 
Correlated Spectroscopy; ECACC, European Collection of Authenticated Cell 
Cultures; DMEM/F12, Dulbecco's Modified Eagle Medium: Nutrient Mixture 
F-12; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; FBS, Fetal 
Bovine Serum; CI, Cell Index; RP-HPLC, reversed phase HPLC; D2O, 
Deuterium Oxide; DQF-COSY, Double-quantum filtered correlation 
spectroscopy; ANOVA, ANalysis Of Variance; LC-MS, Liquid 
chromatography-mass spectroscopy;  
	
	
	
	
	
	
	
	
	
	
	
 
	 143	
5.8 References 
 
1. Bhutia, S.K. and T.K. Maiti. Targeting tumors with peptides from natural 
sources. Trends Biotechnol. 2008; 26(4): 210-7. 
2. Edwards, C., M. Cohen, and S. Bloom. Peptides as drugs. QJM: Int. J. Med. 
1999; 92(1): 1-4. 
3. Smout, M.J., et al. A granulin-like growth factor secreted by the carcinogenic 
liver fluke, Opisthorchis viverrini, promotes proliferation of host cells. PLoS 
Pathog. 2009; 5, DOI: 10.1371/journal.ppat.1000611. 
4. Smout, M.J., J.P. Mulvenna, M.K. Jones, and A. Loukas. Expression, 
refolding and purification of Ov-GRN-1, a granulin-like growth factor from 
the carcinogenic liver fluke, that causes proliferation of mammalian host cells. 
Protein expression and purification. 2011; 79(2): 263-70. 
5. Papatpremsiri, A., M.J. Smout, A. Loukas, P.J. Brindley, B. Sripa, and T. 
Laha. Suppression of Ov-grn-1 encoding granulin of Opisthorchis viverrini 
inhibits proliferation of biliary epithelial cells. Exp. Parasitol. 2015; 148: 17-
23. 
6. Dastpeyman, M., et al. Structural Variants of a Liver Fluke Derived Granulin 
Peptide Potently Stimulate Wound Healing. J. Med. Chem. 2018; 61(19): 
8746-53. 
7. Bansal, P.S., et al. Development of a potent wound healing agent based on the 
liver fluke granulin structural fold. J. Med. Chem. 2017; 60(10): 4258-66. 
8. Botelho, M.C., H. Alves, and J. Richter. Wound healing and cancer 
progression in Opisthorchis viverrini associated cholangiocarcinoma. 
Parasitol. Res. 2016; 115(7): 2913-4. 
9. Smout, M.J., et al. Carcinogenic Parasite Secretes Growth Factor That 
Accelerates Wound Healing and Potentially Promotes Neoplasia. PLoS 
Pathog. 2015; 11, DOI: 10.1371/journal.ppat.1005209. 
10. Haugen, B., S.E. Karinshak, V.H. Mann, A. Popratiloff, A. Loukas, P.J. 
Brindley, and M.J. Smout. Granulin Secreted by the Food-Borne Liver Fluke 
Opisthorchis viverrini Promotes Angiogenesis in Human Endothelial Cells. 
Front. Med. 2018; 5, DOI: 10.3389/fmed.2018.00030. 
11. Zheng, S., Y. Zhu, Z. Zhao, Z. Wu, K. Okanurak, and Z. Lv. Liver fluke 
infection and cholangiocarcinoma: a review. Parasitol. Res. 2017; 116(1): 11-
9. 
12. Dastpeyman, M., M.J. Smout, D. Wilson, A. Loukas, and N.L. Daly. Folding 
of granulin domains. Peptide Sci. 2018: 10.1002/pep2.24062. 
	 144	
13. Bateman, A. and H.P. Bennett. The granulin gene family: from cancer to 
dementia. BioEssays. 2009; 31(11): 1245-54. 
14. Bateman, A. and H. Bennett. Granulins: the structure and function of an 
emerging family of growth factors. J. Endocrinol. 1998; 158(2): 145-51. 
15. Hrabal, R., Z. Chen, S. James, H.P. Bennett, and F. Ni. The hairpin stack fold, 
a novel protein architecture for a new family of protein growth factors. Nat. 
Struct. Biol. 1996; 3(9): 747-52. 
16. Tolkatchev, D., et al. Structure dissection of human progranulin identifies 
well‐folded granulin/epithelin modules with unique functional activities. 
Protein Sci. 2008; 17(4): 711-24. 
17. Palfree, R.G., H.P. Bennett, and A. Bateman. The Evolution of the Secreted 
Regulatory Protein Progranulin. PLoS One. 2015; 10, DOI: 
10.1371/journal.pone.0133749. 
18. Wang, P., B. Chitramuthu, A. Bateman, H.P.J. Bennett, P. Xu, and F. Ni. 
Structure dissection of zebrafish progranulins identifies a well-folded 
granulin/epithelin module protein with pro-cell survival activities. Protein Sci. 
2018; 27(8): 1476-90. 
19. Tolkatchev, D., A. Ng, W. Vranken, and F. Ni. Design and solution structure 
of a well-folded stack of two β-hairpins based on the amino-terminal fragment 
of human granulin A. Biochemistry. 2000; 39(11): 2878-86. 
20. Vranken, W.F., Z.G. Chen, P. Xu, S. James, H.P. Bennett, and F. Ni. A 30-
residue fragment of the carp granulin-1 protein folds into a stack of two beta-
hairpins similar to that found in the native protein. J. Pept. Res. 1999; 53(5): 
590-7. 
21. Vranken, W.F., S. James, H.P. Bennett, and F. Ni. Solution structures of a 30-
residue amino-terminal domain of the carp granulin-1 protein and its amino-
terminally truncated 3-30 subfragment: implications for the conformational 
stability of the stack of two beta-hairpins. Proteins. 2002; 47(1): 14-24. 
22. Bateman, A., D. Belcourt, H. Bennett, C. Lazure, and S. Solomon. Granulins, 
a novel class of peptide from leukocytes. Biochem. Biophys. Res. Commun. 
1990; 173(3): 1161-8. 
23. Wüthrich, K. NMR studies of structure and function of biological 
macromolecules (Nobel Lecture). J. Biomol. NMR. 2003; 27(1): 13-39. 
24. Guntert, P. Automated NMR structure calculation with CYANA. Methods 
Mol. Biol. 2004; 278: 353-78. 
25. Shen, Y. and A. Bax. Protein structural information derived from NMR 
chemical shift with the neural network program TALOS-N. Methods Mol. 
Biol. 2015; 1260: 17-32. 
	 145	
26. Koradi, R., M. Billeter, and K. Wüthrich. MOLMOL: a program for display 
and analysis of macromolecular structures. J. Mol. Graphics. 1996; 14(1): 51-
5, 29-32. 
27. Wishart, D.S., et al. 1H, 13C and 15N chemical shift referencing in 
biomolecular NMR. J. Biomol. NMR. 1995; 6(2): 135-40. 
28. Bhandari, V., R. Palfree, and A. Bateman. Isolation and sequence of the 
granulin precursor cDNA from human bone marrow reveals tandem cysteine-
rich granulin domains. Proc. Natl. Acad. Sci. U.S.A. 1992; 89(5): 1715-9. 
29. Shoyab, M., V.L. McDonald, C. Byles, G.J. Todaro, and G.D. Plowman. 
Epithelins 1 and 2: isolation and characterization of two cysteine-rich growth-
modulating proteins. Proc. Natl. Acad. Sci. U.S.A. 1990; 87(20): 7912-6. 
30. Qiao, G., et al. Granulin A Synergizes with Cisplatin to Inhibit the Growth of 
Human Hepatocellular Carcinoma. Int. J. Mol. Sci. 2018; 19, DOI: 
10.3390/ijms19103060. 
31. Chen, X., et al. Interaction between granulin A and enolase 1 attenuates the 
migration and invasion of human hepatoma cells. Oncotarget. 2017; 8(18): 
30305-16. 
32. Wang, X., H. Xu, X. Chen, Y. Tian, F. Wang, and X. Lin. Cloning, expression 
and cytotoxicity of granulin A, a novel polypeptide contained in human 
progranulin. Biosci. Trends. 2016; 10(3): 181-7. 
33. Tolkatchev, D., P. Xu, and F. Ni. A peptide derived from the C-terminal part 
of a plant cysteine protease folds into a stack of two beta-hairpins, a scaffold 
present in the emerging family of granulin-like growth factors. J. Pept. Res. 
2001; 57(3): 227-33. 
34. Ghag, G., L.M. Wolf, R.G. Reed, N.P. Van Der Munnik, C. Mundoma, M.A. 
Moss, and V. Rangachari. Fully reduced granulin-B is intrinsically disordered 
and displays concentration-dependent dynamics. Protein Eng. Des. Sel. 2016; 
29(5): 177-86. 
 
 
 
	 146	
 
 
 
 
 
 
Chapter 6.  Conclusions and Future 
Directions  
	 147	
6.1 Conclusions 
Disulfide-rich peptides are widely distributed in nature and the disulfide bonds 
generally play a crucial role in enforcing the native conformation of this class of 
peptides and proteins (1-4). The potential of a range of disulfide-rich peptides as novel 
therapeutics or diagnostic agents is currently being explored (5-9).  One such promising 
peptide is chlorotoxin, a 36-residue peptide originally isolated from scorpion venom, 
which is being pursued as an imaging agent (BLZ-100) (10-13) and angiogenesis 
inhibitor (131I-TM-601) (14-16). Ov-GRN-1 from the carcinogenic liver fluke 
Opisthorchis viverrini, has potential as a wound healing agent but the protein is 
difficult to make in high yields (17-22). Downsizing and exploring the structure-
function relationships of chlorotoxin and Ov-GRN-1 was the focus of this thesis. 
 
Chapter 2 of this thesis addressed the recent study that has shown fully reduced 
chlorotoxin, despite being unstructured in solution, has biological effects. This finding 
suggested that the inter-cysteine loops might be responsible for the bioactivity, and 
here we confirmed this hypothesis by showing small, unstructured regions of 
chlorotoxin displayed bioactivity and cell internalisation. The outcomes from this 
chapter provide insight into the structure-function relationships of chlorotoxin, which 
might facilitate its use as a cancer treatment agent.  
 
Chlorotoxin has the potential to significantly increase the success of surgery, a 
cornerstone in the treatment of cancer (23).  However, the mechanism of action of 
chlorotoxin is largely unknown (24). Deciphering its structure-function relationships 
might lead to the design of new lead molecules based on the chlorotoxin scaffold with 
more specific applications. Interestingly, in a study that was published while our 
chlorotoxin truncation study was “under review”, the C-terminal region of chlorotoxin 
was used to develop a cyclic peptide, miniCTX3, that effectively passes through the 
blood brain barrier (BBB) (25). MiniCTX3 corresponds to residues 30-35 of 
chlorotoxin and was conjugated to gold nanoparticles to increase the permeability of 
this biomedical cargo (25).  This study further suggests that CTX-4, corresponding to 
residues 28-36 of chlorotoxin, might be useful for the development of new tumour-
imaging agents.  
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The overall objective for Chapters 3 and 4 was to downsize Ov-GRN-1 into a 
bioactive peptide, because low yields of the recombinant protein limited its potential 
as a therapeutic agent. The specific aim of Chapter 3 was engineering bioactive 
peptides from the N-terminal region of Ov-GRN-1 with similar potency to the full-
length protein in a mouse wound-healing assay. This aim was achieved through the 
development of a suite of peptides, including a 24 residue peptide, Ov-GRN12-35_3s, which 
contains a unique structure. Although the non-native disulfide bond incorporated into this 
peptide was shown to be critical for formation of β-hairpin structure, it was not critical 
for wound healing bioactivity, because peptides with only two disulfide bonds also had 
wound healing activity.  
 
Following on from the findings from Chapter 3, in Chapter 4 the influence of the proline 
residues on Ov-GRN12-35_3s folding yield, structure and activity was analysed. Ov-GRN12-
35_3s was chosen for further study because it was the shortest peptide analysed, making it 
potentially cheaper to produce, and it contained the most well-defined structure, which 
could potentially have an impact on stability. Despite the relatively well-defined structure 
of Ov-GRN12-35_3s compared to the two-disulfide bond analogues, it still displayed 
multiple conformations in solution most likely due to isomerisation of the proline residues. 
Mutation of the proline residues indicated that each of the three proline residues had a role 
in the multiple conformations, and importantly an influence on the folding yields, 
indicating that the proline residues have a direct influence on the folding pathways. 
Removal of proline 4 significantly improved the folding yield and enhanced the 
wound healing activity in vivo. Understanding why removal of this proline residue 
improved bioactivity will only be fully rationalised when the biological target has 
been elucidated, but it is possible that the conformational flexibility lowers the 
binding affinity. The wound healing potency of GRNP4A surpasses that observed for 
Regranex, a growth factor approved for human clinical use for wound healing (26, 
27). 
 
Chapter 5 shed light on the folding properties and bioactivity of the C-terminal region 
of Ov-GRN-1. This study showed that although the C-terminal region does not 
independently fold into a well-defined structure, in contrast to the N-terminal region, 
it was still able to promote fibroblast cell proliferation. Furthermore, regarding the 
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sequence diversity in granulin proteins it was important to determine the influence of 
sequence variation on wound healing properties. Hence, the other specific aim of 
Chapter 5 was to assess the structure and bioactivity of a fragment of human granulin 
A equivalent to the Ov-GRN-1 N-terminal fragment. The results suggest that even 
though the human granulin A N-terminal truncated analogue also folds independently 
with three disulfide bonds into a similar structure as Ov-GRN12-35_3s, it does not 
significantly induce fibroblast cell proliferation. The results obtained from this 
chapter expand the knowledge of the structure activity relationships of the granulin 
family of protein and in particular for Ov-GRN-1.  
 
The Ov-GRN-1 studies carried out as part of this thesis have the potential to lead to 
the development of a drug lead for wound healing. New treatments for wound healing 
are particularly needed for treating diabetic patients (28, 29). Diabetics have a 25% 
lifetime risk of developing foot ulcers that can develop into non-healing wounds (29-
32). With diabetic foot ulcers being the second leading cause of diabetes related 
mortality, second only to cardiovascular disease (31, 33, 34), we need new treatments 
for wound healing to improve the quality of life of the significant proportion of 
Australians at risk of diabetic complications. Diabetes is a particularly severe health 
issue in Indigenous populations with higher proportions and earlier age of onset than 
non-Indigenous populations (35-38). There are reports in the Northern Territory that 
more than 90% of people with diabetes admitted to hospital with feet problems are 
Indigenous (www.healthinfonet.ecu.edu.au). Being able to engineer versions of Ov-
GRN-1 that are smaller and therefore less likely to be immunogenic, more stable and 
cheaper to manufacture is likely to enhance its potential as a drug lead. 
 
Overall, the studies in this thesis highlight the potential of disulfide-rich peptides as 
well as the importance of structure-function studies for developing more potent 
analogues and for improving production efficiency. This thesis has also expanded the 
studies utilizing the approach of down-sizing peptides/proteins, which has previously 
been applied to proteins such as DNA-binding proteins (39) and Bcl2 homology 
proteins (40), and confirms this approach can be valuable for the design of novel drug 
leads.  Interestingly, in both the chlorotoxin and granulin studies, there were examples 
of peptides that did not have well-defined structures in solution but were still 
bioactive.  It is often thought that the structure of disulfide-rich peptides is critical for 
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bioactivity (8, 41, 42), but this is not always the case and further study is required to 
fully understand how peptides such as chlorotoxin and granulin interact with their 
biological targets. Suggested future directions are outlined below.   
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6.2 Future directions 
The studies on chlorotoxin suggest that a small stretch from the C-terminal region is 
involved in anti-migration bioactivity. Although the identification of a bioactive 
region in chlorotoxin has potential for the design of novel lead molecules for tumour 
imaging, there are limitations associated with these small, unconstrained peptides. 
The chlorotoxin fragments that showed binding or bioactivity (CTX-3 and CTX-4) 
were highly unstable in serum. Hence, improving stability is likely to be required if 
they are to be developed as drug leads. In this regard, a recent study has shown that 
the enzymatic stability of a six-residue peptide comprising residues 30-35 of 
chlorotoxin was successfully increased by replacing the cysteine residues with 
diaminopropionic acids to form a lactam bridge (25). In addition, there are several 
other strategies available to improve the stability of peptides, including binding 
acylated peptides to albumin which has been successfully done to increase the half-
life of a heptapeptide in human plasma (43). 
 
To confirm the cell internalization result observed with the chlorotoxin fragments, 
specific inhibitors are needed to be used such as filipin, which inhibits caveolae-
dependent endocytosis, amiloride, which inhibits non-selective macropinocytosis, and 
chlorpromazine, which inhibits clathrin-dependent intracellular transport of coated 
pits (44). Extensive studies on a range of cell lines could also be carried out to further 
confirm that CTX-4 has tumour cell type specific activity/internalization. Moreover, 
synthesising and characterisation of over-lapping fragments from the C-terminal 
region and point mutagenesis study might be useful to discern the residues important 
for bioactivity.  
 
The protein array result identifying cortactin as a binding partner for chlorotoxin has 
not been validated. Hence, further characterization of chlorotoxin binding to cortactin 
utilizing different techniques such as surface plasmon resonance (SPR) and 
heteronuclear NMR experiments, and determining whether different chlorotoxin 
fragments bind/interact with the same receptor using structure-activity relationship 
(SAR) by NMR will shed more light on the chlorotoxin mechanism of action (45-50). 
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In terms of developing Ov-GRN-1 as a wound-healing agent, further structural studies 
will provide fundamental information in this field. Determination of the structure of 
full-length Ov-GRN-1 will provide a better understanding of Ov-GRN-1 structure-
activity relationships. Further structural characterization of other truncated human 
granulins in addition to GRN A will help define the fine details for the role/influence 
of the non-native disulfide bond in structure stabilisation of the granulin family of 
proteins. Moreover, critical amino acids/sequence motifs involved in inducing 
fibroblast cell proliferation could be identified by assessing and comparing cell 
proliferation bioactivity of these analogues.  
 
Further examination of the influence of conserved residues in the Ov-GRN-1 
bioactivity should define the minimum consensus motif and/or amino acids necessary 
for the cell proliferation bioactivity. In this regard, moving forward beyond the scope 
of this PhD study, we intend to investigate the role of inter cysteine loops in Ov-
GRN-1 N-terminal truncated peptide. This future direction is currently being started 
and the preliminary results highlight the important role for the disulfide bonds in 
GRN9-35_3s bioactivity.  
 
The next phase of this study, which is beyond the scope of the PhD, is to attempt to 
initiate advanced studies facilitating the clinical trial studies of GRNP4A. Perhaps the 
most important direction of study will be related to elucidating the mechanism of 
action. Chemical crossing-linking studies using mass spectrometry, protein array 
technologies and computational modelling could be used to define the interactions of 
Ov-GRN-1 and the engineered peptides with a biological target. 
 
It would also be quite interesting to further study the wound-healing activity in the in 
vivo diabetic mouse wound model such as the genetically hyperglycemic db/db mice 
(51-53). The majority of chronic wounds in humans are associated with disease states, 
making it of significant interest to determine if the granulin peptides are still 
efficacious in the presence of a disease state.  In addition, punch biopsy models in 
pigs could also be used to study wound healing and skin regeneration, as the skin of 
pigs is considered very similar to human skin and likely to be more relevant for 
subsequent clinical applications (54). Pharmacokinetics studies could also be used to 
predict the bioavailability, metabolism, stability and toxicity profile of GRNP4A, in 
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vivo and in vitro (55).  
 
Overall, the future directions given in this section might further advance the potential 
of both chlorotoxin and Ov-GRN derived peptides as drug leads. 
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